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Abstract  
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are two of the most 
common chronic respiratory diseases causing a major burden of ill health to 
populations across the world. Respiratory medication prescribing can be used as an 
indicator of air pollution effect on asthma and COPD, capturing patients with any 
severity of disease from mild to severe. In contrast, the traditional indicators of 
asthma exacerbation, such as hospital admissions and emergency room visits, only 
capture events of patients who suffer severe symptoms.  
In this study, I aimed to develop statistical models for assessing the spatio-
temporal patterns of salbutamol prescribing in relation to air quality, in a primary 
health care setting. Salbutamol represents 93% of short-acting β2-agonists, which 
are prescribed for quick-relief of symptoms and acute exacerbations to individuals 
that suffer from asthma or COPD. I analysed salbutamol medication (approximately 
67 billion Average-Daily-Quantities) prescribed by 64 GP practices in Newcastle and 
North Tyneside Primary Care Trusts, Northeast England, in 2002-2006. I used a 
mixed-effects model suitable for data that are not independent in time or space.  
My study found ambient Particulate Matter (PM10) concentrations to have a 
significant relationship to salbutamol prescribing in primary care.  An increase of 
10µg/m3 in ambient PM10 concentrations was associated with an increase of 1% in 
salbutamol prescribing. Income deprivation and average age of patients registered 
per practice also had a significant relationship with salbutamol prescribing. The 
findings showed that the variation of salbutamol prescribing was subject not only to 
health needs caused by deprivation and air quality, but also random effects that 
were practice specific, such as facilities within the practice or experience and 
prescribing pattern of practitioners. Overall, the findings demonstrated that 
respiratory prescribing in primary care can be used as indicator of air pollution 
effect on asthma and COPD, increasing the scope of its use for health surveillance 
in the future.  
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Preface 
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are two of the most 
common chronic respiratory diseases. According to the latest WHO estimates, 
approximately 300 million people have asthma and 210 million people have COPD. 
It is recognised that COPD is an under-diagnosed disease and is expecting to be the 
third biggest cause of death during the coming decades (2008). In Europe, it is 
estimated that 30 million people are asthmatics, six million suffer symptoms which 
are characterised as severe, and 1.5 million people live in fear of dying from an 
attack.   
Early epidemiologic studies have used data from secondary and tertiary care, such 
as admissions to hospital or emergency room visits, to quantify air pollution effect 
on respiratory exacerbations. However, those indicators capture patients that suffer 
from relatively severe symptoms. Primary care data offer a great source of 
information as the vast majority of patients suffering from respiratory diseases are 
fully treated at primary care level. Prescribing of respiratory medication in primary 
care, as an indicator of air pollution effect on asthma and COPD can capture 
patients with all levels of severity.  
The majority of primary care consultations in the UK are by patients with 
respiratory disease compared to any other type of illness (British Thoracic Society, 
2006, Pinnock and Sheikh, 2009). This figure emphasizes the important role of 
primary care in managing respiratory diseases. The World Health Assembly set out 
an action plan in 2008, to prevent and control chronic non-communicable diseases, 
including asthma and COPD (World Health Organization, 2008a). Part of this action 
plan is to strengthen the management of the diseases at primary care level. The 
WHO report also suggested that accessibility to medication in primary care can be 
used as indicator to monitor progress (World Health Organization, 2008b). One of 
the main long-term priorities for National Health Service (NHS) reform in UK, is the 
shift from provision of hospital-based acute care to proactive care, delivered in 
primary care (Department of Health, 2006, Department of Health, 2005). In the 
case of asthma, 75% of hospital admissions are avoidable (Asthma UK, 2010), no 
equivalent information was available for COPD. The importance of exploiting data at 
primary care level and especially data of respiratory diseases is discussed below.  
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Aims and Objectives 
Statistical models should account sufficiently for temporal and spatial variation of 
the variables that are not distributed independently in space and time. A key 
weakness of traditional statistical techniques is that they have to assume 
independence of health events. Complex spatio-temporal associations of health 
hazards, exposures and outcomes may therefore be misrepresented or result in 
associations being biased.  
My study aimed to develop an adequate statistical model at the level of primary 
care to assess the relationship between asthma/COPD medication prescribing and 
air quality. I tested the hypothesis that exposure to air pollution increases the 
frequency and duration of asthma and COPD symptoms, generating a consequent 
increase in the use of salbutamol medication and consequently an increase of 
prescriptions. Salbutamol represents 93% of short acting β2-agonists (Prescription 
Pricing Authority, 2006), which are prescribed for quick-relief of symptoms and 
acute exacerbations to individuals that suffer from asthma or COPD. I evaluated 
possible time-lags in response to medication use and air quality. I also considered 
contextual factors of the local environment, such as income, employment and 
educational deprivation and demographic factors (age and gender of patients) as 
covariates.  
To the best of my knowledge, this study is the first in the UK to assess the effect of 
air pollution on prescribing of respiratory medication, at GP practice level. In order 
to achieve the aim of this study, the following objectives had to be met: 
• To collate data on potential explanatory variables of the association between 
air pollution exposure and respiratory prescribing.  
• To explore the potential relevance of covariates, as well as understand the 
structure of the data, in order to build an adequate statistical model. 
• To quantify and evaluate the relationship between salbutamol prescribing, 
air quality indicators and the other covariates. 
• To examine delayed responses of salbutamol prescribing to the trigger 
factors of asthma/COPD exacerbations. 
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A Brief Outline of the Thesis 
The thesis comprises five chapters. The first chapter outlines the scientific 
background and consists of five sections. I initially present an overview of the 
literature on asthma and COPD prevalence as well as their main risk factors. I then 
focus on the pharmacological interventions for asthma and COPD, and present a 
comprehensive review of studies that used respiratory prescribing as indicator of air 
pollution effect on respiratory diseases. The fourth section discusses the role of 
primary care on respiratory diseases and its application in environmental 
epidemiology. In the last section I present the literature on the main aspects of 
spatial and spatio-temporal analysis, as they apply to this study. 
The second chapter, consisting of four sections, describes the data collection, 
collation and exploration process. In the first section I present the prescribing data 
and GP registered population that I used to create GP service areas. In the second 
section I give details on the indicators of air quality. The third part describes the 
deprivation data, and the final section reports on the demographic data. 
Chapter three presents the statistical analysis and consists of four sections. The 
first section is dedicated to describing the methods of statistical analysis. The 
second section presents the preliminary stages of the statistical model 
development. The third section describes the modelling of salbutamol prescribing 
seasonal variation, while in the fourth section I present the final model and its 
findings. The main discussion points are presented in chapter four while the 
conclusions as well as main limitations and strengths of the thesis are presented in 
chapter five.  
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Chapter 1. Scientific Background 
1.1  Chronic Respiratory Diseases – Asthma and Chronic Obstructive 
Pulmonary Disease (COPD) 
Hundreds of millions of people suffer every day from chronic respiratory diseases, 
which are chronic diseases of the airways and other structures of the lung. The two 
most common respiratory diseases are asthma and Chronic Obstructive Pulmonary 
Disease (COPD), also known as obstructive lung diseases. Asthma is a disease in 
which inflammation of the airways causes airflow into and out of the lungs to be 
restricted (Figure 1-1). COPD is a lung ailment the main components of which are 
chronic bronchitis and emphysema (Global Initiative for Chronic Obstructive Lung 
Disease (GOLD), 2008). Chronic bronchitis and emphysema used to be considered 
separate conditions but the terms are now replaced by COPD (Global Initiative for 
Chronic Obstructive Lung Disease (GOLD), 2008). In people with chronic bronchitis, 
the airways are narrowed, tight, swollen and are often filled mucus, resulting in 
reduced airflow. In emphysema, air sacs (alveoli) in the lungs are damaged and 
overstretched, resulting in air being trapped in the lungs, limiting the space for air 
exchange (Figure 1-2). 
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Figure 1-1. Airway (bronchiole) with inflammation (MedlinePlus - A.D.A.M. Inc, 
2006). 
 
 
 
 
 
 
 
 
 
 
Figure 1-2. Alveoli damaged by COPD. 
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1.1.1 Asthma Prevalence   
According to the latest WHO estimates, currently 300 million people have asthma 
(World Health Organization, 2009a). In 1992, the World Health organisation (WHO) 
formed the Global Initiative for Asthma (GINA) to promote the investigation of the 
disease. In Europe it is estimated that 30 million people are asthmatics, six million 
suffer symptoms which are characterised as severe, while 1.5 million people live in 
fear of dying from an attack (European Federation of Allergy and Airways Diseases 
Patients Associations, 2003). The United Kingdom (UK) is one of the countries with 
the highest asthma prevalence in the world (Woodruff and Fahy, 2001, Masoli M. et 
al., 2004c) along with USA, Canada, Australia, New Zealand, Brazil, Peru and South 
Africa (Figure 1-3). 
 
 
Figure 1-3. World map of The Prevalence of Asthma, Source: Global Initiative for 
Asthma (GINA) (2004) (Masoli M. et al., 2004b). 
 
Figure 1-4 shows fatality rates of asthma; the highest mortality rates occurred in 
countries with some of the lowest prevalence of the disease, such as Russia, China 
and Mexico. In contrast, countries with a very high prevalence of asthma often 
have the lowest rates of fatality, including the UK, Canada, Finland, and Australia 
(Masoli M. et al., 2004c). Asthma fatality rate corresponds to the number of deaths 
caused by asthma to the number of diagnosed cases of asthma. The pattern 
observed indicate that the countries with low asthma fatality rate are better on 
containment of mild cases.
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Figure 1-4. World map of the asthma case fatality rates, Source: Global Initiative 
for Asthma (GINA) (2004) (Masoli M. et al., 2004a). 
 
For England, data from the Quality and Outcomes Framework (QOF) showed that 
asthma prevalence was 5.9% (NHS The Information Centre for Health and Social 
Care, 2010). Asthma UK estimated that there are approximately 5.4 million people 
in UK (8.9% of the total UK population) with asthma (Prescription Pricing Authority, 
2006, Asthma UK, 2004); (Prescription Pricing Authority, 2007). Comparing asthma 
prevalence based on Asthma UK and QOF data, the latter appears to be an 
underestimate, however the figures are not directly comparable as QOF does not 
include the populations of Scotland, Wales and Northern Ireland.  
I compared data from the 4th Morbidity Study and Asthma UK in order to review the 
trend of asthma prevalence in UK over the most recent decade. According to the 4th 
Morbidity Study (Calverley and Sondhi, 1998) the diagnosed prevalence of asthma 
in UK was 4% (approximately 2.5 million people) at the end of 1990s. Comparing 
this figure to current Asthma UK estimate of approx. 8.9%, would show an increase 
of 4.9%. I also compared the estimate of 5.4% of UK’s population from Asthma UK 
in 1998 (called National Asthma Campaign) to the current Asthma UK estimate of 
8.9% that showed a 3.5% increase in asthma prevalence, during the last decade. 
The two numbers (4.9% and 3.5%) differ by approximately 1.5%. These indicative 
numbers of asthma prevalence increase in England during the last decade, are 
lower compared to asthma prevalence increase rates observed in earlier decades. 
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Experts were finding it difficult to understand why rates, world-wide, were rising by 
50% on average during the 1970s and 1980s (World Health Organization, 2000). 
Asthma prevalence was increasing worldwide at such a rate that asthma was 
classified as epidemic. Figure 1-5 shows the significant increase of asthma 
medication for England, between 1980 and 1993. However, for the last 10-15 years 
there are conflicting views on time trends of asthma, as recent trends show that the 
asthma epidemic has slowed down and prevalence may have declined. There are 
some studies indicating that asthma prevalence may be stabilising in high & middle 
income countries (Bollag et al., 2005, Fleming et al., 2000). Bollag et al., (2005) 
argued that asthma consultations in Switzerland have declined and suggest further 
research to be conducted in other cities and regions, in order to assess if the 
asthma epidemic has started to stabilise or even decline. In their recent work, 
Bollag et al (2009) also observed a fall in the proportion of asthma patients who 
had hay fever, and have argued that the asthma prevalence in Switzerland has 
been reduced because allergic induced asthma has declined.  
Those results were consistent with findings of an English study in children 
(Anderson et al., 2004). Anderson et al (2004) also found no increase in prevalence 
of asthma symptoms in children 12-14 years old, in British Isles.  The study on the 
British Isles reported decreases of eczema and hay fever as well. This would be 
similar with another study in Switzerland where prevalence rates of asthma and 
current asthmatic symptoms remained constant, and at the same time no further 
increase was observed for hay fever rates and allergic sensitisation rates (Braun-
Fahrlander et al., 2004). However, a study in Australia found a fall in asthma 
prevalence but an increase in prevalence of eczema and hay fever (Robertson et 
al., 2004). 
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Figure 1-5. Number of prescriptions for asthma preparations in England between 
1980-1993, Source: (Department of Health, 1995). 
 
The reported findings on the stabilisation or even decrease of the asthma 
prevalence over the last decade are to some extent reassuring but “should not be 
taken to indicate that the global pandemic of asthma is easing and that the worst is 
over” (Pearce and Douwes, 2005) page 763. The International Study of Asthma and 
Allergy in Childhood (ISAAC) phase III showed that the increase of asthma 
prevalence in Latin American countries may lead to describing asthma as a 
“Spanish and Portuguese speaking rather than an English speaking disease” (Asher 
et al., 2006). 
ISAAC is one of the two major multicentre studies that are able to provide evidence 
on the trends of asthma prevalence. The second one is the European Community 
Respiratory Health Survey (ECHRS) that focuses on centres of high income 
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countries, located mainly in Western Europe. I will now describe these two studies 
in more detail.    
1.1.1.1 International Study of Asthma and Allergy in Childhood  
ISAAC phase I has shown an approximately thirty-fold variation of asthma 
prevalence between countries, from data collected by June 1996 (ISAAC Steering 
Committee, 1998b). The survey was completed in 156 collaborating centres in 56 
countries with a total of over 700,000 children, aged 6-7 and 13-14 years, 
participating. The highest 12-month prevalence for asthma symptoms were 
reported from centres in UK, New Zealand, Australia, and Republic of Ireland 
(Figure 1-6).   
The time trend of the asthma prevalence was assessed by ISAAC survey phase III, 
carried out between 2001 and 2002 (Asher MI et al., 2006). This time 193,404 
children aged 6-7 years in 37 countries and 304,679 children aged 13-14 years 
from 106 centres in 56 countries participated. For the UK an increase of the 12-
month prevalence of asthma in children 6-7 years old was observed, while a 
decrease of asthma was reported for children aged 13-14 years (Asher MI et al., 
2006). The results from the ISAAC III study showed no increase in the prevalence 
of asthma symptoms in centres with pre-existing high prevalence in the older age 
group (age 13-14), such as UK 
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Figure 1-7). At the same time the results showed an increase in the prevalence of 
asthma in many other centres, such as Spain, Portugal and in countries of Latin 
America. 
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Figure 1-6. 12-month prevalence of self-reported asthma symptoms from written 
questionnaires, Source: ISAAC Steering Committee (1998) (ISAAC Steering 
Committee, 1998a). 
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Figure 1-7. World map showing direction of change in prevalence of asthma 
symptoms for 6–7 year and 13–14 year age-group (Asher et al., 2006). 
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1.1.1.2 European Community Respiratory Health Survey 
The European Community Respiratory Health Survey (ECRHS) started in 1993 
aiming to estimate the geographical variation in asthma prevalence in young adults 
(20-44 years) (Janson et al., 1997). Data were collected on a total of 17,029 
individuals from 34 centres in 14 countries. The highest prevalence of diagnosed 
asthma was found in New Zealand. In Europe, the highest asthma prevalence was 
found in all centres of the UK and in some of the centres in France (Figure 1-8). 
A follow up of ECRHS was conducted in 14 countries 5-11 years later, collecting 
data between 1998 and 2003 from 11,168 subjects, 20-44 years, in 1991-3 (Chinn 
S et al., 2004, Janson et al., 2001).  
Figure 1-9 shows the geographical variation of asthma as measured by people 
having an attack of asthma in the last 12 months and/or currently taking medicine 
for asthma. The ECHRHS found large geographical differences in the prevalence of 
asthma. Some of the UK fell within the category with the highest asthma 
prevalence >7% (Janson et al., 2001). The ECRHS follow-up found an increase in 
the number of people diagnosed with asthma but the same was not reported for the 
symptom prevalence. 
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Figure 1-8. Age-sex standardised prevalence of physician-diagnosed asthma and 
antiasthma medication, adjusted for non-participation, Source: Janson et al (1997) 
http://www.ecrhs.org/. 
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Figure 1-9. Geographical variation in prevalence of asthma (having an attack of 
asthma in the last 12 months and/or currently taking medicine for asthma), 
Source: Janson et.al. (2001) 
1.1.2 COPD Prevalence  
Similar maps to those produced for asthma prevalence by GINA do not exist for 
COPD. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) was 
formed in 1998, in an effort to carry out similar work for COPD.  According to the 
latest WHO estimates, currently 210 million people have COPD. However, it is 
recognised that COPD is an under-diagnosed disease (World Health Organization, 
2009a). Estimates of the European Federation of Allergy and Airways Diseases 
Patients Associations (EFA) stated that “there are more than 600 million people 
worldwide with COPD”, which is almost three times higher than the estimate 
provided by WHO (European Federation of Allergy and Airways Diseases Patients 
Associations, 2009a).  
COPD is one of the leading causes of death worldwide and was predicted to become 
the third leading cause of death by 2030 (World Health Statistics, 2008). In 2005, 3 
•   < 4% 
   4–7% 
   > 7% 
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million people across the world died of COPD, which was considerably higher than 
the numbers who died of asthma (250,000). In 2006 though, WHO launched The 
Global Alliance against Chronic Respiratory Diseases (GARD) aiming to establish an 
integrated approach on monitoring (surveillance) of chronic respiratory diseases 
and their determinants as well as to strengthen national policies for their prevention 
and control. The WHO GARD Planning Committee also works with the EFA patient 
society as well as respiratory, allergological and general practitioners societies and 
government organisations (World Health Organization, 2009b, Viegi et al., 2007). 
EFA is a European network of allergy, asthma patient organizations that was 
founded in 1991, in Sweden and added COPD to its mandate, in 2002 (European 
Federation of Allergy and Airways Diseases Patients Associations, 2009b) 
In Europe there are currently, approximately 44 million people suffering from COPD 
(European Federation of Allergy and Airways Diseases Patients Associations, 
2009a). I reviewed data on COPD prevalence in UK.  According to the 4th Morbidity 
Study (Calverley and Sondhi, 1998), the diagnosed prevalence of COPD in the UK 
was 1% (approximately 600,000 people). Data from the Quality and Outcomes 
Framework (QOF) showed that 816,341 (1.6% of England’s population) people 
were registered with COPD between April 2009 and March 2010 (NHS The 
Information Centre for Health and Social Care, 2008), however the QOF database 
was considered to underestimate the prevalence of some disease domains (Martin 
and Wright, 2009, Prescription Pricing Authority, 2007). In addition, the QOF figure 
(1.4%) is not directly comparable to that published by the 4th Morbidity Study (1%) 
because the latter was based on the whole UK population, while the former was 
based on the population of England only.  
COPD is often under-diagnosed (Coultas and Mapel, 2003, Vestbo, 2004) because 
repeated measurements are required to establish the diagnosis and differentiate it 
from other respiratory diseases, such as asthma (Vestbo and Lange, 2002).  The 
availability of spirometry tests in primary care can also influence the degree of 
under-diagnosis and under-treatment (Cazzola et al., 2009, Walters et al., 2008). 
Because spirometry is underused for the assessment of COPD in primary care, the 
development of simple and standardised questionnaires has been suggested by 
Miravitlles et al (2009) for the assessment of COPD severity. A study in Northern 
Sweden by Lindberg et al (2006a) recently estimated the under-diagnosis of COPD 
by disease severity and reported that COPD under-diagnosis is related to disease-
severity.  
The Northern Ireland Cost and Epidemiology of COPD (NICECOPD) study, estimated 
COPD prevalence to be 6.3% in adults aged 44-69 years (Murtagh et al., 2005). 
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The project PLATINO (Proyecto Latinoamericano de Investigación en Obstrucción 
Pulmonar) in five Latin American cities on populations aged ≥40 years, showed 
prevalence estimates ranging from 11.9% in Mexico City (Mexico) to 19.4% in 
Montevideo (Uruguay) (Menezes et al., 2005, Menezes et al., 2008).  
In Asian countries a high prevalence of COPD was reported as well. In Korea, the 
COPD prevalence was 17.2% among adults aged ≥45 years, while 7.8% among 
adults aged >18 years (Kim et al., 2005). Prevalence of airflow limitation was 
10.9% in adults aged ≥ 40 years, in Japan (Fukuchi et al., 2004). The overall 
prevalence of COPD was 8.2%, in a Chinese study (Zhong et al., 2007). 
In Scandinavia, surveys of population samples provided estimates of newly 
occurring cases (incidence rates). The 7-years cumulative incidence of COPD was 
11.0% and 4.9% in middle-aged and elderly adults respectively, in Northern 
Sweden (Lindberg et al., 2006b). The 30-yr cumulative incidences of chronic 
bronchitis and COPD in middle-aged males from two rural Finish cohorts, were 42% 
and 32% for continuous smokers, respectively, compared to 22% and 12% for 
never smokers, respectively (Pelkonen et al., 2006). 
Large variability in the prevalence and incidence of COPD may occur depending on 
the definition of airway obstruction (Viegi et al., 2000). Lindberg et al (2005) 
estimated prevalence of COPD using the guidelines of the British Thoracic Society 
(BTS), the European Respiratory Society (ERS), the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD), and the American Thoracic Society (ATS). The 
ATS and ERS have issued guidelines for the diagnosis and treatment of patients 
with COPD (Celli et al., 2004), in order to make comparable data on COPD. 
Halbert et al. (2006) conducted a systematic review and meta-analysis on global 
burden of COPD, the results of which approximated a COPD prevalence of 9-10%  
in adults aged ≥ 40 yrs. They suggested though that bodies such as the GOLD 
should help to standardise COPD prevalence measurement. A regional study in the 
North East of England conducted by Melville et al. (2010), in 6,000 males and 
6,000 females aged 45–69 randomly selected from a primary care database, also 
showed a COPD prevalence of 10%. 
The ECRHS project is the largest multicentre study providing information on COPD 
prevalence. More details on the results of the ECHRS are presented below.   
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1.1.2.1 European Community Respiratory Health Survey 
The ECHRS assessed the prevalence of COPD in high income countries, mainly  
located in Western Europe, analysing data on more than 18,000 young adults (20-
44 years). According to ECHRS results, in total 3.6 % had COPD and 11.8% had 
chronic respiratory symptoms, without airflow limitation (De Marco et al., 2004). 
The former is classed as COPD stage I+ and the latter COPD stage 0, according to 
WHO GOLD standards. Overall, ECHRS found COPD to be a considerable issue on 
young adults. This added to the evidence that COPD is not a burden only in elderly 
population. Studies that focused on middle age or elderly subjects limit the findings 
of real COPD burden and the view that COPD is a disease of those aged >50 yrs 
should be revised (Viegi et al., 2007, Vestbo, 2004). 
ECHRS findings also reported that female gender was significantly associated with 
chronic cough and phlegm (Cerveri et al., 2003). This finding is contrary to the old 
belief that COPD is a disease of males (Siafakas et al., 1995). In 2000, the number 
of COPD deaths in USA was higher in females than males. A retrospective cohort of 
British patients with COPD, found that, from 1990 to 1997, COPD became more 
frequent in 20-44 year old females (Soriano et al., 2000). This is likely to be related 
to the increase in smoking prevalence in women. 
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1.2 Aetiology and Risk factors for Asthma and COPD 
Asthma has a long history described first by Hippocrates and his school (460-360 
B.C.) (Hippocrates, 1881), however it is difficult to determine whether in referring 
to "asthma," Hippocrates meant a distinct clinical entity or simply a symptom. 
Asthma in now well defined as a disease but its causes are not fully understood. 
Asthma aetiology has a genetic component and there is also evidence that 
environmental factors are linked to its development (Mutius E. et al., 1992, Cullinan 
P. and A., 2003). The development of COPD is also considered to be influenced by 
genetic susceptibility but its main cause is considered to be inhalation of tobacco 
smoke and other inhaled particles.  
There is epidemiologic evidence that long-standing asthma can lead to COPD and 
patients can have both diseases (Bleecker, 2004, Global Initiative for Chronic 
Obstructive Lung Disease (GOLD), 2008, Viegi et al., 2007, Soriano et al., 2003, 
Viegi et al., 2004, Lange et al., 1998).  A major difference between asthma and 
COPD is that the airways obstruction in asthma is reversible while that in COPD is 
not fully reversible and gets progressively worse over time. Asthma can disappear 
particularly in children, however in a substantial proportion of cases the disease 
may come back (Martinez et al., 1995, Strachan et al., 1996, Sears et al., 2003).  
The incomplete understanding of causes of both asthma and COPD has motivated 
many studies investigating avoidable risk factors that exacerbate symptoms in 
those who already have the disease.  
1.2.1 Exacerbation of Asthma and COPD  
Studies have found that air pollution is a major risk factor for both asthma and 
COPD exacerbation (Romeo et al., 2006, Donaldson et al., 2000, Halbert et al., 
2006, Anderson et al., 1997, Katsouyanni et al., 2001). Poor air quality caused by 
tobacco smoke or inhaled particles is one of the major triggers for worsening 
symptoms and exacerbations for COPD and asthma (Pope C.A. et al., 1995). Other 
environmental factors that can worsen symptoms are cold air and respiratory 
infections. 
Asthma exacerbations are also linked to allergens like pollen and fungal spores that 
are seasonal.  Few studies have focused on the association of allergens and asthma 
(Rossi et al., 1993, Atkinson et al., 2006, Glikson et al., 1995). The majority of 
studies for asthma and COPD have focused on analysing their association with air 
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pollution, as environmental exposure can potentially become an avoidable risk 
factor. Socioeconomic differences are associated with asthma and COPD like many 
other diseases (e.g ischaemic heart disease, many types of cancer, mortality 
related to alcohol and violence) and this has been reported in the literature since 
the 1970’s.  
1.2.2 Air Pollution as Risk Factor for Asthma and COPD Exacerbations 
I present below major studies that have focused on analysing the association of 
asthma and COPD to air pollution. First, I describe the air pollutants analysed in 
those studies.  
1.2.2.1 Air Pollutants 
The concentration of air pollutants is often used to assess air quality and to define 
thresholds that can be harmful to human health and the environment.  An air 
pollutant is a substance in the air that can have the form of a gas, solid particles 
and liquid droplets. Pollutants are classified as either primary or secondary based 
on their origin. The primary pollutants are emitted directly from sources such as 
vehicle exhausts, factories or volcanic eruptions. The major primary pollutants 
produced by human activities are: 
 
• Sulfur dioxide (SO2), which is produced in various industrial processes. 
• Nitrogen dioxide (NO2) that is emitted from high temperature combustion. 
Traffic emissions are a major source of NO2. 
• Carbon monoxide (CO) that is a product of incomplete combustion of fuels 
such as natural gas, coal or wood. Traffic emissions are a major source of 
carbon monoxide. 
• Particulate matter (PM) consists of tiny particles of solid or liquid, suspended 
in a gas and is categorised with respect to size. The most widely used 
definition of PM size is the aerodynamic diameter, the ranges of which are 
presented in Table 1-1. Human activities, such as the burning of fossil fuels 
in vehicles, and power plants, and various industrial processes can generate 
significant amounts of PM. 
 
Scientific Background     
19 
 
Fraction  Size range 
PM10  ≤10 µm 
PM2.5   ≤ 2.5 µm 
PM1  ≤ 1 µm 
Ultrafine (UFP or UP)  ≤ 0.1 µm 
Table 1-1. Size of Particulate Matter Fractions. 
 
• Volatile organic compounds (VOCs) are numerous and vary a lot as chemical 
compounds. They are often divided into the separate categories of methane 
(CH4) and non-methane (NMVOCs). Methane is a greenhouse gas. Within 
the NMVOCs, the aromatic compounds benzene, toluene and xylene are 
known or suspected carcinogens. 
Secondary pollutants are formed when primary pollutants react or interact. The 
main secondary pollutants are: 
• Particulate matter (PM) formed from gaseous primary pollutants and 
compounds in photochemical smog. 
• Ground level ozone (O3) formed by the reaction of sunlight on air containing 
NOx and VOCs.  
There are many studies that have investigated the effect of a range of air pollutants 
on asthma and/or COPD, in an environmental epidemiology context. I present some 
of those studies in the next section. 
1.2.2.2 Association of Air Pollution to Asthma and COPD 
The Air Pollution and Health - A European Approach (APHEA) study analysed air 
pollution in relation to respiratory diseases in 10 European countries. APHEA is the 
largest scale study in Europe in the field of respiratory diseases and air pollution 
and analysed the following main types of pollutants: PM, SO2, NO2 and O3. APHEA 
looked at hospital admissions for asthma, asthma and COPD and all-respiratory 
disease admissions. The study confirmed that air pollution in European cities was 
positively associated with increased numbers of admissions for respiratory diseases 
(Katsouyanni et al., 2001, Atkinson et al., 2001b, Anderson et al., 1997, Sunyer et 
al., 1997, Katsouyanni et al., 1997). Variation in air pollutants effect estimates 
between cities could be explained by cities’ characteristics.  
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Romeo et a.l (2006) conducted a review of the time series and panel studies on the 
short term effects of PM10 on increases of the illness in childhood. The results 
showed that exposure to PM10 was associated with an increase in hospitalizations 
for asthma. In addition, exposure to PM10 of asthmatic children was associated with 
the frequency of asthmatic symptoms (wheezing and cough), the use of anti-
asthma medications (in addition to regular therapy) and a decrease in lung 
function. 
A study in London investigated the relationship between daily GP consultations for 
asthma and other lower respiratory diseases (LRD) and air pollution. Associations 
were found between air pollution and daily consultations for asthma and other 
lower respiratory disease. The most significant associations were observed in 
children and the most important pollutants were NO2, CO, and SO2, while in adults 
the only consistent association was with PM10 (Hajat et al., 1999). 
Some studies assessed the relationship between air pollution and respiratory 
diseases by using indicators measured directly in individuals with asthma. In 
Germany, the association between particulate air pollution and asthma medication 
use and symptoms was investigated, in a panel study of 53 adult asthmatics, 
during the winter 1996/1997. The study reported that asthma medication use and 
symptom increase was associated with particulate air pollution and gaseous 
pollutants, such as nitrogen dioxide (von Klot et al., 2002). A study in eight North 
American cities, investigated the relationship between ambient concentrations of 
five pollutants and asthma exacerbations (daily symptoms and use of rescue 
inhalers) among 990 children (November 1993-September 1995). PM10 and O3 were 
found unrelated to exacerbations while strong association was found with CO3 and 
NO2 (Schildcrout et al., 2006).   
COPD emergency department visits were associated with the daily ambient 
concentrations of PM10, SO2, NO2, CO and O3 in the City of São Paulo, Brazil (Arbex 
M A  et al., 2009). PM10 and SO2 readings showed both acute and lagged effects on 
COPD emergency department visits. Increases in CO concentration showed impacts 
in the female and elderly groups. NO2 and O3 presented mild effects on the elderly 
and in women, respectively (Arbex M A  et al., 2009). A study in Barcelona, found 
significant associations between the number of emergency room admissions for 
COPD and SO2 and Black Smoke (BS) (Sunyer et al., 1993). 
Medina-Ramon et al. (2006) analysed hospital admissions of COPD and pneumonia 
in relation to O3 and PM10 in 36 US cities. The study confirmed an increased risk of 
COPD and pneumonia admissions associated with ambient concentrations of PM10 
and O3. This study included a large number of cities and analysed more years of 
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follow-up than previous multicity studies on respiratory effects of PM10 and O3 
(Medina-Ramon et al., 2006). 
Pope A.C. et al (2004) observed, unlike previous studies, no association of elevated 
exposures to PM with prevalence of COPD symptoms. A possible reason for this is 
that the study relied on cause-of-death coding that has a potential for estimation 
bias for specific causes of death, such as COPD. COPD patients are likely to die 
from pneumonia or cardiovascular disease (Speizer et al., 1989, Pope Iii et al., 
2004). A study focusing on COPD patients living in rural areas of England, between 
2006 and 2007, did not observe any positive association between PM10, O3 and 
COPD, while positive relationships were observed between CO, NO2  and COPD 
admissions (Sauerzapf et al., 2009). 
Overall, the existing evidence suggests that air pollution contributes to the 
exacerbation of asthma and COPD, while the type of pollutants as well as the air 
pollution levels is modified by city characteristics, such as widely varying climates 
and geomorphology. 
1.2.3 Socioeconomic Status as Risk Factor for Asthma and COPD 
Socio-economic factors are linked to asthma and COPD, just like so many other 
diseases. Socio-economic characteristics of an area expressed as indicators of 
poverty or housing are linked to susceptibility (Jerrett and Finkelstein, 2005, Yen 
and Syme, 1999, Pickett and Pearl, 2001). Using local areas’ contextual data is an 
ecological approach accounting for population susceptibility. Even studies that 
control covariates at the individual level, such as cohort studies, can potentially 
misinterpret the impact of individuals susceptibility, when not taking into account 
local area effects (Jerrett and Finkelstein, 2005, Yen and Syme, 1999). According to 
Pickett and Pearl (2001) this is because “population inequalities in disease are not 
accounted for, by any known combination of individual genetic and environmental 
risk and must therefore be attributable to other unmeasured factors, some of which 
may operate at an aggregate level”. The community-level variables are discussed in 
detail in relevant literature (Wilkinson, 1996, Robert, 1998, Kennedy et al., 1996, 
Diez-Roux et al., 1997, Diez-Roux, 1998). 
1.2.3.1 Association of Socioeconomic Status to Asthma and COPD 
A relationship between social class and respiratory symptoms in adults was 
observed in an early UK study (Speizer and Tager, 1979). Many late studies 
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confirmed this (Cohen et al., 1977, Marmot et al., 1984, Higgins et al., 1977, Burr 
and Holliday, 1987, Demissie et al., 1996, Lebowitz et al., 1990).  
Two recent studies have shown significant association between greater 
neighborhood income inequality and higher childhood asthma hospitalization rates 
(Watson et al., 1996, Cagney and Browning, 2004). In New Zealand, Salmond et al. 
(1999) found a linear increase in a 12-month period prevalence of asthma with 
increasing area deprivation. In Vancouver, Canada, Lin et al. (2004) found that 
exposures to nitrogen dioxide were associated with asthma hospitalization for 
males in the low socioeconomic group but not in the high socioeconomic group. 
Nauenberg et al (1999) showed that low family income could predict better asthma 
exacerbations associated with air pollution than lack of insurance coverage, while 
Neidell (2004) reported that the effect of pollution was greater for children of lower 
socio-economic status (SES). 
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1.3 Medication for Asthma and COPD   
The majority of epidemiological studies that have investigated risk factors for 
asthma and COPD have used hospitalization and visits to emergency departments, 
to assess the relationship between respiratory conditions and ambient air pollution. 
In recent years, prescribing of respiratory medication has been used increasingly as 
a marker of respiratory diseases’ morbidity. I used prescribing of respiratory 
medication to assess asthma and COPD exacerbation in relation to air pollution. 
Next, I will describe the pharmacological interventions for asthma and COPD and 
review the studies that have adopted prescribing of respiratory medication as an 
indicator of air pollution effects on asthma and COPD. 
1.3.1 Pharmacological Interventions in Asthma and COPD  
The medication for asthma and COPD is classed into two main types: 1) β2-
agonists that dilate the airways (bronchi and bronchioles) facilitating airflow and 2) 
corticosteroids that are used for long-term management of asthma and COPD 
(British National Formulary, 2009). There are two types of β2-agonists, the short-
acting and long-acting β2-agonists. Short-acting β2-agonists (SABA) - often called 
short-acting bronchodilators or “quick relief” medication – help reduce asthma and 
COPD symptoms or stop the symptoms of an attack in progress. In cases where the 
airways obstruction is more severe the short-acting β2-agonists are prescribed 
regularly. In patients who remain symptomatic or have two or more exacerbations 
in a year, long-acting β2-agonists are prescribed (British National Formulary, 
2009). 
Mucolytic medication is related to COPD management, as it hydrolyzes mucus 
reducing its viscosity. This type of medication was used in many countries, such as 
Germany but currently its use is controversial. Studies on their efficacy at 
preventing exacerbations have shown that they are effective in preventing acute 
exacerbations (Allegra et al., 1996, Petty, 1990) but also that they are ineffective 
at preventing exacerbations or deterioration of lung function (Decramer et al., 
2005). Long-term studies with mucolytics have shown little effect on lung function 
or symptoms, although some have shown a reduction in exacerbations. The GOLD 
guidelines state that the widespread use of mucolytics cannot be recommended for 
COPD management, given the current evidence (Global Initiative for Chronic 
Obstructive Lung Disease (GOLD), 2008).  
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1.3.1.1  Prescribing of short-acting β2- agonists   
Respiratory prescriptions account for 7% of all prescribed drugs, in the UK (British 
Thoracic Society, 2006).  In England in 2004 about 51 million prescriptions were 
dispensed in the community for the prevention and treatment of respiratory 
disease. Almost half of these (24,785,000 or 49%) were for inhaled β2-agonists 
(bronchodilators) used in the treatment of asthma (Table 1-2) (British Thoracic 
Society, 2006).  
 
 
Prescriptions 
(thousands) 
General respiratory drugs 
 
Inhaled bronchodilators 24,785 
Inhaled corticosteroids 13,480 
Cromoglycate and realted therapy 74 
Leukotriene receptor antagonists 597 
Antihistamines, hyposensitisation and allergic 
emergencies 8,741 
Oxygen 704 
Mucolytics 97 
Aromatic inhalations 22 
Cough preparations 1,672 
Systemic nasal decongestants 624 
  
Antituberculous Drugs 71 
 
 
Cystic fibrosis drugs (pancreatin) 153 
  
Total 51,020 
this table does not include drugs dispensed in hospitals  
Table 1-2. Prescriptions used in the prevention and treatment of respiratory 
disease. England 2004 (Department of Health, 2004). 
 
Figure 1-10 shows the quantities of different types of medication prescribed for 
asthma and COPD in general practices in England. One of the most notable 
observations is that the short-acting β2-agonists were prescribed most often to 
treat asthma and COPD in England compared to other medication.  
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Figure 1-10. Prescribing of drugs for Asthma and COPD in General Practices in 
England (Prescription Pricing Authority, 2007). 
 
A second observation is that prescribing of medication increased over the last five 
years and this is mainly due to increased prescribing of Symbicort and Seretider 
(Figure 1-10). These are combination products containing a long-acting β2-agonist 
plus corticosteroid. However, concerns have been expressed recently regarding the 
side effects of the components of such combination products and the effectiveness 
of therapy and discontinuing of drugs that do not produce measurable 
improvements is reviewed (Prescription Pricing Authority, 2007). The prescribing of 
short-acting β2-agonists has not had any noticeable changes during the period of 
2002–2007, other than increasing in the quarter to December each year (Figure 
1-10). The drug salbutamol represents 93% of all prescribing for short-acting β2-
agonists and 89% of the cost (Prescription Pricing Authority, 2006).  
1.3.1.2 Respiratory Prescribing as Indicator for Respiratory Diseases 
The majority of studies that have analysed the association between air pollution 
and asthma and COPD used hospital admissions and attendance & emergency visits 
as indicators (Walters et al., 1994, Schwartz, 1994, Atkinson et al., 2001a, Tolbert 
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et al., 2000, Arbex M A  et al., 2009, Sunyer et al., 1993, Sunyer et al., 1997, 
Medina-Ramon et al., 2006). These indicators capture patients with severe asthma 
or COPD symptoms.  
According to the National Asthma Campaign only 20% of people with asthma are 
described as having a 'severe or very severe' asthma (National Asthma Campaign). 
There is lack of epidemiological data on COPD severity but a few studies that have 
investigated COPD severity reported that the majority of subjects analysed had 
mild COPD (Lindberg et al., 2006a). COPD prevalence was studied in Japan, and 
56% of cases were found to be mild, 38% moderate, 5% severe, and 1% very 
severe (Fukuchi et al., 2004), while a study in Korea reported that the majority of 
these cases were found to be mild in degree (Kim et al., 2005). 
The main advantage of prescribing in relation to traditional indicators for asthma 
and COPD is therefore the fact that prescribing is considered to capture patients 
from any severity class. The Asthma Insights and Reality in Europe (AIRE) Survey 
is a multi-national survey for the severity, control and management of asthma in 
children and adults (Vermeire et al., 2002). Medication usage was assessed among 
many other aspects of asthma control and management. Figure 1-11 shows that 
quick relief medication was prescribed to patients with any severity type. More 
details on AIRE study are presented in Appendix A. 
 
 
 
 
 
 
 
 
 
 
Figure 1-11. Asthma medication use per symptoms’ severity, Source: Asthma Insights 
and Reality in Europe (AIRE) Survey.  
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No similar data exist on use of medication per COPD severity class. As mentioned 
earlier, COPD is under-treated, which means a lack of appropriate medication use, 
especially corticosteroids that are suitable for long-term management of COPD. The 
lack of appropriate prescribing for long term management of COPD leads to patients 
having more frequent exacerbation of symptoms, making them rely more on the 
use of β2-agonists (quick relief medication). Therefore, I would expect that β2-
agonists would also be used often by COPD patients of any severity. 
Naureckas et. al. (2005) evaluated the use of short acting β2-agonist prescriptions 
as a surrogate indicator for asthma exacerbation with respect to traditional 
indicators (hospital admissions & emergency-department visits) during 1996-1998 
in Illinois, Chicago. They concluded that a very strong and significant association 
was observed between those two indicators, which suggested that β2-agonists 
prescriptions can be used as a marker for asthma morbidity (Naureckas et al., 
2005). 
1.3.2 Respiratory Prescribing as Indicator of Air Pollution Health Effects – 
Literature Review 
I found only a few studies that used respiratory prescribing as an indicator of the 
air pollution effect on respiratory exacerbations. I used the databases Web of 
Science, Medline and Scopus for my search. The searching keywords were 1) 
Topic=(respiratory prescribing) AND Topic=(air pollution), 2) Topic=(respiratory 
drug sales) AND Topic=(air pollution) and 3) Topic=(respiratory drug sales) AND 
Topic=(air pollution).  
My searches in May 2010 returned four studies  that analysed the association of 
respiratory prescribing in relation to air pollution (Laurent et al., 2009, Pitard et al., 
2004, Zeghnoun et al., 1999, Vegni et al., 2005). Three of the four studies were 
from France, while the fourth was conducted in Italy. To conduct such studies 
requires the availability of prescribing data at population level. Such availability is 
determined by the structure of the health care system of each country. I also 
located an unpublished study, currently in development, in California, US (Griffiths 
et al., 2009, Griffiths et al., 2003). I present below the studies and then discuss the 
main aspects on them.  
1.3.2.1 Literature Review Outcome 
Zeghnoun et al.’s (1999) study had a temporal ecological design, choosing 
respiratory medication sales data as an indicator for the short-term effects of 
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ambient air pollution in the city of Le Havre (200,000 inhabitants), in France, from 
June 1993 to December 1996. Mucolytic medication, prescribed for the 
management of COPD, as well as anti-cough medication for children and adults, 
were assessed in this study. The total number of daily respiratory drug sales data 
was related to daily ambient air concentrations of SO2, NO2, and black smoke (BS). 
The air pollutants concentration data were recorded by a number of stations and 
exposure was calculated as the average of values from the selected stations, 
defining a spatially homogenous air pollution exposure. They employed an 
autoregressive Poisson regression model adjusting for time trends, seasonal 
variations, influenza epidemics, and weather. Respiratory drug sale was associated 
with BS-24h, NO2-24h and SO2-1h, with reported lag 0 to 3 days. The strongest 
association was observed for BS-24h, where an increase of two standard deviations 
above the mean (13.2 to 36µg/m3) was linked to a 3.7% increase in respiratory 
drug sales, for 1 day lag. For NO2 and SO2, an increase of two standard deviations 
above the mean of NO2 h (33.7 to 64 µg/m
3, 1 day lag) and SO2 h (97.8 to 355 
µg/m3, 3 days lag) was associated respectively with an increase of 3.3% and 2.7% 
of respiratory drug sales. Respiratory drug sales were associated with most 
pollutants studied with lags varying from 1 to 9 days (Zeghnoun et al., 1999).  
Pitard et al. (2004) also used a temporal ecological design to assess the effect of air 
pollution on bronchodilators (β2-agonists), and cough and cold preparation sales in 
the city of Rouen (106,592 inhabitants), in France, from July 1998 to June 2000. 
Asthma and COPD medication was used (β2-agonists and corticosteroids) that 
represented 33% of the total respiratory drug sales in the city as well as cough and 
cold medication that represented 67% of the total respiratory drug sales. The air 
pollution exposure was calculated as the average of daily concentrations of NO2, 
SO2 and BS recorded by two air pollution stations, defining a spatially homogenous 
air pollution exposure. Lags of up to 10 days were included in the analysis for each 
pollutant. A generalized additive model (GAM) was employed, adjusting for day of 
the week, seasonal variation, influenza epidemics, weather and bank holidays. A 
10- µg/m3 BS increase was significantly associated with a 6.2% (95% CI, 2.4-
10.1%) increase in the sales of anti-asthmatic and COPD medication, and with a 
9.2% (95% CI, 5.9-12.6%) increase in the sales of cough and cold preparation for 
children aged under 15 years. For the anti-asthma and COPD medication, 
associations were found for lags ranging from 5 to 7 days with NO2, and for lags 
ranging from 1 to 7 days with BS. There was no association between SO2, and anti-
asthmatic and COPD drug sales. The results of this study suggested that an 
increase in anti-asthmatic and COPD drug sales was directly associated with BS and 
NO2 concentrations but not with SO2 (Pitard et al., 2004).  
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Vegni et al. (2005) also used a temporal ecological design. They evaluated 
respiratory drug dispensing data as a health indicator in relation to air pollution in 
the city of Como (84,713 inhabitants), in Italy, for 1995-1997. For this study, 
respiratory drugs were defined as the anti-asthma therapeutic group including both 
β2-agonists as well as corticosteroids prescribed by GPs. They used two health 
indicators: 1) count of individual patients with respiratory drug dispensed (Cases) 
and 2) weekly dispensed Daily Defined Doses (DDD) of drugs. Weekly air mean 
concentrations of total suspended particles (TSP) were recorded by one available 
station, defining a spatially homogenous exposure. The health indicators were 
modelled using a random effects Poisson regression model adjusted for long-term 
trends, seasonal variations, calendar variations due to holidays, and weather. The 
analysis showed a strong association of health indicators with pollution, with an 
increase of 8.2% (95% CI 0.2%-16.9%) of cases and 13.7% (95% CI 4.4%-
23.8%) for DDD from the 10th to 90th percentile of TSP (29-92 µg/m3). Overall, 
these results were interpreted as an approximate increase of 13% of Cases and 
22% of DDD for a 100 µg/m3 increase of TSP (Vegni et al., 2005).  
Laurent et al.’s (2009) spatio-temporal ecological study evaluated the short-term 
relations between ambient air pollution and sales of short-acting β2-agonists 
(SABA), in Strasbourg (450,000 inhabitants), France in 2004. The date, age group, 
sex and census block of residence were also extracted for each SABA sale. The 
Atmospheric Dispersion Modelling System (ADMS) urban Gaussian dispersion model 
was used to model hourly mean concentration of PM10, NO2 and O3  at small-area 
level (census block). Socioeconomic status, meteorological data, pollen counts as 
well as counts of influenza cases were included in the conditional logistic regression 
model. Increases of 10µg/m3 in ambient PM10, NO2, and O3 concentrations were 
associated, respectively, with increases of 7.5% (95% confidence interval [CI], 4 to 
11.2%), 8.4% (95% CI, 5 to 11.9%), and 1% (95% CI,- 0.3 to 2.2%) in SABA 
sales. Deprivation had no influence on these relations.  
The study by Griffiths et al (2009) is work in progress and I have not located 
relevant publications in peer reviewed journals as yet. Griffiths et al.’s (2009) 
spatio-temporal ecological study examined the effects of chronic exposure to air 
pollution on asthma exacerbation through asthma prescriptions for quick-relief 
medications (β2-agonists) in California, US, for each quarter from 1998 to 2001. 
They aggregated information on the use of maintenance therapies by each patient 
at the 5 digit zip code level in California. Using individual data they were able to 
stratify prescribing data by asthma severity as well as by age. The spatial variation 
of exposure to air pollutants PM10 and O3 was predicted for each zip code in 
California using ordinary kriging, capturing a spatial prediction of the ambient 
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pollution and weather conditions for each zip code, defining a heterogenous 
exposure (Griffiths et al., 2009). A negative binomial model was employed to 
approximate the expected number of prescriptions for each zip code  with additional 
covariates, such as the population demographics (e.g., median household income, 
percent urban population, race/ethnicity). In general, they reported a positive 
relationship between asthma and both PM10 and O3 levels (Griffiths et al., 2009). 
1.3.2.2 Discussion of Literature Review 
The points of discussion regarding these studies lie in the following areas: 1) air 
pollutants, 2) exposure assessment and 3) medication type. I will compare and 
discuss those areas below, in order to highlight the variation and challenges on this 
area of research. 
Respiratory medication 
The five studies presented above use asthma and/or COPD medication to 
investigate the association between air pollution and asthma and/or COPD. Two 
earlier studies (Pitard et al., 2004, Vegni et al., 2005) used β2-agonists and 
corticosteroids as indicators of respiratory symptoms (asthma and COPD), while the 
two most recent studies (Griffiths et al., 2009, Laurent et al., 2009) focused on 
short-acting β2-agonists as indicator of asthma exacerbation. The earliest study in 
this field, conducted by Zeghnoun et al. (1999), used mucolytic medication and 
anti-cough medication. 
Zeghnoun et al.’s  (1999) study initiated the use of respiratory prescribing as a 
health indicator of air pollution effects in respiratory diseases, however the specific 
medication they used as marker of COPD exacerbation should not be used 
anymore, given contradictory evidence on its efficacy. Choosing a medication as an 
indicator of a medical condition is not straightforward and a very good knowledge 
on medication and the disease under study is required.  
Air pollutants 
The Zeghnoun et al. (1999) and Pitard et al. (2004) studies from France used 
ambient concentrations of SO2, NO2, and BS as indicators of air quality. Vegni et al. 
(2005) in Italy used total suspended particles (TSP). The most recent published 
study by Laurent et al. (2009) used concentrations of PM10, NO2 and O3, and the 
unpublished study by Griffiths et al. (2009) also used concentrations of PM10 and O3 
as indicators of air quality.  
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Black smoke consists of fine solid particles suspended in air, which mainly arise 
from the incomplete burning of fossil fuels, in the domestic, industrial or transport 
sectors. Total suspended particulate matter (TSP) is a collective name for airborne 
particles or aerosols that are less than 100 micrometers. Most modern air pollution 
stations have stopped measuring BS or TSP and instead record  particulate matter 
of specific sizes (Table 1-1 page 19), such as PM10. The BS and TSP were reported 
by the earliest studies (Zeghnoun et al., 1999, Vegni et al., 2005, Pitard et al., 
2004), while the recent studies (Laurent et al., 2009, Griffiths et al., 2009) have 
used PM10. I have also used PM10 as air quality indicator,  therefore my study is 
most similar to the two most recent studies.   
Pollutants recorded in the same station are correlated most of the time. Zeghnoun 
et al. (1999), Pitard et al. (2004), Laurent et al. (2009) and Griffiths et al. (2009) 
also reported that the mean levels of air pollutant concentrations measured at 
stations appear to be highly correlated in time. Due to the correlation of air 
pollutants replication of information can occur when using all in the same model, as 
indicators of air quality. 
Air pollution exposure 
The previous studies on air pollution and respiratory prescribing assumed 
homogenous air quality exposure except the study of Laurent et al. (2009)  where 
heterogeneous exposure was estimated at census block level. The study under 
development has also used heterogeneous exposure (Griffiths et al., 2009). 
Preliminary work for this study in 2003, had assumed homogenous exposure and 
the authors had reported that their initial model suffered from the lack of 
heterogeneity (Griffiths et al., 2003). 
The assumption of homogenous air pollution exposure on the other studies may be 
related to the absence of an air pollution monitoring network. Many epidemiological 
studies in the past have used homogenous exposure (Katsouyanni et al., 1996). 
Vegni et all (2005) explicitly stated the presence of only one monitoring station in 
the area. The most recent published study by Laurent et al. (2009) reported the 
use of the existed urban atmospheric dispersion model ADMS to model air exposure 
in time (hourly) and at small-area level (census block).   
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Covariates 
All previous studies used air pollutants, which are the primary factors of concern 
but also included additional covariates that are relevant to worsening of respiratory 
symptoms. The three earlier studies (Zeghnoun et al., 1999, Vegni et al., 2005, 
Pitard et al., 2004) controlled for seasonal factors, influenza, pollen levels, and 
weather (temperature and humidity). In addition, the studies by Zeghnoun et al. 
(1999) and Pitard et al (2004) took into consideration  the day of the week and 
bank holidays. Both studies analysed daily data and observed zero pharmacy sales 
of respiratory medication (prescribed by GPs) on specific days (i.e. Sundays).  
Vegni et al. (2005), on the other hand, stated that they aggregated the data on a 
weekly basis avoiding assumptions on the closure days of different pharmacies and 
complicating the model. 
Vegni et al.’s (2005) model investigated only the effect of air pollution on a weekly 
basis. No attempt was made to assess lag times on cumulative periods of exposure 
and respiratory medication sales. In contrast, other studies tested whether there 
may be a lag period between air pollution exposure and sales/prescribing of 
respiratory medication. Zeghnoun et al. (1999) investigated lags of 1 to 14 days 
and found strong associations for lags 0 to 3 days as well as 6 to 9 days. Pitard et 
al. (2004) included lags up to 10 days. The strongest associations were observed 
for 6 to 7 days lag with NO2, and 2 to 5 days lag for BS. The most recent published 
study (Laurent et al., 2009) observed associations involving latency periods of 4 to 
10 days. Finally, no analysis of lag days was reported in the ongoing study of 
Griffiths et al (2009), even though they discussed that increase in asthma 
medication use due to air pollution exposure eventually (perhaps with a lag) leads 
to the filling of a prescription. 
The recent study in France (Laurent et al., 2009) accounted for socioeconomic 
characteristics in addition to the other covariates. They used an index of 
socioeconomic status built from 52 socioeconomic variables (income, educational 
level, employment, housing characteristics). Overall, socioeconomic status was not 
found to be a significant covariate. The authors discussed that similar studies in 
other settings should confirm whether the lack of interaction with deprivation was 
due to specific local conditions. The ongoing study by Griffiths (2009) includes 
population characteristics, such as median household income, percent urban 
population and race/ethnicity as well as seasonal or quarterly factors. In this study 
household income was negative statistically significant, suggesting that households 
with lower incomes obtained more asthma prescriptions. 
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1.4 Primary Care and Chronic Diseases 
In 2007, the World Health Assembly set out actions to be implemented over the 
next six years, in order to prevent and control chronic non-communicable diseases, 
such as asthma and COPD (World Health Organization, 2008a). Part of the plan to 
achieve this was to strengthen the management of the diseases in primary health 
care and use accessibility of medication in primary care as an indicator to monitor 
progress (World Health Organization, 2008b). In order to use primary care based 
prescribing data as an indicator, baselines of medication use have to be available, 
which will have to be established by collecting relevant data (World Health 
Organization, 2008b). In the UK, a consistent priority for NHS reform is the shift 
from provision of hospital-based acute care to proactive care delivered in primary 
care (Department of Health, 2006, Department of Health, 2005, Department of 
Health, 2010). The importance of exploiting data at primary care level and 
especially data of respiratory diseases is discussed below.  
1.4.1 Primary Care and Chronic Respiratory Diseases 
Most epidemiological studies use data from secondary and tertiary care such as 
hospitals and emergency care, even though the vast majority of patients are fully 
dealt with at the primary care level. The important role of primary care for health 
services has been well recognised (World Health Organization, 1978, World Health 
Organization, 2003) and the UK is one of the countries that has developed it 
comprehensively (Starfield B et al., 2005, Starfield B., 1994).  The majority of 
primary care consultations in the UK are for patients with respiratory disease 
(Pinnock and Sheikh, 2009, British Thoracic Society, 2006), emphasizing the 
significant role of primary care in managing respiratory diseases.  
High quality research, focusing on primary care management, is fundamental to 
understanding and developing a comprehensive healthcare service for respiratory 
disease. Several studies have been conducted regarding management of respiratory 
diseases at a primary care level. However, I located only two studies that utilized 
GP level respiratory data from an environmental health perspective, in UK (Hajat S. 
et al., 1999, Dunn et al., 1995). Dunn et al. (1995) investigated airborne emissions 
from a factory (producing plastic coated wallpaper) and prevalence of asthma as 
identified from a computerised repeat prescribing system of three GP practices. 
Hajat et al. (1999) investigated the relationship between daily GP consultations for 
asthma and other lower respiratory diseases (LRD) and air pollution in London.  
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One of the main challenges in environmental epidemiology is linking health data to 
environmental and socioeconomic data that are available on spatially and 
temporally misaligned units.   
1.4.2 Spatial Analysis of Primary Care Population Data  
If patients want to access primary care services in UK, they register with a GP 
practice, and there are no geographic constraints on their choice. However, most 
people choose to register with a practice that is close to the place they live or work. 
Several factors such as area deprivation and transportation links or other factors 
may influence their choice. Consequently, there is no formal definition of 
boundaries of primary care service areas and the population of any given area can 
be affiliated to a number of practices. A traditional way to define GP practice 
catchment areas has been to align them to administrative boundaries (Congdon 
and Best, 2000). If we assume that 60% of a practice population A come from the 
administrative spatial unit of Lower Social Output Area (LSOA) 1 and 40% come 
from practice population B, then this LSOA would be part of practice A catchment 
area. 
The use of administrative boundaries is a common method for the regionalisation of 
health care and there are certain advantages of such approach. Main advantages 
are that these spatial units are readily available and represent to some extent the 
area the practice population live. Main disadvantages are that they provide no 
information on the overlap between catchment areas, as they form adjacent spatial 
units, and they are rough approximations of the distribution of registered patients, 
so few will probably relate directly to the GP health service utilisation areas. In 
addition, because they are not accurate, any measure on catchment areas or 
health, well-being and determinants of ill-health within them can result in 
compromising the reliability of those measurements. In particular, the spatial 
distribution of environmental data does not follow the spatial distribution of 
administrative boundaries. Therefore, when using the traditional GP catchment 
areas to derive measures of environmental exposure of a practice population 
increases error in exposure misclassification. 
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1.5 Spatial Analysis  
Spatial analysis is defined as the: “the quantitative study of phenomena that are 
located in space” (Bailey and Gatrell, 1995). Epidemiology has a geographical basis 
when it characterises disease occurrence by time and place. Consequently disease 
mapping has a long tradition (Timmreck, 2002), dating back to 1800s when maps 
of diseases were used to analyse causes and spread of disease outbreaks (Walter, 
2000).  
Over the last two decades, epidemiologists have applied statistical spatial analysis 
in geographical information systems (GIS). Studies have looked at cases of 
leukaemia, lymphoma, larynx and lung cancer in relation to industries (Gardner et 
al., 1990, Elliott et al., 1992, Elliott and Wartenberg, 2004). This type of spatial 
analysis has been previously used extensively in other scientific disciplines, such as 
ecology, economics and sociology (Diggle, 1983 , Bronars and Jansen, 1987, White 
et al., 1981, Rushton et al., 2006, Rushton et al., 1997, Lurz et al., 1997). 
Geographical Information Systems (GIS) and statistical spatial analyses are 
applications of what is known as spatial analysis. Spatial analysis is used to: 1) 
increase the basic understanding of spatial processes, 2) test hypothesis regarding 
the relationship of the variables under study and at best 3) predict the strength of 
the relationship of variables in the future.  
1.5.1 Geographical Information Systems  
GIS is a computer based technology that captures, stores, analyses and presents 
data which are referenced spatially on the earth’s surface. Spatial data used in a 
GIS environment can be generated by satellites, digital aerial photographs and 
Global Positioning Systems (GPS) as well as by scanning and digitising paper maps 
and aerial photographs (Schuurman, 2004). Conversion of postcodes to grid 
references is also a method for acquiring spatial data, called geo-coding (Crampton, 
2005). Core functionality of GIS is the creation and display of maps electronically. 
Two of the most useful GIS operations are overlay and proximity analysis (Heywood 
et al., 1998). With overlay analysis it is possible to integrate large amounts of data 
in map layers format (i.e. overlay asthma health outcomes on air pollution and 
socio-economic data). Proximity analysis is used to determine relationships 
between selected points or areas and their neighbours (i.e. identify the population 
present in a 2.5km radius around an industrial facility).  
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The true power of GIS, however, lies in its modelling and exploratory capability. 
Modelling is applied when we want to test a hypothesis or estimate the relationship 
between two or more variables with some precision. Exploratory analysis on the 
other hand may lead to insights into the data and formulation of a hypothesis 
(Fotheringham and Rogerson, 1994, Bailey and Gatrell, 1995). Modelling and 
exploratory analysis can not always be clearly distinguished. This is due to the level 
of complexity of various techniques. Examples of this are the widely used 
interpolation techniques. With such techniques it is possible to estimate values of 
variables in unsampled areas, based on data provided from sampled areas (i.e. 
estimate air pollution based on air pollution monitoring). Some interpolation 
techniques such as ordinary or universal kriging require statistical modelling and 
are described as models, while other simpler techniques such as Thiessen polygons 
fall into exploratory analysis (Bailey and Gatrell, 1995). Statistical analysis is not a 
primary operation in GIS software, therefore it is linked to statistical software when 
statistical modelling is involved.  
A range of GIS operations and functionalities have been used for research on 
asthma and air pollution. Wilkinson (1999) assessed the hospital admission of 
children with asthma in relation to road traffic in London, using proximity analysis 
(Wilkinson et al., 1999). Lu et al. (2003) analysed ozone and asthma in children in 
the South Coast of California, using a kriging interpolation technique to estimate air 
pollution and a Poisson spatial regression model (Lu et al., 2003). Maantay (2007) 
investigated asthma and air pollution in the Bronx, New York, using proximity 
analysis as well as applying air dispersion modelling for estimating exposure.  
GIS techniques have been widely used for public health research.  WHO, European 
Community (EC) and Centre of Disease Control and Prevention (CDC) recommend 
such techniques for environmental health studies (World Health Organization, 1994, 
National Center for Health Statistics, 2005, European Commission, 2004). A variety 
of GIS software is now available, both commercial and open source (software 
developed and distributed free), that allows storing and manipulating of all different 
types of digital spatial data. The commercial software ArcGIS and the open source 
GRASS GIS (Neteler and Mitasova, 2004) are two of the most software packages 
(Kennedy, 2006).  
1.5.2 Spatial Statistical Modelling  
Spatial statistical modelling is determined by the theories of spatial statistics that 
give explicit consideration to the possible importance of the spatial arrangement of 
spatial data. Spatial statistics was developed during the late 40s and early 50s by 
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statisticians such as Moran, Geary and Whittle (Florax and van der Vlist, 2003). The 
development of spatial statistics was slow until the early 1970s when Cliff and Ord 
presented their influential work on spatial autocorrelation (Cliff and Ord, 1973). In 
the 1980s, Cliff and Ord added models and applications of spatial processes with an 
example from epidemiology. They analysed the spatial pattern of cholera in London 
(Cliff and Ord, 1973, Cliff and Ord, 1981). Since then the literature on spatial 
statistical analysis has been expanded as well as their application (Diggle and 
Ribeiro Jr, 2007, Lawson, 2001, Lawson, 2009, Elliott et al., 2000, Waller and 
Gotway, 2004b, Cressie, 1993). 
Spatial statistics focus on two spatial effects: spatial heterogeneity and 
autocorrelation. Spatial heterogeneity refers to the variability between entities and 
processes in space (Fotheringham and Rogerson, 1994). Spatial autocorrelation 
refers to the level of interdependence between those processes as well as the 
nature and strength of their interdependence (Cliff and Ord, 1973). The idea of 
spatial interdependence can be to some extent expressed by Tobler’s Law of 
Geography: “everything is related to everything else, but near things are more 
related than distant things” (Tobler, 1970). Spatial autocorrelation tests should be 
carried out for the residuals of a model, as the presence of such correlation 
amongst the residuals indicates inadequacy of the regression model (Maguire et al., 
2005).  In my analysis, I used spatial autocorrelation tests to examine the residuals 
of the final statistical model for spatial interdependence. 
Accounting for spatial autocorrelation allows more realistic inferences to be made, 
although due to the wide range of spatial models the selection of an appropriate 
model is often not straightforward (Langford, 1994, Goldstein, 1995). Some spatial 
models assess the variation of spatial patterns over time and space. These are 
called spatio-temporal models and are considered an improvement of simple spatial 
models. Various techniques have been applied for spatio-temporal analysis of 
mortality rates, ranging from log-linear regression (Cogdon, 1994), to more 
complex techniques such as thin plate splines (van der Linde et al., 1995), and 
more recently to mixed effects or random effects models. Mixed effects models take 
into account fixed and random effects related to the phenomenon under study that 
in turn allows accounting for complex spatio-temporal structures (Gelman, 1995, 
Gelman et al., 2009, Pinheiro and Bates, 2000).  
Mixed-effects models can be implemented either in a frequentist or Bayesian 
context (Xia and Carlin, 1998, Richardson et al., 2006). Markov Chain Monte Carlo 
(MCMC) algorithms have revolutionized both approaches to frequentist and 
Bayesian statistical inference but primarily Bayesian (Maritz and Lwin, 1989, Carlin 
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and Louis, 1996). Bayesian models have been used for assessing paediatric asthma 
hospitalizations in relation to traffic density in San Diego (Zhu et al., 2000) as well 
as ambient O3 concentrations and paediatric asthma emergency room visits in 
Atlanta (Zhu et al., 2003). 
1.5.3 Spatial Analysis of Health Data and Policy Making  
In May 2007, a Directive establishing an Infrastructure for Spatial Information in 
Europe (INSPIRE) was published and came into effect on 31 December 2009. One 
of the themes of INSPIRE is Human Health. INSPIRE does not intend to initiate a 
programme of new spatial data collection but instead “it is designed to optimise the 
scope of exploiting the data that are already available” (Commission of the 
European Communities, 2004). One of the most important Directives that INSPIRE 
complements is the Directive on the Re-use of Public Sector Information. The 
Directive on Re-use of Public Sector Information applies amongst others to NHS and 
local authorities and was implemented in the UK on 1st July 2005 (Office of Public 
Sector Information, 2005).  
The INSPIRE directive complements other important policies, such as the Global 
Monitoring for Environment and Security (GMES) Directive as well as the European 
Environment and Health Strategy. GMES directive will bring an understanding of 
environmental factors potentially having adverse health effects and identifies air 
pollution as a major environmental health problem (Commission of the European 
Communities, 2004). In order to increase knowledge on those issues it is 
recognised that links should be established between environmental, geographical 
and health data (Commission of the European Communities, 2004).  
In addition, the European Environmental and Health Action Strategy proposes the 
development of tools that link spatial health and environmental data, picturing of 
the demography and exposure patterns contributing to adverse health effects. 
Moreover it identifies asthma as one of the six priority diseases for which further 
research is required. This policy, complemented by INSPIRE could, for example, 
improve the identification of those at risk of respiratory diseases and target 
measures to reduce those risks (INSIPRE Framework definition support working 
group, 2003).  
A preliminary estimation of the benefits of INSPIRE shows that one of the greater 
benefits will be the development of policies that reduce the impact of environmental 
pollution on health (INSIPRE Framework definition support working group, 2003). A 
pan-government initiative to improve the sharing and re-use of public sector 
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location information and implementation of INSPIRE, called UK Location, was 
established in UK (DEFRA, 2010). This study utilises existing spatial data as well as 
re-using information from the NHS and Local Authorities, to provide results on 
respiratory health outcome in primary care. 
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Chapter 2. Data Collection and Exploration 
This is a study of ecological design at primary health care level, accounting for both 
temporal and spatial variability. The study area comprised the area of Newcastle-
upon-Tyne and North Tyneside Primary Care Trusts (PCTs), in the Northeast of 
England, for the period of January 2002 until July 2006 (Figure 2-1). PCTs are local 
organisations and their role is to commission health services. The recent reform of 
the NHS has set GP consortia the leading role for commissioning health services 
(Department of Health, 2010). Every UK resident has access to GP practice services 
regardless of income or insurance cover. The total population under study was 
approximately 450,000 according to the 2001 Census (Newcastle: 260,000, North 
Tyneside: 90,000). 
All data had to be subject to exploratory analysis, in order to be converted to the 
appropriate temporal and spatial format that would allow them to be used as 
variables in a statistical model. In the first section, I present the respiratory 
prescribing data as well as the patients’ data and how they were used to define GP 
service areas. In the second section I present the air quality indicators, while the 
socioeconomic and demographic (age and sex) characteristic of patients registered 
per GP practice are presented in the third and forth section, respectively. 
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Figure 2-1. Study area 
 
2.1 Health Data 
I accessed respiratory prescribing data from the Regional Drugs and Therapeutics 
Centre (RDTC) and the patients’ data per GP practice from the Exeter database, via 
the North East Public Health Observatory (NEPHO). In order to access both 
datasets, ethical approval was required by the PCTs’ Caldicott Guardians. It took 
over a year to get approval for accessing the health data.  
2.1.1 Respiratory Prescribing Data 
The Newcastle RDTC holds prescribing data for England. They are based on 
prescriptions that are handed into pharmacies. These get forwarded to RDTC where 
they are added into a database. The data I accessed are not linked to individual 
patients but only to their prescribing GP practices. The prescribing data were 
available to me aggregated per month. Prescribing data were retained on the 
prescribing system for 60 months. The asthma prescribing data were acquired on 
22/12/2006 for the period: 01/11/2001–31/10/2006. In order to link the 
prescribing data to the other datasets of interest, I removed two months from the 
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beginning and three months from the end of the dataset, analysing a total of 55 
(01/01/2002 – 31/07/2006) months of salbutamol prescribing data. The prescribing 
data for this period covered approximately 67 billion Average Daily Quantities 
(ADQs) (Prescribing Support Unit, 2000). ADQ is a unit of measurement developed 
in order to calculate drug volume usage more accurately than the prescription item 
(Walley and Roberts, 2000). 
Consulting a respiratory physician and a GP as well as studies on asthma and COPD 
pharmacological interventions (British National Formulary, 2009), I decided to 
access data for short-acting β2-agonists as an indicator of asthma and COPD 
exacerbations (British Thoracic Society, 2006). Short-acting β2-agonist inhalers are 
quick-relief medication, available as salbutamol, salmeterol, turbetaline and 
formoterol (British National Formulary, 2009). Salbutamol was employed in this 
study, as it is the drug most frequently prescribed, accounting for 93% of all short-
acting β2 agonists prescriptions (Prescription Pricing Division, 2008). 
2.1.1.1 Exploring Prescribing Data 
The WHO produces the Defined Daily Dose (DDD) values for measuring prescribing 
volume, however DDD included data from many countries outside Europe, making 
these values less appropriate for measuring drug volume usage in a European 
country (Whiteside et al., 2001). The measurement unit ADQ was developed by an 
expert group in 1995 to be used for the analysis of English prescribing data 
(Prescribing Support Unit, 2005). ADQ is designed to be used as a numerator or 
denominator in studying variations in prescribing between general practices or 
primary care groups. All salbutamol data were standardised by total number of 
people registered with each GP before the analysis, therefore the unit of analysis 
was ADQs per 1,000 population.  
The inhaler containing salbutamol medication is prescribed in a standard size, in 
England. Each inhaler contains 200 inhalations, also called doses or puffs, which is 
equivalent to 100mcg. The maximum suggested daily dose for adults is 8 puffs. 
This is important as all patients have the same amount of medication to consume, 
therefore the period between replenishing an inhaler is affected only by the 
frequency of medication use. I created a conceptual model on three simple 
scenarios of inhaler usage. The scenarios I have created are a coarse 
representations of reality as inhaler consumption is determined by several factors 
that often vary daily. Nonetheless, these scenarios can provide a broad estimate of 
the period in which patients would consume most of their inhaler and then seek to 
replenish it. The first scenario assumes that 8 doses (the maximum suggested 
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doses) are consumed daily, while 5 and 2 doses are assumed on the second and 
third scenarios, respectively (Table 2-1). According to the first scenario, a patient 
can consume most of the inhaler in 21 days (three weeks). A less frequent use 
represented by the second scenario showed that 30 days (four weeks) is the time 
that most of the medication would be consumed, while the last scenario of 
infrequent use showed that the medication could last for almost two months.  
I wanted to check how frequently one can consume the daily maximum suggested 
8-doses of salbutamol.  After communication with a patient who suffered from 
severe chronic asthma, I found that salbutamol may also be prescribed “as 
needed”, allowing consumption of more than 8 doses per day (Appendix B). In 
addition, this patient consumed double the maximum suggested daily dose for a 
few months (Personal communication with Alison Copeland, May 2010), which led 
to a much shorter period (7-14 days) before need for inhaler replenishment.  
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Scenario A :  8 doses - maximum suggested dose  
Days of Inhaler 
Consumption Dose Total Dose 
Proportion of Inhalers 
Consumed 
58 8 464 2.3 
51 8 408 2.0 
44 8 352 1.8 
37 8 296 1.5 
30 8 240 1.2 
21 8 168 0.8 
14 8 112 0.6 
7 8 56 0.3 
    
Scenario B : 5 doses  
Days of Inhaler 
Consumption Dose Total Dose 
Proportion of Inhalers 
Consumed 
58 5 290 1.5 
51 5 255 1.3 
44 5 220 1.1 
37 5 185 0.9 
30 5 150 0.8 
21 5 105 0.5 
14 5 70 0.4 
7 5 35 0.2 
    
Scenario C : 2 doses - minimum usual dose   
Days of Inhaler 
Consumption Dose Total Dose 
Proportion of Inhalers 
Consumed 
58 3 174 0.9 
51 3 153 0.8 
44 3 132 0.7 
37 3 111 0.6 
30 3 90 0.5 
21 3 63 0.3 
14 3 42 0.2 
7 3 21 0.1 
Table 2-1. Scenarios on inhaler consumption 
2.1.1.2 Discussion/Conclusions 
Newcastle RDTC archives the prescribing data older than 5 years and it was not 
possible to easily access them after they had been archived. Accessing prescribing 
data for periods longer than 5 years where data exist, is important for 
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epidemiological studies which benefit from longer time trends. It is a great 
advantage to have prescribing data in electronic format for several years.  
Not all countries can use prescribing data in epidemiological public health research 
because the population the prescriptions refer to is not always known. The 
availability of population based prescribing data depends on the health system of 
each country. For example, in United Kingdom and France it is possible to know the 
population that the prescribing refers to, while in other countries such as Germany 
this is not known and therefore it is not possible to use this as health indicator of a 
population. 
The electronic prescribing data were well edited and organised, requiring little 
editing before analysing them. Finally, the RDTC database system did not allow a 
distinction between salbutamol prescribed to people suffering from asthma or 
COPD, however plans existed on how the database could also provide prescribing 
data per diagnosis, in the future. 
The three salbutamol consumption scenarios I created are very basic, however they 
show that a patient would look to replenish his/her inhaler after a period of three 
weeks (21 days) to two months and probably more. In addition, after my 
communication with a patient who was prescribed salbutamol medication, I found 
evidence that more than 8-doses can be used daily, causing shorter replenishment 
periods (7-14 days). 
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2.1.2 Practice Population Data 
Postcodes are an abbreviated form of address in the UK. On average there are 15 
delivery points per postcode (Cabinet Office, 2009). The patients’ postcodes per 
practice were provided for the 1st of April for each year of interest and assumed to 
remain the same for the rest of the year. The patients’ data were unlinked to 
individuals and to prescribing data. I obtained over 2 million postcodes of patients 
for the period 2002-2006. I used an Access database and GIS to clean the 
datasets, explore and link them to prescribing data. The main issues I faced when 
editing the population data are presented below. 
Outliers: I removed outliers from the patients’ postcodes dataset. There 
were a few postcodes (approximately 10) that were not based within the 
Northeast Region (e.g. Wales).  I considered it unlikely that those postcodes 
were correct patients’ residence addresses. They were probably caused by 
data entry mistakes. I considered these as outliers and removed them from 
the dataset. 
Datasets Linkage: I linked the GP population dataset to the prescribing 
dataset based on the matching GP practice codes. I was in contact with the 
North East Family Health Services Agency (2008), to check why some GP 
practices did not match between the two datasets.  I went through the 
unmatched GP codes, in order to check that no one, who should have been 
included was missing. Some practice codes that appeared in the population 
data were irrelevant to asthma prescribing, as some practices specialized in 
specific health outcomes, such as sexual diseases. In another case a GP 
practice had ceased operation during the study period.   
Missing Data: I discovered that some patients had no GP practice assigned 
to them. A cluster of missing data appeared in North Tyneside PCT. The 
North East Family Health Services Agency could not help me in tracing 
individuals’ records; therefore I contacted the North Tyneside PCT directly. 
After providing information on the missing data and relevant maps, I found 
that the GP practice those patients were registered with, was the A86029 
practice (Figure 2-2). This had been caused due to a database management 
error, during the data transfer between two government bodies.  
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Figure 2-2. Postcodes of patients with no GP practice assigned to them 
 
The annual numbers of patients per PCT are presented on Table 2-2, while a map of 
the GP practices is shown in Figure 2-2. A list of practices’ names that correspond 
to each practice code is presented in Appendix C. 
 
 
 
Year 
Newcastle PCT  
(35 GP practices) 
North Tyneside PCT   
(29 GP practices) 
2002 230,464 173,123 
2003 236,181 179,391 
2004 244,023 185,314 
2005 252,845 191,711 
2006 264,614 199,545 
Table 2-2. Number of patients per PCT per year.
 
  
 
 
Figure 2-3. GP practices in Newcastle and North Tyneside PCTs.
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2.1.2.1 Visual Exploration of Patients Data  
Figure 2-4 shows the distribution of patients’ postcodes that were mainly 
distributed within the study area. I plotted the same data also in grid format, in 
order to show the counts of postcodes in the study area. 
 
 
Figure 2-4. Postcodes of GP registered patients in the study area. 
 
 
 
Figure 2-5 shows the number of postcodes for sub-regions of the study area, in grid 
format. We noted that some grids had thousands of postcodes, others had 
hundreds or tens, while a few postcodes were distributed sparsely in the periphery. 
Comparing the output of the grid plot to local knowledge of the area, revealed that 
the high numbers of postcodes coincided with the two main residential areas; 
Newcastle upon Tyne city centre and the area of Tynemouth, located at the eastern 
border of North Tyneside. 
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Figure 2-5. Grid format: Counts of patients’ postcodes in sub-regions of the study 
area. 
 
2.1.2.2 Spatial Exploration of Patients’ Data 
I started the analysis by separating the patients’ postcodes by practice and drawing 
a Minimum Convex Polygon (MCP) for each one. Figure 2-6 depicts the service 
areas by GP practice for Newcastle and North Tyneside PCTs. It appeared that there 
was a tremendous amount of overlap between GP service areas within and between 
the two PCTs. Many GP practices appeared to serve very similar areas that covered 
the majority of the study area. Therefore, this method was not useful for capturing 
the GP service areas for the purpose of my further analysis. Some refinement was 
required to estimate service areas. As a next step, I used kernel analysis to define 
the area that each practice served.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-6. Service areas per GP practice, as defined by Minimum Convex Polygons. 
 
 
GP service areas 
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GP service areas 
Newcastle PCT 2006 
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Kernel estimation was developed to obtain a smooth estimate of a probability 
density from an observed sample of observations. The density of points is 
calculated using a bandwidth specified to a circle of a given radius centred at each 
point of interest. I used kernel analysis to estimate the patients density per GP and 
define a spatial unit that could depict the area where the majority of patients were 
expected to reside. There are various types of kernels, but the quartic kernel is the 
most widely used (Bailey and Gatrell, 1995). The formula for this is given as:  
∑
≤
−=
τ
τ τpi
λ
ih
ihs )/1(
3)( 22                                                                                (1) 
where, λτ(s) is the intensity at the point of estimate s, hi is the distance between the 
point s and the observed event location si and τ is the bandwidth which is sampled 
around point s. The region of influence within which observed events contribute to 
λτ(s) is a circle of radius τ centred on s. The selection of the bandwidth is critical for 
kernel estimation, as it can cause over or under smoothing. Methods to estimate 
bandwidths are discussed in the relevant literature (Waller and Gotway, 2004a, 
Silverman, 1986, Scott, 1992). I used Equation 2 for calculating the bandwidth, as 
suggested by Bailey and Gatrell (1995): 
2.068,0 −= nτ                                                                                                (2) 
where n is the number of spatial observations (postcodes of registered patients) per 
GP. The output of this equation was scaled up to fit the particular dimensions of the 
areas that the total n per GP was distributed in. Those areas were estimated by 
calculating the surface of each minimum convex polygon. The output values of 
kernel analysis produced continuous maps in raster format with a cell size of 25m. 
I then used contour lines to define spatial units that represented GP service areas. 
Three contour lines were created per GP practice that contained 95%, 98% and 
99% of the practice population, respectively. I conducted the analysis for these 
three cut off points to check how sensitive the analysis was to this factor. The 
contour lines cut-off points are produced automatically by most software, according 
to the values of the raster map, and it is not possible for the user to define cut-off 
points. For this analysis, I required consistent cut-off points to define the contour 
lines, so that service areas would be comparable per year and per GP practice. By 
adding an algorithm in ArcGIS I managed to define the cut-off for the contours’ 
creation. The analysis of GP practice population data was conducted using ArcGIS 
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software (ESRI) with the Spatial Analyst and Hawth’s Tool extensions (Beyer, 
2004). 
2.1.2.3 Results – GP Practice Service Areas 
Kernel analysis took into account the density of patients’ postcodes. Service areas 
were estimated for each of the 64 GPs for five years, creating in total 320 service 
areas. Because of the large number of GP practices I used seven GP practices to 
demonstrate the results of kernel analysis.  
Figure 2-7 presents an example of a few raster maps produced by kernel analysis, 
showing the density of patients for seven GP practices in the area. In some cases a 
lot of patients were concentrated in a small area creating high values of intensity, 
while in other cases the intensity was less as the postcodes were distributed in a 
wider area. As a final step of the analysis, the borders of each GP practice area 
were calculated based on the values of kernel probability density distribution. 
Figure 2-8 shows the area that 98% of registered patients are expected to live in 
per GP practice.  In Figure 2-9, I also present the area that all registered patients 
live per practice, in order to allow comparison between the areas drawn using the 
minimum convex polygons and kernel analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-7. Raster maps produced by kernel analysis showing the density of 
patients per GP practice. 
 
 
Study Area 
 Kernel values 
A86026 
A86008 
A87017 A87612 
A87020 
A87030 
A86011 
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Figure 2-8 Contour lines representing the GP practice service areas. 
 
Figure 2-9 Minimum convex polygons showing the area that all registered patients 
live, per GP practice. 
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As mentioned earlier, I created three contour lines per GP practice that contained 
the 95%, 98% and 99% of the practice population, in order to check the sensitivity 
of the GP service area to different cut off points. Figure 2-10, Figure 2-11, Figure 
2-12 and Figure 2-13 show examples of the contour lines that were produced as GP 
service area, for the 95%, 98% and 99% of kernel probability density distribution, 
respectively. Little variation was observed between the three cut off points. I 
decided to use the middle contour line that is the area that 98% of the patients are 
expected to live in, to define the GP service areas. I chose such a high value as the 
cut off point, as I wanted to remove areas that did not represent the exposure 
conditions of the majority of patients but at the same time I wanted to include the 
area in which the vast majority of registered patients lived.  
 
 
 
Figure 2-10 Examples of GP practice service areas.  
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Figure 2-11 Examples of GP practice service areas 
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Figure 2-12 Examples of GP practice service areas 
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Figure 2-13 Examples of GP practice service areas 
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The service areas for all 64 GP practices, as summarised by kernel analysis, are 
presented in Appendix D. In Appendix E,  I present the service areas for each of the 
five years of the study to demonstrate that very little variation existed in service 
areas through the years of the study.  
 
2.1.2.4 Discussion/Conclusions 
Results 
Kernels have often been used in ecology to assess habitat selection and population 
dynamics and have been recently used in health research (Petersen J. et al., 2008, 
Lurz et al., 1997). Gatrell AC et al. (1996) have discussed the use of kernel density 
in geographical epidemiology and its application has been demonstrated in public 
health research recently (Shi X, 2009, Carlos et al., Petersen et al., 2009). Caution 
is required to define the bandwidth when applying kernel analysis. There is no 
unique equation to determine the selection of bandwidth, however there are a few 
proposed, like the one I employed. The responsibility lies on the researcher to 
examine whether the kernel output is a meaningful and representative summary of 
point observations. I considered the contour lines created based on kernel analysis 
to be representative summaries of the areas that registered patients were expected 
to live in. 
Potential for Future Applications 
Patients’ postcodes are considered as sensitive data by the NHS and confidentiality 
rules apply to their storage and analysis. Kernel analysis allowed me to completely 
anonymise them by converting point data to area data and therefore removing 
consideration of individuals’ identification. Ecologial studies that use aggregated 
rather than point data are useful in epidemiology, provided that their limitations are 
understood and their results are interpreted carefully.  
The fact that GP catchment areas formed overlapping rather than adjacent 
polygons limited their spatial analysis. Kernel analysis reduced the degree of 
overlap allowing them to be used meaningfully for my study and as tools for 
surveillance. A variety of data that do not conform with administrative boundaries 
can be visualised within the spatial boundaries produced by this analysis, giving 
great scope to their future applicability. In the case of GP practices, using kernel 
estimates to define their service areas can be a practical tool to assist their new 
role as health services commissioners that was assigned to them under the recent 
fundamental NHS reform (Department of Health, 2010). 
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2.2 Air Quality Indicators 
The association between salbutamol prescribing rate and air pollution was assessed 
in the regression model I developed. Ideally, individuals would be monitored on a 
regular basis using portable exposure equipment to derive estimates of their 
ambient or total exposure to environmental hazards, as those can provide greater 
and more significant effect estimates (Wilson, 2004, Ebelt et al., 2004). In reality, 
this is complex due to cost and practical difficulties, therefore proxies of human 
exposure to air pollution are often used in research (Jerrett and Finkelstein, 2005).  
2.2.1 Ambient Concentration of Air Pollutants 
In epidemiological studies, the ambient concentration of air pollutants is often 
utilized as a proxy for ambient or total exposure of populations. I used the ambient 
air pollution concentration as a surrogate to estimate the inhaled volume of air 
pollutants likely to occur.  
I firstly identified monitors recording ambient air quality in my study area. There 
are over 1500 sites across the UK which monitor air quality and these are classed 
into two major categories: automatic and non-automatic networks. Automatic 
networks produce hourly pollutant concentrations from individual sites. Non-
automatic Networks measure less frequently - either daily, weekly or monthly - and 
samples are collected by some physical means (such as diffusion tube or filter). 
These samples are then subjected to chemical analysis, and final pollutant 
concentrations are calculated from these results. The non-automatic monitors can 
be moved to more than one location. 
In my study area there was only one automatic monitor that measured the five 
major air pollutants - PM10, SO2, NO2, CO and O3. This monitor was located in 
Newcastle city centre (Figure 2-14). I accessed the data recorded by the automatic 
monitor via the UK National Air Quality Archive website (UK National Air Quality 
Archive, 2010). I examined the availability of air pollution data recorded by the 
non-automatic network in the area. I  also accessed these data from the Tyne and 
Wear Air Quality Information website (Tyne and Wear Air Quality Information, 
2010) maintained by Sunderland University, however this source had only recent 
data and did not cover the initial years of my study period.  Aiming to find previous 
records of these data I contacted the relevant Local Authorities but only few records 
were held for the early years of my study period. Unfortunately, the datasets from 
the non-automatic network were incomplete and I could not use them.  
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Figure 2-14. Air pollution monitor 
 
I focused on deciding which and how many of the pollutants recorded by the 
automatic monitor in Newcastle, I should use. Levels of pollutant concentrations on 
the same monitor correlate, therefore it may be sufficient to use only one pollutant 
in regression for assessing the relationship of interest. I was primarily interested in 
PM10 and O3 concentrations as indicators of ambient air pollution exposure. O3 is 
long-range transport pollutant that does not only capture local air pollution 
emissions and is more likely to have similar concentrations through out my small 
study area. Primary particulate matter of small size also remains in suspension for 
some hours or days and travel considerable distances from the source. PM10 
pollution episodes in UK have been attributed in UK sources but in other cases from 
sources outside the UK (Malcolm et al., 2000).  
PM10  concentration levels are attributed in both long-range transport and in local 
traffic sources (ApSimon et al., 2000).The highest concentrations of PM10 are likely 
to occur in urban and industrialised environment and attention has been drawn to 
formation of secondary PM10, particularly sulphate, and nitrate components 
resulting from oxidation of SO2 and NOx emissions (CORINAIR - Core Inventory of 
Air Emissions Methodology, 1996). Secondary PM10 exhibits greater spatial 
variability than primary PM10, as it is mainly attributable to traffic. Air pollution 
concentrations linked to vehicular traffic pollution, are reduced significantly with 
distance from the road network. There are detailed emission inventories for the 
secondary particulate matter (CORINAIR - Core Inventory of Air Emissions 
Methodology, 1996) and local authorities have been responsible for controlling 
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particulate matter episodes. In late 1990s a few studies provided evidence on the 
contrary to the belief that the elevated levels of particulate matter in urban areas 
were largely related to traffic emissions, showing that rural measurements of PM10 
become elevated at the same time as urban measurements during pollution 
episodes in the UK (King and Dorling, 1997, Stedman, 1997). This indicated that 
elevated levels of PM10 in urban centres were also attributable to long-range 
transport and originated from outside the local area.  
Overall, given that only one monitoring site was available in the study area, PM10 
and O3 concentrations would provide a better exposure indicator, due to their partly 
long-range transport characteristics described on the previous paragraphs. The 
PM10 data had very few missing records while in the case of O3 many months of data 
were missing. Based on data quality issues I used only the recordings of PM10. The 
main concern associated with particulates is their potential effect on human health, 
notably the respiratory system, as particles of small size can be inhaled into and 
deposited in the respiratory system and remain there for long periods of time. 
Epidemiological studies have shown an impact of particles below 10µm (PM10) on 
health. Future legislation in Europe and US is also focusing on monitoring of fine 
particles (i.e. PM2.5, PM1) in addition to PM10. However, colocated parallel 
measurements of PM10 and finer particles have revealed strong associations in their 
concentrations, and therefore the efficiency of their colocated monitoring is under 
question (Gehrig and Buchmann, 2003).  
The PM10 data were accessed as 24h mean daily data. Figure 2-15 shows the daily 
PM10 concentrations recorded by the monitor located in Newcastle. I averaged the 
daily means to monthly values in order to assess its relationship to monthly 
salbutamol prescribing. I evaluated possible time lags between salbutamol 
prescribing and PM10 concentrations, therefore monthly averages of PM10 recorded 
7, 14, 21 and 30 days preceding the month of prescribing were calculated. 
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Figure 2-15. 24h-mean daily PM10 ambient concentrations.  
 
 
Figure 2-16 Monthly averaged PM10 ambient concentrations. 
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2.2.1.1 Discussion/Conclusions 
The PM10 data were of good quality provided in fine temporal resolution but 
monitored only in one site. In an attempt to increase the spatial information on 
ambient PM10 concentrations, I also accessed PM10 data recorded by two non-
automatic monitors; however those covered only the last two years of my 5 year 
study period. Therefore, I only used ambient air pollution data from one monitoring 
station for my analysis and I had to assume homogenous PM10 concentrations 
across my study area, like many previous similar studies (Pitard et al., 2004, Vegni 
et al., 2005, Zeghnoun et al., 1999, Katsouyanni et al., 2001). However, I knew 
that in addition to background air pollution there were local sources of pollution, 
possibly creating within city-variation of air quality which I would have liked to 
capture. Given that no ambient concentration data were available on a local level, I 
looked for data on sources of pollution. The study area is predominantly an urban 
environment, with traffic the main mobile pollution source. I present below how I 
used traffic data to develop an air quality indicator with a temporal and spatial 
domain.  
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2.2.2 Traffic Data 
Road type has been used in several epidemiological studies as an indicator for 
exposure. “A” roads are usually related to higher levels of air pollution exposure 
while “B” roads and minor roads to lower levels. The road network was accessed via 
the Digimap website of the EDINA database. I downloaded A and B roads by 
Ordnance Survey Meridian 2 map, at 1:50,000 scale.  
Traffic flow monitors recording the numbers of vehicles passing by individual sites 
24 hours per day were also available for the study area. I accessed the traffic flow 
data from the Tyne and Wear Traffic and Accident Data Unit Transport Centre, 
based at Gateshead City Council. Monthly traffic flows were estimated, based on 7-
day or 5-day averages. The latter excluded weekends and therefore provided 
average traffic flows only during working days. This measuring unit can better 
differentiate sites with increased/congested traffic at peak hours. Sites with 
congested traffic lead to higher exposures to traffic related air pollution, therefore I 
used the monthly flows based on 5-day averages. 
2.2.2.1 Visual Exploration of Traffic Data 
I accessed monthly traffic flow data for 50 monitoring sites which had complete 
data for my study period, located on A-roads and on a few B-roads (Figure 2-17). 
Details of the traffic monitoring sites are presented in Appendix F. 
Figure 2-17 shows that the number of vehicles using some A and B roads could be 
similar and in some cases B roads had more traffic than A roads. In addition, great 
variability of traffic flows among A roads was observed. Due to the great variability 
of traffic flows, I considered that the traffic flow data could create a better proxy of 
traffic conditions than the length or type of road. 
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Figure 2-17. Traffic flows per monitoring site and type of road. 
 
2.2.2.2 Spatial Exploration of Traffic Data 
The traffic flow data were point data recorded in individual sites of the road network 
for each month of my study period (55 months). I interpolated them within the 
main road network, in order to estimate traffic flows in between the monitoring 
points. I employed a model called spline with barriers that produced a minimum 
curvature surface at the desired row and column space. The spline interpolation 
estimated values using “a series of simple functions, such as polynomials, which are 
fitted to successive groups of data points and constrained to give some degree of 
continuity at their joins” (Bailey and Gatrell, 1995). Splines are analogous to 
flexible rulers that pass through the points while minimising the total curvature of 
the surface, producing a smooth surface. The software ArcGIS with the Spatial 
Analyst extension was used to conduct the analysis of filling new grid nodes on a 
finer grid from a coarser grid. It is beyond the scope of this work to explain the 
algorithm but one can review the literature of the mathematical approach applied in 
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Refinement Griding (Terzopoulos, 1988, Zoraster, 2003, Smith W.H.F. and Wessel 
P., 1990). 
I carried out the spline interpolation for each set of monthly traffic flows. To 
evaluate the output of the interpolation, I re-ran the spline model after removing 
one of the 50 monitoring sites and then comparing the predicted value to the 
original data on that site. This validation process was conducted for 10 randomly 
selected monitoring sites, which was 20% of the total traffic monitors. The spline 
output was also assessed in time by repeating the validation process for those 10 
monitoring sites at 6 randomly selected months out of the 55 months, which was 
almost 10% of the total number of months. 
As a final step, I linked the traffic flow maps to GP service areas (2.1.2.3) and 
summed the estimated traffic flows per service area, in order to create an index of 
traffic conditions per GP practice. I built an automated process within ArcGIS for 
executing the linkage of traffic flow maps to the GP practice service areas for each 
year, producing 3,520 traffic indices. 
2.2.2.3 Results – Traffic Indices per GP Practice Service Area 
Continuous maps of traffic flows within the main road network were created, for 
each one of the 55 months of the study period. Figure 2-18 presents a map of the 
interpolated traffic flows within the road network as well as the raw traffic flows 
recorded on the monitoring sites. The darker colour in the road network symbolizes 
areas with more traffic flows, while the lower traffic flows are represented by lighter 
shades. The monitors located in the south west of the road network are located on 
England’s main motorway (A1) and recorded the highest number of traffic flows in 
the study area (around 100,000 vehicles monthly averages). I had concerns that 
the interpolation model may have over-predicted the traffic flows on the south-
western part of the network. The prediction on this part of the network was 
influenced by the two sites with the highest recorded traffic flows. I had no 
monitoring data for the roads on the south-west to check the degree of 
overprediction, and since the predicted values fell within the range of plausible 
traffic flows, I accepted the model’s output. 
 
.
   
 
Figure 2-18 Traffic monitoring sites and estimated traffic flows within the main road network. 
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I validated the interpolation results by removing a monitoring site and after re-
running the splines model, I compared the interpolated value to the observed. I 
used 10 randomly selected sites and repeated the process for six randomly selected 
months per site. The observed and predicted values on those ten sites at six 
randomly selected months correlated highly, with R2 values ranging from 0.77 to 
0.85 (Table 2-3).  
 
Month R2 
Mar-02 0.77 
Sep-02 0.85 
Oct-03 0.83 
Dec-04 0.79 
Jul-05 0.83 
May-06 0.81 
Table 2-3 R-squared values of observed traffic flows against estimated values. 
 
I then summed the estimated traffic flows per service area, in order to create an 
index of traffic related pollution per GP practice. A summary of descriptive statistics 
is presented in Table 2-4. The traffic index values were divided to 1,000,000 to 
enhance practicality during the analysis. I present histogram of the traffic indices 
per GP service area in Figure 2-19. In Appendix G present the traffic index per 
month during the five years for each GP practice. 
 
  Min. 
1st 
Quartile Median Mean 
3rd  
Quartile Max. 
Traffic 
Index 
191,903,920 495,411,112 781,850,528 903,878,380 1,267,545,088 3,235,041,024 
Table 2-4 Descriptive statistics for estimated traffic index 
   
 
Figure 2-19 Histogram of estimated traffic index per GP service area
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2.2.2.4 Discussion/Conclusions 
Traffic Flow Interpolation 
The splines with barriers technique has been previously applied in geology and 
geosciences (Zoraster, 2003) and I used it in a new context  by applying it to traffic 
data. The interpolation of flows was used in order to create continuous maps of 
traffic flows that would in turn allow assessment of traffic within a variety of spatial 
units. The spline interpolation with barriers may have over-predicted the traffic 
flows in the south-western part of the road network. I could have checked that and 
perhaps alleviated the potential over-prediction, if I had accessed traffic data for 
the wider area surrounding my study area. This problem is also related to the fact 
that information about the direction of the traffic flows could not be included in the 
interpolation model. For instance, heavy traffic observed in monitors that are 
located on the motorway (at the south-western part of the road network), would 
not influence the traffic flows on A-roads, should the model allowed to control the 
direction of traffic flow along the motorway. To the best of my knowledge there is 
limited availability of interpolation techniques within lines that allow accounting for 
flow direction (Cressie et al., 2006).  
Overall, I had no monitoring data for the roads on the south-west to check the 
degree of over-prediction, and since the predicted values fell within the range of 
plausible traffic flows, I accepted the model’s output. The model performed well in 
predicting traffic flows based on the results of the validation process. The validation 
process showed that the observed and predicted values on ten randomly selected 
sites, at six randomly selected months, correlated highly with R2 values ranging 
from 0.77 to 0.85.  
 Estimation of Traffic Index 
In the absence of a network of air pollution monitors in the study area I created a 
traffic index, by summing the interpolated traffic flow per GP service area. I added 
the traffic flows values depicted at each 25m cells of the raster maps, thus the 
index does not represent actual numbers of cars that pass through the road 
network within each GP cathment area. The traffic index values are analogous to 
the number of cars as well as the length of road network within each GP catchment 
area. The sum of the interpolated traffic flows can cause bias in the index 
calculation. This is because a large GP service area with long road network but low 
volume of traffic, situated probably in the periphery of the study area, may has an 
index value close to that of a small GP service area with high traffic flows, situated 
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probably in the urban centre. I have not been able to measure the number of 
catchment areas that may have been affected by this measurement bias. However, 
I understand that its effect on the analysis is to smooth the differences between 
traffic flow variability among catchment areas.  
In addition, the traffic index I constructed does not take into account the spatial 
distribution of patients within a GP service area.  The continuous raster traffic maps 
could have been linked to raster maps created by kernel analysis or actual 
postcodes of registered patients, to create exposure metrics of traffic related air 
pollution. Such approaches would have the advantage of accounting for the non-
homogenous distribution of patients within a GP service area or any other 
population under study. Continuous traffic flow maps allow assessment of traffic 
conditions in a variety of spatial units, such as Local Authorities and Lower Super 
Output Areas. 
Overall, given the absence of spatial air pollution data, I constructed an index of 
traffic conditions per GP practice, providing a proxy measure of traffic conditions’ 
spatial variability within the study area. However, analyses that use data such as 
number of cars or number of cigarettes smoked, to derive proxies of exposure, give 
rise to misclassification of exposure. I consider such measures of exposure to be 
further from the true exposure concentrations, when compared to indicators that 
use ambient air pollutant concentrations. Therefore, the main exposure metric in 
this study is the homogenous monthly ambient PM10 air pollution concentrations, 
while the traffic index was constructed in an attempt to account at some extent for 
the spatial variability of air pollution within the study area. Future research would 
be to use mobile PM10 monitors to investigate the association between monitored 
PM10 and traffic flows. 
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2.3 Socioeconomic Data 
The association between salbutamol prescribing rate and socio-economic conditions 
of the group of patients registered per GP practice was also assessed in the 
regression model. Socio-economic characteristics of an area expressed as indicators 
of deprivation are linked to susceptibility (Jerrett and Finkelstein, 2005, Yen and 
Syme, 1999, Pickett and Pearl, 2001). Using local areas’ contextual data is an 
ecological approach to account for population susceptibility. It is expected that sub-
populations living in areas characterised by high deprivation, will be more 
susceptible to respiratory disorders. 
2.3.1 Index of Multiple Deprivation 
I accessed socioeconomic data by the Index of Multiple Deprivation (IMD). IMD was 
published in 2000 for England and was provided by the Office for National 
Statistics. In 2004, an improved version was released, called IMD 2004 
(Communities and Neighbourhoods, 2004). IMD 2004 was mainly based on data 
collected between 2002 and 2004. One of the key features of the updated version 
was that census data (Department of the Environment Transport and the Regions, 
2000) were not used in the derivation of the index, which made it possible to 
update it more frequently than a decade. IMD 2007 was published in 2008 
(Communities and Neighbourhoods, 2008), while IMD 2010 is expected to be 
released soon.  
One key characteristic of IMD 2004 is that it is available for smaller spatial units, 
compared to IMD 2000. Those spatial units are called Super Output Areas (SOAs) 
and consist of similar numbers of residents. Parliamentary wards have been divided 
into Super Output Areas (SOA) by the Office for National Statistics, creating three 
layers, defined by spatial scale: lower, middle and upper.  
2.3.1.1 Exploration of Index of Multiple Deprivation 
I used IMD 2004 as it is relevant to the time period of my study. IMD 2004 consists 
of seven domains: 1) income, 2) employment, 3) education, skills & training, 4) 
health, 5) living environment, 6) crime, and 7) barriers to housing and service. I 
extracted data for the three main aspects of socio-economic deprivation; income, 
employment and educational deprivation. The index of income deprivation captures 
people living in families dependent on income benefits. The employment 
deprivation index measures the working age population characterized as 
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involuntarily excluded from work, while the index of educational deprivation 
captures the proportion of working age adults with no or low qualifications as well 
as pupils’ attainment. The indices are measured using different scores (Government 
Office for the North East, 2007) and each was weighted differently in the 
construction of the IMD 2004. Table 2-5 presents the scales used for depicting the 
deprivation scores of interest. 
 
 
Deprivation Indices 
(IMD 2004) 
Range of Deprivation Scores in England 
least deprived most deprived 
Income  0.00 0.96 
Employment  0.00 0.69 
Education, Skills & Training  0.03 99.22 
Table 2-5 : Scale of measurement of Deprivation Scores (2004) 
The deprivation data were accessed in the lower layer of SOA, with a mean 
population of 1,500. The borders of LSOAs are available in the Edina database. I 
created maps of income, employment and educational deprivation in the study area 
(Figure 2-20, Figure 2-21, Figure 2-22). The levels of deprivation have been 
categorised in quartiles (4-quantiles).  
 
Figure 2-20. Income Deprivation 
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Figure 2-21. Educational Deprivation 
 
 
Figure 2-22. Employment Deprivation 
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2.3.1.2 Results - Practice Level Deprivation 
 
I estimated a practice level deprivation score for each practice. This was derived by 
assigning each postcodes with the deprivation scores of the LSOA it fell within. 
Then, I averaged the deprivation scores over all postcodes affiliated to each 
practice. Three deprivation scores were estimated for each practice: 1) income, 2) 
employment and 3) education. Figure 2-23, Figure 2-24 and Figure 2-25 show 
histograms of the deprivation indices. 
 
 
 
Figure 2-23. Histogram of Income Deprivation 
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Figure 2-24. Histogram of Employment Deprivation 
 
 
Figure 2-25. Histogram of Educational Deprivation 
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2.3.1.3 Discussion/Conclusions 
An alternative way of estimating the practice deprivation would have been by 
assigning the deprivation scores to the postcode of practices’ premises. However, 
such practice deprivation scores would not be representative of the contextual 
conditions in the areas that each practice served. To be representative, the 
majority of registered patients would have to live within the same LSOA where the 
practice premises were based or in LSOAs with similar deprivation. This could be 
true for some practices with small service areas, but would not apply to practices 
with large service areas. Overall, I considered that the estimated practice level 
deprivation scores were representative of the social composition of the patients 
registered to each practice. 
 
 
.
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2.4 Demographic Data 
Demographic data are important for understanding disease prevalence and 
incidence in epidemiological studies. The two main demographic 
characteristics are age and sex of the subjects or population under study. 
The age and sex characteristics of practice populations were assessed in 
relation to salbutamol prescribing rate in the regression model I developed.  
2.4.1 Age and Gender of Patients Registered per Practice 
The age and sex data of registered patients were accessed from the Exeter 
database via NEPHO, after receiving ethical approval by the PCTs’ Caldicott 
Guardians. I received data for each of the five years of study, extracted for 
the 1st of April for each year. 
2.4.1.1 Exploration of Age and Gender Data 
Figure 2-26 shows the age profile of populations registered per practice. 
Most of the practices had a similar age profile, while two of the practices had 
very high number of young population registered with them. These practices 
were close to Newcastle University and had a high number of students 
registered with them.  
 
 
 
  
 
 
Figure 2-26 Age profiles of practice populations
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The proportions of males and females in the total population registered per practice 
were estimated. These proportions are presented in Figure 2-27 using violinplots, 
which are similar to boxplots but depict density as well. The violinplots for males 
and females are mirror images because if 55% of a practice population consists of 
males the remaining 45% will have to be females and vice versa.  
The most notable observation appeared in the violinplots of Newcastle PCT where a 
practice’s population consisted of 65% males and 35% females. In order to 
investigate it further, I created violinplots per GP practice in Newcastle and North 
Tyneside PCT.  In Figure 2-28, I present only the proportion of males per practice 
as the respective graphs for females were mirror images, as explained above. The 
practice with the high proportion of males was the A86027 practice, which is 
located within the campus of Newcastle University. I considered that the high 
proportion of registered males reflected the high number of males working for the 
university.  
Two practices in North Tyneside PCT appeared to have a higher proportion of male 
patients than the other practices. However, the proportion was approximately 54%, 
which was much lower that the 65% observed in practice A86027. The vast 
majority of GP practices in North Tyneside appeared to have more female 
registered patients than males. 
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Figure 2-27 Percentage of males and females registered to GP practices, per PCT. 
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Figure 2-28 Percentage of males registered to GP practices, per practice
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2.4.1.2 Results 
I averaged the age of population per practice in order to create an indicator of the 
practice population age. I calculated the ratio of males and females registered per 
practice, with higher values when a practice population consists of more males than 
females and with lower values in the other way around.  
Table 2-6 shows the descriptive statistics of the two variables to be included in my 
regression model. The histograms of the two variables are presented in Figure 2-29 
and Figure 2-30. 
 
 
 Min. 1st Qu. Median Mean 3rd Qu. Max. 
Average age 29.0 38.0 39.0 39.0 41.0 46.0 
Sex ratio 0.8 0.9 1.0 1.0 1.0 1.8 
 
Table 2-6. Descriptive statistics of covariates 
 
 
 
 
Figure 2-29 Histogram of average age of registered patients 
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Figure 2-30 Histogram of sex ratio of registered patients 
 
2.4.1.3 Discussion/Conclusions 
The average age of registered patients per practice and the ratio of males and 
females gave a profile of the population served by each practice. Older people tend 
to suffer more from COPD, whilst asthma is more common in children. Gender 
appears not to be related to asthma or COPD. COPD was once considered a disease 
of males, probably due to the historically high smoking prevalence among males 
but it is not anymore. If the prescribing data were available per diagnosis, it would 
be possible to test per diagnosis how the age and gender profile of patients relates 
to respiratory prescribing, in a primary health setting.   
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Chapter 3. Statistical Modelling 
3.1 Statistical Method 
The statistical method to be employed was considered in parallel with the 
exploratory analysis. It is useful to have some consideration on the type of 
statistical model that in principle would be appropriate for the data and questions of 
interest before the model building process. A linear regression model was the 
starting point of my model building strategy. Careful consideration was required as 
to whether the data under analysis could satisfy the assumptions of the model to be 
used. There are several approaches that can be adopted to address the linear 
regression assumptions, depending on which assumption is not met. The grouped 
nature of prescribing data, with repeated measurements per GP practice over time, 
violated the basic assumption of independence that underlies the statistical 
methods used in linear regression (2000). Mixed models or mixed-effects models 
are a form of generalized linear model that has been extended to dependent data 
(Breslow and Clayton, 1993, Diggle and Ribeiro Jr, 2007, J.C. Pinheiro and Bates, 
2000). I present below an overview of the theory behind mixed-effects model, in 
order to clarify the reason for considering this statistical method to be appropriate 
for my study. 
3.1.1 Mixed-effects Model 
Mixed-effects models provide a powerful tool for analysing grouped data. Data can 
be grouped in time and/or space so mixed models could be used to analyse 
repeated measurements over time (e.g. response of a patient to treatment as a 
series of observations over time) and/or data recorded at several centres (e.g. 
hospital, clinics, general practices). The term mixed-effects is used to describe the 
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fact that the models account for both fixed and random effects. Fixed effects refer 
to the parameters of the model that have a constant value and are estimated by 
traditional regression models. Random effects assume that some parameters take 
values that have arisen from a distribution. They are selected at random from the 
population of interest and are called effects because they represent a deviation 
from the overall mean (Pinheiro and Bates, 2000). Those effects assist in depicting 
more accurately the phenomenon under study by accounting for the random 
variation associated with given parameters.  
Fixed effects models in classical statistics only have random variation in the error 
term, while mixed effects models introduce additional random variation in the 
parameters of the model. Any number of random effects can be specified in a 
model. For example, when assessing the effect of two treatments that are provided 
to several individuals by several centres, it is possible for the model to capture the 
by-treatment random effect as well as to include the centre providing the treatment 
as a random effect. This type of design is called hierarchical or multilevel as 
individuals are grouped per treatment and centre.  Mixed-effects models are often 
called hierarchical (Raudenbush and Bryk, 2002, Lindley and Smith, 1972) or multi-
level models (Goldstein, 2003). However, not all mixed-effects model are 
hierarchical (Pinheiro and Bates, 2000). Careful consideration is required when 
assigning random effects to variables as they have to be representative of the real 
case. Cases where an identical treatment is given to the same individual, no 
random effect by treatment is necessary, and only centre would be included as 
random effect. 
More precise estimates of the treatments’ effects can be estimated by assigning 
random variation to both centre and centre/treatment effects. In such hierarchical 
designs, the treatment effects are allowed to vary randomly across centres and the 
treatment standard error increases to allow for this. The inference of this model can 
be applied to the whole population of centres unlike conventional models where 
centre and centre/treatment effects are fixed and inferences on treatment effects 
are specific to the centres observed (Brown and Prescott, 2006). This important 
aspect of mixed-effects models is that the question of interest is for the whole 
population and not only for the population being sampled (Pinheiro and Bates, 
2000). Especially when analysing health data that need ethical and confidentiality 
considerations to be assesed, using the fewest patients’ data as possible to make 
inferences with same level of accuracy is desirable.   
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3.1.1.1 Application of Mixed-effect Models 
Overall there are many reasons for using such model and its benefits can be applied 
to a range of data (Demidenko, 2004). Mixed effects models have started becoming 
established as the appropriate tool for modelling data with complex structure. 
Mixed effects models have been frequently applied in agriculture to analyse crop 
variety trials (Talbot 1984) and have been used extensively in animal breeding to 
predict heritability and predict genetic gain from breeding programmes (Smith et 
al., 2001, Johnson and Thompson, 1995). They are also applied in other fields such 
as engineering, ecology, medical science and in social sciences like education, 
linguistics, economics (Elmhagen and Rushton, 2007, Zhou et al., 2003, Revelt and 
Train, 1998, Clayton et al., 1996, Baayen et al., 2008).  
The adoption of mixed effects models has been increasingly accepted in medical 
research, especially after a review of clinical trials by Brown and Kempton (1994). 
Mixed-effects models have been used in different aspects of asthma and COPD 
research, such as the response of portable peak expiratory flow meters to changes 
in true peak expiratory flow in 12 children with asthma (Burton et al., 1998), as 
well as to evaluate the effect of inhaled budesonide in subjects with mild COPD who 
continued smoking (Pauwels et al., 1999). The last two decades have seen several 
examples of using mixed models in relation to health (Pitt et al., 2000, Drake et al., 
1999, Clark et al., 1996, Unutzer et al., 2002), however their use is still in the 
process of becoming regular practice. Mixed-effects models are also accepted by 
regulatory authorities. The US Food and Drug Administration website recommends 
such models for assessing the degree to which two drugs are the same in terms of 
efficacy and safety (Centre for Drug Evaluation and Research, 2001). 
The application of mixed effects models is very much linked to the development of 
computers. Mixed effects models are fitted using the method of maximum likelihood 
or the residual maximum likelihood (RELM) method, proposed by Patterson and 
Thompson (1971). Likelihood-based methods are computationally intensive and 
demanding in terms of computational power, which has been a factor in restricting 
the application of such models.  
A variety of commercial software, including SAS, SPSS, MLwin, HLM, Stata and S-
plus is available for fitting mixed-effects. They differ mainly in whether they include 
programmes that allow fitting mixed-effects to normal, non-normal or categorical 
data. The commercial software Egret specialises in the application of mixed-effects 
models for epidemiological and biomedical studies. Software like WinBUGS and 
BayesX apply a Bayesian approach to such models. To the best of my knowledge 
WinBUGS is the most widely applied software for Bayesian statistics and can be 
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used to fit models of all types of data. It is open source software (distributed freely 
in the public domain) developed by the Medical Research Council Biostatistics Unit 
in Cambridge. Both WinBUGS and BayesX are integrated within R and can be used 
via this software. 
R is open source statistical software that includes algorithms for fitting mixed-
effects models. R allows one to fit mixed models to larger datasets compared with 
other software and is one of the most versatile software packages for application of 
mixed-effects models, using “nlme” and “lme4” packages. The latter package has 
been launched in recent years and is currently under continuous development to 
improve computation of mixed models and include new functions that deal with 
more complex datasets. For instance, lme4 allows the use of an offset in a mixed-
effects model, which is not available in the nlme package. An offset specifies a 
priori known components to be included in the linear predictor during fitting. R also 
contains special functions to improve the modelling of the aforementioned types of 
data, like a function for fitting longitudinal models with missing data that is based 
on work in this field by Diggle and Kenward (1994) and  Diggle and Farewell 
(2007). A recent addition in R is the package called “geoR” and its extension 
“geoRglm” that allows the application of mixed-effects models to geostatistical data 
(Diggle and Ribeiro Jr, 2007).  
 
3.1.1.2 Mixed-effects model in perspective 
Mixed effects models have random variation in the error term but also introduce 
additional random variation for which assumptions have to be made about the type 
of distribution they follow. The two sources of random variation are the main 
characteristic of mixed effects model. This is a potential disadvantage of mixed 
models as they rely on more distributional assumptions. Often a class of mixed-
effects models is used that assume that both the random effects and errors follow 
Gaussian distributions. This assumption always has to be checked, by examining 
the linearity of residuals and random effects with normality plots. Non-linear mixed 
models are also applied (Pinheiro and Bates, 2000).  
As mentioned above, in contrast to classical statistics, the mixed-effects model 
assumes two sources of variation, within groups and between groups. The within 
groups variation has the same meaning as in traditional statistics and is depicted by 
the model’s error terms (residual variance). The between groups variation is also a 
random source of variation like the error terms, even though may behave like 
parameters in a model. As such we do not “estimate” them but form predictions of 
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the values of those random parameters, given the data observed (Pinheiro and 
Bates, 2000).  
The fact that a mixed-effects model assumes that the parameters are random 
makes it similar to Bayesian statistical models. In a Bayesian context where all 
unknown parameters are considered as “random”, the mixed-effect model is known 
as a random-effects model (Gelman, 1995). As in the Bayesian approach, in a 
mixed-effects model one has to make a decision in defining the prior distribution of 
random parameters. In the frequentist approach, the unknown parameters of the 
distribution are estimated from the data. In a mixed effects model, the fixed effects 
can also be estimated based on specified repeated-sampling properties that are 
equivalent to the Bayesian posterior inference under a non-informative (uniform) 
prior distribution (Gelman, 1995). In summary, a mixed model combines major 
features of the frequentist and Bayesian approaches. 
3.1.1.3 Example of Mixed-effects Model 
To illustrate the importance of accounting for the grouping factor of this study’s 
prescribing data by means of mixed-effects model, I used a basic fixed effects 
regression model initially. For simplification I considered the relationship of 
particulate matter as an explanatory variable xk with salbutamol prescribing in 
several GP practices as response yk, where K=1,…,k in our study K=55 months. The 
model took the form:   
kkk xy εαµ ++=                                                                                        3-1 
Where, yk is the salbutamol prescribing rate, µ is the mean salbutamol prescribing 
across the population of GP practices being sampled, and the εij are independent 
and identically distributed random variables with zero mean and constant variance, 
),0( 2σΝ . The parameter (coefficient) of the model is α with respect to the 
particulate matter covariate xκ. In this model it is assumed that the data were 
collected from similar, homogenous practices. However the practices are not 
homogenous and prescribing varied a lot between them. Figure 3-1 illustrates that 
some practices tended to have systematically higher or lower prescribing than 
others and it would be better to account for that.  
The grouping factor of prescribing is categorical data. There is no inherent ordering 
of GP practices so I reordered the data to make the plot of prescribing between 
groups more informative. Figure 3-2 shows a dotplot of salbutamol prescribing per 
GP practice that reinforced the impression of considerable variability between GP 
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practices. The line observed in Figure 3-2 joined the mean salbutamol prescribing 
of the 64 general practices, which had been reordered accounted to increasing 
mean salbutamol prescribing. 
 
 
   
 
Figure 3-1 Monthly average of salbutamol prescribing per GP Practice. 
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Figure 3-2 A dotplot of salbutamol prescribing per GP Practice.
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An improvement of this initial model was to assume that each practice has its own 
practice-specific prescribing (in statistical language, intercept). The model now has 
a double index because I have grouped data: i corresponds to the ith GP practice 
(i=1,…,N ) and j to the jth observation of the ith practice ( j=1,…ni), where ni= is 
the number of observations from the ith practice. The total number of observations 
is ∑
=
=Κ
N
i
in
1
. In this study, the number of GP practices was i=1,…,64 and the 
number of observations per practice was j=1,…55, so K= 3,520. 
 
ijijiij xy εαµ ++=                                                                                       3-2 
Where, yij is the salbutamol prescribing rate for observations j in group i, µi is the 
GP practice specific intercept. The εij is the error term for jth observation of the ith 
practice, again assumed independent and identically distributed, N (0, σ2).  This 
second model seemed more appropriate for the prescribing data as it included the 
GP practice effect. However, it assumed that the practice effect takes constant 
(fixed) values and the only assumption about variation is that the residuals εij are 
normally distributed. As the individual observations are modelled as the sum 
of iji xαµ + , which are all constants, plus the residual term, it follows that the 
variance of individual observations equals the residual variance. The covariance of 
any two separate observations yij  and yi’j’ is zero since all the residuals are assumed 
independent (i.e. uncorrelated).This means that data sharing the same grouping 
factor (e.g. prescribing per GP practice) are considered independent. However, 
prescribing per GP practice was not expected to be independent due to various 
random influences, such as the prescribing pattern individual doctors may have.   
 An improvement of this second model was to set the GP practice as a random 
parameter to allow the model to capture the by-practice random effects. The new 
model assumed that the practice effect also arises from independent samples from 
a normal distribution and is an example of mixed-effects model. The equation 3.2 
(fixed-effects model) modelled the specific sample of GP practices used in this 
study, while the random effects model treated the practices’ effect as random 
variations around a population mean. This central assumption of the mixed models, 
that intercepts µι, i=1,…,N are random and belong to a general population, can be 
expressed in the following equation as  
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ii b+= µµ                                                                                                3-3  
where µ is the population-average prescribing of salbutamol (intercept) and bi is a 
random variable, or the deviation of the practice-specific prescribing from the 
population-averaged prescribing for the ith GP practice. Taking into account the 
random part of the intercept expressed by equation 3-7, the model 3-2 could be 
written as:  
 
ijiijij bxy εαµ +++=                                                                                 3-4 
),0( 2σε Ν=ij  & ),0( 2bib σΝ=  
Where the random variable εij is the error term for jth observation of the ith 
practice, again assumed independent and identically distributed, N (0, σ2).  The bi 
are referred to as random effects also assumed to have come from a normal 
distribution N(0,σ2). Joining the two random terms together, where iijij b+= εη  the 
model can be written as ijijij axy ηµ ++= . In general, the linear mixed effects 
model is written as (Laird and Ware, 1982)  
ijiiijij bZaxy εµ +++=                                                                               3-5 
where Z is a matrix giving the values of random effects bi. It is apparent this model 
is more complex than the previous model (3-2). Consequently, the mixed model 
assumed two sources of variation (variability), the εij or “within groups” and bi or 
“between groups” (Pinheiro and Bates, 2000). The former have the same meaning 
as in traditional statistics but the latter are random and are estimated as posteriori 
means, that links such model to Bayesian statistics (Demidenko, 2004, Gelman, 
1995), as discussed in section 3.1.1.2.   
Furthermore, the variance of individual observations in the mixed effects model is 
the sum of the variance components:  
22)var( σσ += bijy                                                                                      3-6 
σ2b  is the variance for the between group variability (or inter variability) and σ
2 is 
for the εij for the within group variability (or intra variability). The covariance of 
pairs of observations can then be described as: 
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),cov(),cov(
''''''' jiijiijiijjiij bxbxyy εαµεαµ ++++++=                               3-7 
When observations of different GP practices are considered (i.e. i≠i’) then 
0),cov(
''
=jiij yy  because of the independence of the observations. However, when 
two samples from the same practice are considered (i.e. i=i’) (Brown and Prescott, 
2006, Demidenko, 2004, Pinheiro and Bates, 2000), then  
),cov(),cov(
''''' jiiijijiij bbyy εε ++=  
                  
2
'
),cov( bii bb σ==                                                                   3-8 
Thus, observations on the same GP practice are correlated and have covariance 
equal to the practice variance component, while observations on different practices 
are uncorrelated. This contrasts with the fixed effects models where the covariance 
of any pair of observations is zero.  
 
3.1.1.4 Discussion/Conclusions 
In summary, grouping factors induce a correlation structure in the data but mixed 
effect models allow the modelling of such data (Faraway, 2006, Demidenko, 2004, 
Pinheiro and Bates, 2000). Allowing for the interdependence of observations by 
group was the reason for considering this type of statistical method appropriate to 
model the prescribing of salbutamol by GP practice. Each practice has 
characteristics (e.g. age distribution of patients) that I needed to take into account 
in my model as well. In the following section I developed the mixed-effects model 
by adding all the explanatory variables of salbutamol prescribing and carrying out 
tests to assess formally whether this model met the independence assumption 
required by linear regression. 
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3.2 Model Formulation 
In previous chapters, I described how the health, air quality, deprivation and 
demographics datasets were converted to suitable spatial and temporal formats to 
allow them to be used as explanatory variables. I have also discussed the statistical 
model that in principle is relevant for modelling prescribing data at the primary care 
level.  
My aim was to model the monthly prescribing rate of salbutamol (respiratory 
medication) in relation to air quality, at primary health care level. I hypothesized 
that exposure to air pollution increases the frequency and duration of asthma and 
COPD symptoms, generating a corresponding increase in the use of salbutamol 
medication and consequently an increase in prescriptions. I evaluated possible 
time-lags in the response of medication use to air quality. Contextual factors of 
local areas (income, employment and educational deprivation) and demographic 
factors (age and sex) were also included as covariates in the statistical models.  
The response variable was monthly prescribing of salbutamol per GP practice, 
standardized per 1,000 population. The primary health care level was the spatial 
unit of analysis for prescribing and monthly variation was the temporal unit. Not all 
covariates shared the same level of temporal and spatial resolution. The ambient 
air quality (PM10) covariate deriving from one monitoring site accounted for monthly 
temporal but not spatial variation. I attempted to account for within city air quality 
spatio-temporal variability by analysing traffic flows with both spatial (50 
monitoring sites) and temporal (monthly) resolution.  
The demographics and the derived deprivation covariate have one year temporal 
resolution, as the postcodes of patients were provided on the 1st of April for each 
year of study. No significant change in deprivation and demographics variables was 
expected on a monthly basis and I considered that these covariates accounted 
sufficiently for spatio-temporal variation. I summarise below the covariates 
constructed for use in my statistical model: 
x1a-1b:  monthly averaged PM10 with 0-, 7-, 14-, 21-days and 1-month lag time 
x2a-2e:  monthly averaged traffic flows per practice with 0- and 1-month lag time 
x3:      income deprivation per GP practice, annually 
x4:      employment deprivation per GP practice, annually 
x5:      education deprivation per GP practice, annually 
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x6:      average age of registered patients per GP practice, annually 
x7:      ratio of males and females registered patients per GP practice, annually 
x8:      time (months) 
My interest was to explore the potential relevance of covariates, as well as learn 
and understand better the structure of the data, in order to build a model that I 
believed to be both parsimonious and adequate. The inference to be made using 
the p-values, coefficient and confidence intervals of my final model would be 
relevant to the total population of GP practices that my sample was drawn from, as 
well as the sample of practices I analysed.  In the next section I focus on model 
formulation, the preliminary stage of model building strategy. 
3.2.1 Preliminary Statistical Model 
My model building started with the model formulation process that is developing 
and examining the main structure of the statistical model, which was followed by 
the refining process. Preparation and examination of the main aspects of  the 
statistical model reduced the risk of the final model not satisfying the main 
assumptions of regression. As discussed in section 3.1.1, a linear mixed-effects 
model was considered, in principle, appropriate for addressing the aims of this 
study. I fitted this model on my data and examined whether this was the case. 
Firstly, I assessed whether transformation of the data was required and then fitted 
the preliminary mixed-effects model. I present below the process for deciding on 
log transforming the data and then the application of a mixed-effects model.  
3.2.1.1 Linear Mixed Effects Model 
One of the main assumptions that linear regression models have to satisfy is 
homoscedasticity (constant variance). Logarithmic transformation is a common 
approach taken to address the problem of heteroscedasticity (Weisberg, 2005). In 
order to make a decision on whether log transformation of the data was required, I 
estimated the mean prescribing rate of salbutamol per month and its variance and 
plotted them against each other.  
Figure 3-3 shows that the monthly mean of salbutamol prescribing rate increased 
when variance was increased. Log transformation approximately stabilised the 
variance of salbutamol prescribing, as depicted in  
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Figure 3-4, therefore, I proceeded to use log transformed data to model the 
salbutamol prescribing rate using linear regression. I checked again that the 
assumption of homoscedasticity was met by my final fitted model by examining the 
residuals of my model.  
 
Figure 3-3 Mean of monthly salbutamol prescribing rate against monthly variance.  
 
 
Figure 3-4 Mean monthly log salbutamol prescribing rate against monthly variance.  
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Having log transformed the data, I denoted Y the log transformed rate of 
salbutamol prescribing. Figure 3-5 shows the area-wide average salbutamol 
prescribing, tΥ , in each of 55 months of the study period, where the original scale 
is shown on the left vertical axis and the logarithmic scale on the right vertical axis. 
Figure 3-6 depicts the monthly log transformed rate of salbutamol prescribing per 
GP practice.  
 
Figure 3-5 Area wide monthly average of salbutamol prescribing rate. 
  
 
Figure 3-6 Log monthly average of salbutamol prescribing per GP Practice. 
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I fitted both fixed and mixed effects models adding all the information that I had 
gathered about individual practices on particulate matter, traffic, deprivation and 
demographics. All covariates have been listed at the beginning of this chapter. I 
then examined and compared the spread of the residuals of the models. The 
examination of residuals is necessary for identifying whether a model’s results can 
be reliable.  
The fixed effects model with all the covariates of interest took the form: 
ijijijij xaxay εµ ++++= 91 ...                                                                     3-9 
as it fitted eight fixed effect parameters relating to x=1,…,8 covariates. The mixed 
effect model had additionally 64 random effects (q=1,…,64) parameters respective 
to 64 GP practices: 
ijijij xaxay 81 ... +++= µ  ijijij zbzb ε++++ 641 ...                                       3-10 
 
3.2.1.2 Model Criticism  
Figure 3-7 shows boxplots of the fixed effects linear regression model residuals by 
subject. The residuals corresponding to the same subject (GP practice) tend to have 
the same sign, which indicated the need to account for the group effect (Pinheiro 
and Bates, 2000). The anticipation that the mixed effects model would account 
successfully for the GP effects was better illustrated by the boxplots of residuals, 
shown in Figure 3-8. The residuals are centred around zero and have smaller 
magnitudes than those in Figure 3-7. This indicated that the mixed-effects model 
could provide more accurate estimates, which allowed for the by-GP practice 
differences. 
   
 
 
Figure 3-7 Boxplots of the fixed effects model residuals, by GP Practice. 
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Figure 3-8 Boxplots of the mixed effects model residuals, by GP Practice.
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3.2.1.3 Discussion/Conclusions 
The residuals of the mixed effects model were centred around zero and had smaller 
magnitudes than those of the fixed effects model, indicating that the mixed effects 
model had more accurate estimates, taking into account the by-GP practice 
differences. Overall, by examining the spread of residuals, I concluded that the 
reliability of the fixed effects model would be doubted when fitting the salbutamol 
prescribing data in relation to other covariates, while the mixed effects model 
appeared to better account for the grouped nature of for the prescribing data. 
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3.3 Model Refining (Stage A)  
Having fitted and examined the preliminary model, I needed to refine and finalise 
it. A major concern was the covariates that would be included as explanatory 
variables for salbutamol prescribing. Peaks in salbutamol prescribing occured each 
winter and spring, albeit with some variation from year to year (Figure 3-5). I have 
already mentioned that factors like pollen, cold air and respiratory infections can 
increase the frequency and duration of symptoms of patients with asthma and 
COPD. The salbutamol prescribing was consequently determined by such seasonal 
variations.  
In an attempt to account for this seasonal effect, my modelling strategy was 
separated into two stages. Firstly, I modelled the expectation of the area wide 
monthly average log-transformed salbutamol prescribing rate, [ ]tt YΕ=µ , in relation 
to monthly average temperature. Temperature was used to capture the seasonal 
variation of salbutamol prescribing, given the absence of any other covariates to 
account for seasonal trigger factors (e.g. respiratory infections, pollen).  
I then fitted the mixed effects model presented in the previous section, including 
the monthly average log-transformed salbutamol prescribing rate, [ ]tt YΕ=µ , as an 
offset. An offset specifies a priori known component to be included in the linear 
predictor during fitting. Including tµˆ  as an offset in my model would allow me to 
assess the relationship of the remaining prescribing rate in relation to particulate 
matter, traffic, deprivation and demographic characteristics of GP practices. A two 
stage modelling strategy has been previously implemented by Fanshawe et al., 
2008. Implementing a two stage-modelling approach using a mixed effects model 
proved challenging in terms of software requirements. In the next two sections I 
will present the two stages of statistical modelling followed by the results and their 
interpretation. 
 
3.3.1 Modelling seasonal variation of salbutamol prescribing  
I modelled the relationship between the log transformed salbutamol prescribing 
rate and temperature in order to account for the seasonal variation. I accessed the 
daily mean for temperature data, which I averaged monthly. There was only one 
monitoring station recording temperature in the study area, which was considered 
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representative, as no major differences in temperature were expected within the 
study area. Figure 3-9 graphically depicts the temperature data which followed a 
distinct seasonal pattern. Associations between salbutamol prescribing and 
temperature were tested for different time lags. I looked at the relationship of 
monthly average temperature recorded in the same month as salbutamol 
prescribing (lag0) as well as that preceding by 7 days (lag7), 14 days (lag 14), 21 
days (lag21) and a month (lag30).  
 
 
 
 
 
 
 
 
 
 
Figure 3-9 Monthly average temperature. 
3.3.1.1 Method 
Frequency domain models are one of the standard ways to model temporal 
autocorrelation (Gelman, 1995). Such models analyse data with respect to 
frequency rather than time, using a mixture of sinusoids at different frequencies. 
Frequency is the number of occurrences of a repeated observation by any given 
unit of time. There are alternative perspectives on capturing correlation and one of 
them, used by such models, is to transform data into vectors and assess the angle 
between them.  
Variables presented as vectors in a space are commonly used in the physical 
sciences and engineering for plotting forces and visualizing their relationships. 
Vectors pointing in the same direction have a positive relationship and those 
pointing in opposite directions have a negative relationship. Applying the angles of 
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vectors as a measure of correlation can be complicated. The angles take values 
from 0o to 360o degrees, while the correlation coefficient  take values between 1.00 
for perfect correlation, -1.00 for perfect negative correlation, and zero for no 
correlation. A transformation can be done by using basic functions of trigonometry, 
sine and cosine. For instance, the cosine of the angle between vectors will be +1.00 
for vectors with an angle of 0o, -1.00 for an angle of 180o (completely opposite 
directionality), and 0 for an angle of 90o or 270o.  
I have used a type of frequency domain models, called harmonic regression or fixed 
frequency effects models, to estimate area wide monthly salbutamol prescribing in 
relation to temperature. Harmonic regression can be applied to stationary or non-
stationary time series (Young et al., 1999). More details on frequency domain 
models  and harmonic regression models can be found in relevant literature (Artis 
M. et al., 2007, Gelman, 1995, Kay and Marple, 1981, Chiu, 1989, Hannan, 1971, 
Bujosa et al., 2007, Young et al., 1999).  
3.3.1.2 Analysis 
The co-variation of prescribing between months as captured by sine and cosine was 
added as a variable in the model. I defined twelve periods as ω=2π/12 to represent 
an annual cycle. The initial version of the model I used is:  
tttt EttdY +Β+Α+++= )sin()cos( ωωγβα                                                 3-11 
where tY  is the monthly average log-transformed salbutamol prescribing rate for 
month t.  The value dt is the average of the daily mean temperature readings in 
month t. α, β, γ, Α and B are parameters and Et are independent residuals ),0( 2EσΝ  
for month t.  All the parameters of this model were static (fixed) taking constant 
values.  
An improvement of this model was to replace the A and B parameters by variables 
that were estimated randomly. This second model was called a dynamic model and 
differed from the static harmonic regression model in the estimation of parameters 
in the frequency domain. I used the package “sspir” in R software to fit the dynamic 
harmonic regression model (Dethlefsen and Lundbye-Christensen, 2006). This 
method has been previously implemented in an epidemiological context for 
estimating weekly area-wide black smoke averages (Fanshawe et al., 2008).  
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In the dynamic model the parameters α, β, γ and Et were as before, but the 
parameters A, and B were replaced by variables that were estimated by the random 
walks ),(~| 211 Α−− ΑΝΑΑ σttt and ),(~| 211 Β−− ΒΝΒΒ σttt  (Fanshawe et al., 2008): 
tttttt UttdY +Β+Α+++= )sin()cos( ωωγβα                                               3-12 
I evaluated possible time-lags of 1 month and 21, 14 and 7 days for responses of 
medication prescribing to temperature, as mentioned earlier. Consequently, I 
modelled the area wide monthly average log-transformed salbutamol prescribing 
rate, [ ]tt YΕ=µ , against temperature using five static and five dynamic frequency 
domain models. The results of the static models were compared to the results of 
dynamic harmonic regression models.  
 
3.3.1.3 Results 
The rates of prescribing as estimated from the static and dynamic modesl were 
plotted against the monthly log prescribing. Figure 3-10, Figure 3-11, Figure 3-12, 
Figure 3-13 and Figure 3-14 depict the results of fitted static and dynamic harmonic 
regression models for the area-wide average of prescribing in relation to 
temperature at the following time lags: a) 0 days (lag0), b) 7 days (lag7), c) 14 
days (lag14), d) 21 days (lag21) and e) 1 month (lag30). The observed monthly 
prescribing is illustrated as an orange solid line. The estimation of static models 
(dotted line) differed substantially from the observed prescribing, indicating that 
these models were not adequate. In contrast, the dynamic models (solid blue line) 
captured much better the month-to-month variation. Out of the five dynamic 
models the one that used the temperature at 7 days lag, provided the best fit to 
the data, as depicted in Figure 3-11. 
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Figure 3-10 Fit of static and dynamic regression models for the area-wide average 
of prescribing in relation to temperature at 0 days lag. 
 
 
Figure 3-11 Fit of static and dynamic regression models for the area-wide average 
of prescribing in relation to temperature at 7 days lag. 
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Figure 3-12 Fit of static and dynamic regression models for the area-wide average 
of prescribing in relation to temperature at 14 days lag. 
 
Figure 3-13 Fit of static and dynamic regression models for the area-wide average 
of prescribing in relation to temperature at 21 days lag. 
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Figure 3-14 Fit of static and dynamic regression models for the area-wide average 
of prescribing in relation to temperature at 1 month lag. 
 
I calculated the R squared (R2) coefficient of determination, a statistical measure of 
how well the regression line approximated the real data points. An R2 of 1.0 
indicates that the regression line perfectly fits the data. Figure 3-15 shows that the 
model with 7 days lag had the highest R squared value (74,5%). Therefore I 
considered it to be best out of the five in terms of how well it fitted the original 
data. 
 
Figure 3-15 R squared for dynamic models. 
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3.3.1.4 Model Criticism 
I examined the residuals of the dynamic model with lag7 (temperature data 
recorded 7 days preceding the first day of prescribing month), in order to assess 
the validity of the model.  
Normality, Linearity, Homoscedasticity Assumptions 
I created a normal Q-Q plot of the residuals, using the dynamic harmonic 
regression model (lag7). FiFigure 3-17 shows a pattern that is close to a straight 
line, demonstrating that the normality assumption was met by the model. 
 
Figure 3-16 Normality Plot of residuals of dynamic harmonic regression model. 
 
I assessed whether the assumption of linearity was met. By plotting observed 
versus fitted values of salbutamol prescribing (FiFigure 3-17), adequately it was 
met. The plot of residuals versus fitted values (FiFigure 3-18) was also examined to 
assess the linearity and homoscedasticity assumptions. Homoscedasticity was also 
examined by plotting the residuals versus time. The observed versus fitted values 
(FiFigure 3-17) were symmetrically distributed around a diagonal line showing the 
linearity assumption was adequately met. FiFigure 3-18 illustrates that the residuals 
remained constant in relation to fitted values and time (Figure 3- 21) indicating 
that the homoscedasticity (constant variance) assumption was also adequately met.  
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Fi
Figure 3-17 Plot of observed versus the fitted values of salbutamol prescribing of 
dynamic harmonic regression model. 
Fi
Figure 3-18 Plot of residuals versus fitted values. 
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Fi
gure 3-19 Plot of residuals versus time.  
 
Independence Assumption 
I examined whether the residuals of the dynamic harmonic regression model (lag7) 
met the independence assumption and compared that to the respective static 
model. I plotted the autocorrelation function to compare the temporal 
autocorrelation of residuals produced by the two models. The concept of 
autocorrelation functions was explained in Section 3.2.1.2, where I checked the 
reliability of the preliminary mixed-effects model.  
The dynamic model improved the temporal autocorrelation of residuals (Figure 
3-21), compared to the static model (Figure 3-20), as the residuals showed an 
even distribution around zero, within the 95% confidence limit (dotted lines) for 
most lags.  
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Figure 3-20 Temporal autocorrelation of residuals of the static model.  
 
Figure 3-21 Temporal autocorrelation of residuals of the dynamic model.  
 
Overall Figure 3-16, Figure 3-19, Figure 3-21 and Figure 3-23 illustrate that 
assumptions of linearity, normality, and homoscedasticity were met by the dynamic 
harmonic regression model. 
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3.3.1.5 Discussion/Conclusions 
Results 
I evaluated possible time-lags of 1 month and 21, 14 and 7 days, in response of 
medication prescribing to temperature.  This was due to the fact that a delay was 
expected between the event that triggered the increased consumption of 
salbutamol, causing a need for a new inhaler, and thus a visit to the GP for a new 
prescription.  The dynamic harmonic regression model captured the seasonal 
periodicity of salbutamol prescribing, in contrast to the static model which failed to 
capture it. Out of the five dynamic models, the one that used temperature at 7 
days lag captured best the temporal variation in salbutamol prescribing. The 
models that used temperature data measured 14 (lag14) and 21 (lag21) days 
before the prescribing month, also captured salbutamol variation as well as the lag7 
model. All of those three models performed well almost indicating that temperature 
recorded within a time window of 7-21 days preceding the prescribing month was a 
good explanatory variable of asthma and COPD exacerbations due to seasonal 
factors.  
The dynamic model with lag7 performed better than the other models and therefore 
was assessed further in order to examine the reliability of it results. The model’s 
residuals met the normality, linearity and homoscedasticity assumptions of linear 
regression. The residuals were also assessed for interdependence in time (temporal 
autocorrelation) but not in space (spatial autocorrelation). This is because 
temperature was considered spatially homogenous in the study and consequently 
this first stage of the model ignored any spatial variation of the covariate. The 
second stage of the model, which is presented in the next section, included 
covariates with both spatial and temporal variability and therefore the model’s 
residuals were checked for both temporal and spatial autocorrelation. Overall, the 
dynamic harmonic regression model with 7 days lag performed well and was 
considered suitable for estimating the area-wide average of salbutamol prescribing 
attributable to seasonality. The output of this model was used as input on the final 
model that included all covariates, described in the section 3.4. 
Potential Future Applications 
The output of this model could also be used in isolation from the rest of the 
analysis. The model captured 75% of the prescribing variation and after some 
additional robust validation could be used for predicting salbutamol prescribing in 
relation to seasonal factors. This predictive model could be used for management of 
resources at the primary care level. Given that the model validation proved reliable, 
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similar models could also be developed for other types of medication or health 
outcomes that follow a seasonal pattern. 
Other studies that assessed the impact of air pollution on prescribing of short-
acting b2-agonists used data on pollen and influenza epidemics in addition to 
weather conditions in order to account as best possible for the seasonal variation of 
prescribing. Using a dynamic harmonic regression model may appear complicated. 
However collecting, editing and manipulating data on pollen and respiratory 
infections is also a complicated and time consuming process. Overall, I consider 
that using temperature data with a dynamic harmonic regression model, provided 
an efficient and pragmatic approach to capturing the seasonal variation of 
salbutamol prescribing. It might also be useful when analysing other asthma or 
COPD health indicators, such as hospital admissions and emergency room visits, 
which are also subject to seasonal variation. 
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3.4 Model Refining (Stage B)  
In the last stage of statistical model development, I fitted linear mixed-effects 
models with an offset. The offset captured the seasonal variation of log salbutamol 
prescribing rate as described in previous chapter. 
3.4.1 Modelling Spatio-temporal Variation of Salbutamol Prescribing 
The final model included all covariates: 1) PM10, 2) Traffic index, 3) Income 
deprivation, 4) Employment deprivation, 5) Educational Deprivation, 6) Average 
age of patients registered with GP practices and 6) sex (males/females) ratio of 
patients registered with GP practices.  
I tested the influence of air quality indicators (mean 24-h concentrations for PM10 
and monthly traffic flows per GP service area) observed in the same month as the 
prescribing (lag0), and then with a variety of lag periods. I evaluated monthly 
average PM10 levels observed 7 days (lag 7), 14 days (lag 14), 21 days (lag 21) 
and 1 month (lag 30) before the first day of each prescribing month. The traffic 
flow data were provided with a monthly temporal resolution, therefore it was not 
possible to create weekly time lags as in the case of air pollutants. I created time-
lag of one month (lag30) based on data observed in the month before the 
prescribing month. The estimation of air quality covariates for different time points 
was important because a lag period was expected between exposure of individuals 
and prescribing. I was interested to examine whether my models would capture 
that. I was also interested to examine which if any lag period would have a 
statistically significant association with prescribing. 
A summary of the descriptive statistics is presented in Table 3-1 for all covariates 
at different lag times. The mean, minimum and maximum values were estimated. 
However the median, 1st and 3rd quintile were more informative about the data 
distribution. 
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  Min. 1st Qu. Median Mean 3rd Qu. Max. 
PM10_lag0days 13.2 16.1 18.0 18.9 20.9 29.0 
PM10_lag7days 11.7 16.0 18.8 18.9 20.8 33.9 
PM10_lag14days 12.1 16.0 17.7 18.6 20.1 35.5 
PM10_lag21days 12.5 16.0 18.0 18.7 20.8 31.0 
PM10_lag30days 13.2 16.1 17.7 18.7 20.8 29.0 
Traffic_lag0days  191.9 496.4 781.8 905.0 1268.5 3235.0 
Traffic_lag30days  191.9 495.4 781.8 903.9 1267.5 3235.0 
Income Deprivation 0.1 0.1 0.2 0.2 0.3 0.5 
Employment Deprivation 0.1 0.1 0.2 0.2 0.2 0.3 
Educational Deprivation 4.1 17.5 28.9 30.2 42.4 70.8 
Average age 29.0 38.0 39.0 39.0 41.0 46.0 
Sex ratio 0.8 0.9 1.0 1.0 1.0 1.8 
Table 3-1. Descriptive statistics of covariates. 
 
3.4.1.1 Method 
 I fitted the models with all covariates. The mixed effects model took the form: 
ijijij xaxay 81 ... +++= µ ijijij zbzb ε++++ 641 ...  
bi=N(0,σ
2
b) and 
),0( 2σε Ν=ij    
where yij is the log transformed salbutamol prescribing rate for observations j in 
group i, µ is the population-average prescribing of salbutamol (intercept),  α are 
eight fixed effect parameters respective to x=1,…,8 covariates. The random variable 
εij is the error term for jth observation of the ith practice, assumed independent and 
identically distributed, N (0, σ2).  The bi are the random effects also assumed to 
have come from a normal distribution N (0, σ2).  
In cases where both GP practices and PCTs were introduced as random effects the 
vector of random effects b consisted of the 64 practice parameters plus 128 PCT-
practice interaction parameters b65, b66, ..., b192. I fitted models with both types of 
random effects and compared them. 
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3.4.1.2 Analysis 
I fitted separate models for each combination of time lags for which the air quality 
indicators were estimated. These combinations produced 10 mixed-effects models 
which I denoted as:  
 
1) L30PM_30TR: 1 month lag for PM10 and 1 month for traffic flows 
2) L21PM_30TR: 21 days lag for PM10 and 1 month for traffic flows 
3) L14PM_30TR: 14 days lag for PM10 and 1 month for traffic flows 
4) L7PM_30TR:  7 days lag for PM10 and 1 month for traffic flows 
5) L0PM_30TR:  0 days lag for PM10 and 1 month for traffic flows 
 
6) L30PM_0TR:  1 month lag for PM10 and 0 days for traffic flows 
7) L21PM_0TR:  21 days lag for PM10 and 0 days for traffic flows 
8) L14PM_0TR:  14 days lag for PM10 and 0 days for traffic flows 
9) L7PM_0TR:    7 days lag for PM10 and 0 days for traffic flows 
10) L0PM_0TR:  0 days lag for PM10 and 0 days for traffic flows 
 
Random effects in the above models were specified for GP practices. I also 
considered grouping GP practices within PCTs, as PCTs are the administrative 
bodies of GPs and I wanted to examine whether there was an effect on prescribing 
due to such grouping. Consequently, I fitted 10 additional models by grouping the 
data both by GP practices and PCTs. I added the ending “pct” to the model 
descriptions (i.e. L30PM_30TR_pct) to denote that they had random effects 
assigned to both GP practice and PCT. 
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3.4.1.3 Results 
The results of the final models with GP practice random effects are summarised in 
Table 3-2. A few models returned identical results in cases where PM10 was not 
significant in specific time-lags, the results of which are also presented in Table 3-2. 
For instance the models L30PM_30TR, L7PM_30TR and L0PM_30T produced 
identical results as PM10 was not statistically significant in 30-, 7- and 0- days lag, 
and consequently, the coefficients of the statistically significant predictors were 
identical. 
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TRAFFIC 30 DAYS LAG 
L21PM_30TR Estimate Std.Error t value Pr(>|t|) 
(Intercept) -2.01821 0.15007 -13.447986 <0.0001 
PM10_lag21days 0.00102 0.00047 2.185799 0.0288 
Traffic_lag30days 0.00007 0.00002 3.032136 0.0024 
Time (months) -0.00066 0.00012 -5.629881 <0.0001 
Income Deprivation 2.81133 0.30695 9.158998 <0.0001 
Average Age of Patients 0.03296 0.00316 10.439382 <0.0001 
 
L14PM_30TR Estimate Std.Error t value Pr(>|t|) 
(Intercept) 
-2.02196 0.15014 -13.46709 <0.0001 
PM10_lag14days 0.00109 0.00045 2.411585 0.0159 
Traffic_lag30days 0.00007 0.00002 3.138812 0.0017 
Time (months) 
-0.00067 0.00012 -5.660241 <0.0001 
Income Deprivation 2.80937 0.30721 9.144675 <0.0001 
Average Age of Patients 0.03297 0.00316 10.44511 <0.0001 
 
L30PM_30TR  -  L7PM_30TR  -  L0PM_30TR Estimate Std.Error t value Pr(>|t|) 
(Intercept) 
-1.99854 0.14987 -13.33504 <0.0001 
Traffic_lag30days 0.00007 0.00002 3.030806 0.0024 
Time (months) 
-0.00067 0.00012 -5.679115 <0.0001 
Income Deprivation 2.81650 0.30700 9.174114 <0.0001 
Average Age of Patients 0.03292 0.00316 10.42185 <0.0001 
 
TRAFFIC 0 DAYS LAG 
L21PM_0TR Estimate Std.Error t value Pr(>|t|) 
(Intercept) 
-2.02922 0.15001 -13.52753 <0.0001 
PM10_lag21days 0.00093 0.00047 1.975763 0.0482 
Traffic_lag0days 0.00009 0.00002 3.677388 0.0002 
Time (months) 
-0.00067 0.00012 -5.68998 <0.0001 
Income Deprivation 2.81647 0.30843 9.131577 <0.0001 
Average Age of Patients 0.03294 0.00316 10.43984 <0.0001 
 
L14PM_0TR Estimate Std.Error t value Pr(>|t|) 
(Intercept) 
-2.02735 0.14994 -13.52078 <0.0001 
PM10_lag14days 0.00090 0.00045 1.976244 0.0481 
Traffic_lag0days 0.00009 0.00002 3.623905 0.0003 
Time (months) 
-0.00067 0.00012 -5.700385 <0.0001 
Income Deprivation 2.81550 0.30830 9.13223 <0.0001 
Average Age of Patients 0.03294 0.00316 10.43937 <0.0001 
 
L30PM_0TR  &  L7PM_0TR  &  L0PM_0TR Estimate Std.Error t value Pr(>|t|) 
(Intercept) 
-2.01411 0.14991 -13.43565 <0.0001 
Traffic_lag0days 0.00009 0.00002 3.795247 0.0001 
Time (months) 
-0.00068 0.00012 -5.750147 <0.0001 
Income Deprivation 2.82119 0.30879 9.136207 <0.0001 
Average Age of Patients 0.03291 0.00316 10.42655 <0.0001 
Table 3-2. Results of p-values and coefficients’ values from models with GP practice 
grouping as random effect. 
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The results of the models with GP practice and PCT-GP practice random effects are 
presented in Table 3-3. Again models that produced identical results, due to 
identical statistically significant covariates are presented only once. 
 
TRAFFIC 30 DAYS LAG 
L21PM_30TR_pct Estimate Std.Error t value Pr(>|t|) 
(Intercept) -2.04707 0.16230 -12.61292 <0.0001 
PM10_lag21days 0.00102 0.00047 2.17111 0.0299 
Traffic_lag30days 0.00008 0.00002 3.26859 0.0011 
Time (months) -0.00067 0.00012 -5.71480 <0.0001 
Income Deprivation 2.95462 0.31390 9.41270 <0.0001 
Average Age of Patients 0.03290 0.00315 10.43121 <0.0001 
 
L14PM_30TR_pct Estimate Std.Error t value Pr(>|t|) 
(Intercept) -2.05158 0.16268 -12.61130 <0.0001 
PM10_lag14days 0.00110 0.00045 2.42894 0.0151 
Traffic_lag30days 0.00008 0.00002 3.37794 0.0007 
Time (months) -0.00068 0.00012 -5.74695 <0.0001 
Income Deprivation 2.95500 0.31411 9.40743 <0.0001 
Average Age of Patients 0.03291 0.00315 10.43707 <0.0001 
 
L30PM_30TR_pct & L7PM_30TR_pct & 
L0PM_30TR_pct 
Estimate Std.Error t value Pr(>|t|) 
(Intercept) -2.02768 0.16221 -12.50014 <0.0001 
Traffic_lag30days 0.00008 0.00002 3.26898 0.0011 
Time (months) -0.00068 0.00012 -5.76545 <0.0001 
Income Deprivation 2.96043 0.31396 9.42927 <0.0001 
Average Age of Patients 0.03286 0.00316 10.41354 <0.0001 
 
TRAFFIC 0 DAYS LAG 
L30PM_0TR_pct & L21PM_0TR_pct& 
L14PM_0TR_pct & L7PM_0TR_pct & 
L0PM_0TR_pct 
Estimate Std.Error t value Pr(>|t|) 
(Intercept) -2.04608 0.16450 -12.43783 <0.0001 
Traffic_lag0days 0.00010 0.00002 4.04616 0.0001 
Time (months) -0.00069 0.00012 -5.84281 <0.0001 
Income Deprivation 2.98172 0.31551 9.45056 <0.0001 
Average Age of Patients 0.03284 0.00315 10.41621 <0.0001 
Table 3-3. Results of log salbutamol prescribing rate from models with PCT and GP 
grouping as random effect. 
The small p-values associated with the output of the models (Table 3-2 & Table 
3-3) indicated that PM10 had a positive significant association with prescribing of 
salbutamol medication at primary care health level. PM10 levels on 14 and 21 days 
preceding the prescribing month were related significantly to respiratory 
prescribing. No influence of salbutamol prescribing rate was observed for PM10 
concentrations occurring in the same month (lag 0) as salbutamol prescribing, or 
one month (lag30) or 7 days (lag7) earlier than prescribing.  
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The results also indicated that GP practices with different traffic conditions in their 
service area (defined as the area where 98% of their patients are expected to live) 
had significantly different prescribing patterns. The traffic flow index based on data 
observed in the month of prescribing as well as a month earlier to prescribing were 
statistically significant. 
The small p-values also indicated that prescribing was negatively influenced by 
time, meaning that a decrease of salbutamol prescribing occurred during the study 
period. In addition, GP practices with different levels of income deprivation had 
significantly different prescribing. An increase in salbutamol prescribing was 
observed with increase in deprivation. Employment and educational deprivation had 
no significant relation to salbutamol prescribing.  
The average age of patients registered with each GP practice also appeared to be 
associated with different prescribing patterns by GPs. The older the population a GP 
served, the higher the rate of salbutamol prescribing appeared to be. The ratio of 
males to females that GP practices served had a negative relationship with 
salbutamol prescribing (more male patients - more salbutamol prescribing) but it 
was not statistically significant.  
The same covariates were identified as significant by the models that assigned GP 
practice or both PCT \ GP practice as random effects. The main difference was that 
only PM10 levels 21 days before prescribing (lag21), were significant for models with 
the PCT\GP grouping factor, while PM10 with both 21 and 14 days lag was 
significant in models with only GP grouping.  
I referred to the models without PM10, as reduced models because had fewer 
significant covariates (traffic, income, time, average age of patients) compared to 
those that included PM10 as a statistically significant covariate. In the next section, I 
compared the models presented in Table 3-2 and Table 3-3, in order to examine if 
they were statistically different from each other.  
3.4.1.4 Model Comparison – Parsimonious Model 
There is no absolute “correct” model. However, the best model is the simplest one 
out of those that most closely achieve the objectives of the study. Comparison of 
the statistical models I had developed was required, in order to identify the most 
parsimonious. Particulate matter appeared to be significant in some models but not 
in others. I compared only models that included particulate matter as an 
explanatory variable for estimating salbutamol prescribing, because that was the 
main measure of air pollution exposure in my analysis. 
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I carried out anova tests to compare mixed-effects models (Pinheiro and Bates, 
2000). I grouped my models into those that had one level of grouping (GP) and 
those that had two levels (PCT\GP). I firstly assessed whether the models that 
shared the same grouping factor were significantly different from each other. Then, 
I compared the best models from each category to assess whether the grouping by 
GP or PCT\GP made them statistically different. 
If the p-values on the anova output were high, the models were not statistically 
different. In such cases, it is suggested that the Akaike Information Criterion (AIC) 
(Akaike 1973, Skamoto et al, 1976) be used to identify the most parsimonious 
model (Pinheiro and Bates, 2000). The chosen model is the one for which the AIC=-
2lmax+2k reaches a minimum, where lmax is the log-likelihood maximum and k is the 
number of unknown parameters. The smaller the AIC, the better the model 
(Demidenko, 2004, Pinheiro J. et al., 2008). 
Table 3-4 presents the anova tests conducted for models that had been assigned 
random effects on GP level, while Table 3-5 shows the results of anova tests for 
models with PCT\GP random effects. The small p-values show that the first model 
should be rejected in favour of the others. I repeated the process after removing 
the rejected model until there were no further models to reject as significantly 
different. Table 3-4 shows that the most parsimonious model when grouping the 
data by GP was the one that included the following covariates: a) PM10 21 days 
before salbutamol prescribing, and b) traffic index based on traffic flows observed a 
month before prescribing. The same model emerged as the most parsimonious 
from the class of models that had two levels of random effects (PCT\GP), as shown 
in Table 3-5.  
The models with 21 days and 1 month latency period for PM10 and traffic index 
respectively proved more parsimonious under both types of groupings used: i) GP 
level (model L21PM_30TR) and ii) PCT\GP level (model L21PM_30TR_pct). I finally used 
the anova test again to assess if those two final models were significantly different. 
High p-values in anova output (Table 3-6) indicated that I could not reject the 
L21PM_30TR model in favour of the L21PM_30TR_pct, meaning there was no 
significant difference between them.  
A judgment on which was more parsimonious should be based on AIC criterion 
since the p-values were high. The AIC was slightly smaller for the latter model. 
However, the difference between those values was still marginal. In the next 
section (3.4.2), I examined those two models in detail and critically evaluated them 
in order to reach conclusions regarding the validity of their results (Table 3-2, Table 
3-3).  
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Models with 
GP grouping factor Df AIC BIC logLik 
Chisq 
Chi Df  Pr(>Chisq)  
L14PM_0TR 8 
-5374.1 -5324.8 2695.1      
L14PM_30TR 8 
-5370.9 -5321.6 2693.4 0 0 < 2.20E-16 *** 
L21PM_0TR 8 
-5374.1 -5324.8 2695.1 3.2189 0 < 2.20E-16 *** 
L21PM_30TR 8 
-5369.9 -5320.5 2692.9 0 0 < 2.20E-16 *** 
 
L14PM_30TR 8 
-5370.9 -5321.6 2693.4      
L21PM_0TR 8 
-5374.1 -5324.8 2695.1 3.2189 0 < 2.20E-16 *** 
L21PM_30TR 8 
-5369.9 -5320.5 2692.9 0 0 < 2.20E-16 *** 
 
L21PM_0TR 8 
-5374.1 -5324.8 2695.1      
L21PM_30TR 8 
-5369.9 -5320.5 2692.9 0 0 < 2.20E-16 *** 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1      
Table 3-4. Comparison of models grouped per GP. 
 
 
Models with 
PCT\GP grouping factor Df AIC BIC logLik 
Chisq 
Chi Df  Pr(>Chisq)  
L14PM_30TR_pct 9 -5373,7 -5318,2 2695,8      
L21PM_30TR_pct 9 -5372,5 -5317 2695,2 0 0 < 2,20E-16 *** 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1      
Table 3-5. Comparison of models grouped per PCT and GP. 
 
Models with GP vs 
PCT\GP grouping factor Df AIC BIC logLik 
Chisq 
Chi Df Pr(>Chisq) 
L21PM_30TR 8 
-5369.9 -5320.5 2692.9    
L21PM_30TR_pct 9 -5372.5 -5317 2695.2 0 1 1 
Table 3-6. Comparison of models grouped per GP versus model grouped per PCT & 
GP. 
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3.4.2 Model Criticism 
My analysis had produced two statistical models which I needed to examine 
critically, in order to be able to comment on the reliability of their results. Firstly, I 
inspected the structure of their random effects. I then examined the fixed effects 
by checking whether the residuals of the model met the four assumptions of linear 
regression: 1) normality, 2) linearity, 3) homoscedasticity and 4) independence. I 
examined both temporal and spatial independence. Model evaluation was a very 
important part of the statistical modelling process as it allowed assessment of the 
reliability of results produced by those models. 
3.4.2.1 Random Effects Structure 
The two final models included particulate matter with 21 days lag and the traffic 
index with 30 days lag. All fixed effects (covariates) were common to these two 
models but they had different random effects. The first model had GP level as a 
random effect (L21PM_30TR) while the second had two levels of random effect; 
PCT and GP (L21PM_30TR_pct). Based on anova results (Table 3-6) these two 
models were not statistically different and I could not reject the former in favour of 
the latter or vice versa.   
Model with PCT and GP random effects 
I then examined the structure of their random effects. I extracted the random 
effects for each grouping factor and summarised the random effects structure in 
graphical format. Figure 3-22 shows the value of random effects by PCT as well as 
the 95% prediction intervals associated with this value.  
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Figure 3-22 Plot of the random effects for Newcastle (NCL) and North Tyneside (NT) 
PCTs and their respective confidence intervals 
 
Each set of prediction intervals (Figure 3-22) had constant width because of the 
balance of the data used in this study. The prediction intervals for the PCTs’ random 
effects overlapped zero and each other, denoting that the effect of PCTs was not 
statistically significant. This meant that the effect of PCTs in salbutamol prescribing 
was likely to be zero. The fact that the intervals were wide also denoted great 
uncertainty in this prediction, showing that the model had not satisfactorily 
captured those effects. This was related to the very small number of PCTs used in 
this study.  
Based on examination of random effects of the “L21PM_30TR_pct” model (Figure 
3-22), I decided that the model failed to predict the random effects on PCT level 
reliably, and consequently, I could not accept this model’s output.  
 
Model with GP Random Effects 
The structure of random effects of the remaining final model (L21PM_30TR) was 
then examined further by plotting again the random effects in the form of 95% 
prediction intervals, arranged in increasing order of conditional mean.  
Figure 3-23 shows that the model satisfactorily captured the random effects of GP 
practices, with small prediction intervals associated with each one. Most of the 
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prediction intervals for the random effects did not overlap zero, meaning that the 
effect of GP practices was statistically significant. In other words, effect of GP 
practices was unlikely to be zero, or more accurately the effect found in this sample 
of 64 GP practices was not the sort of effect one would expect to see if there was 
no effect in the population from which this sample was drawn. 
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Figure 3-23. Plot of the random effects for 64 General practices and their respective confidence intervals.  
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For linear mixed models the conditional distribution of the random effects, given the 
data, written (B/Y=y), is a multivariate Gaussian distribution with zero mean. Since 
the random effects were assumed to follow a Gaussian distribution I created a QQ-
plot to assess the normality of random effects in the final “L21PM_30TR” model.  
 
 
 
 
 
 
 
 
 
 
Figure 3-24. Normality plot of random effects of final model. 
 
Figure 3-24 shows that the random effects satisfactorily approximated a straight 
line. An outlier was observed at the bottom of the graph that refers to the GP 
practice A86027, which is located within the campus of Newcastle University. This 
practice had the lowest prescribing rate of salbutamol and also a different 
demographic profile compared to other practices. A large number of its registered 
patients were young people and a significantly larger proportion of population of the 
registered patients were male. This was explained due to its proximity to the 
university, making it one of the two practices within Newcastle that have large 
numbers of students registered with them.  
The very low prescribing rate of salbutamol in this practice was not considered to 
be an outlier caused by error in data recording. According to the NHS Information 
Centre data, this practice scores lower than the regional and national average for 
all main chronic diseases, including asthma and COPD (NHS The Information Centre 
for Health and Social Care, 2008).  
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3.4.2.2 Fixed Effects Structure 
I checked the fixed effects as well, in order to ascertain whether the most 
parsimonious model “L21PM_30TR” I arrived at, provided a satisfactory fit to the 
data. I examined the model for normality, linearity, homoscedasticity and 
independence. 
Normality, Linearity, Homoscedasticity Assumption 
The best test for normally distributed errors is a normal probability plot of the 
residuals. 
 
Figure 3-25. Normal probability plot of the residuals of the final model. 
The normal probability plot of residuals was close to a straight line with slight 
curves at the edges. This indicated a longer tail for the lower and upper levels of 
salbutamol prescribing, suggesting the model was not adequate to capture variation 
at these levels. However because of the large number of observations (3,520 
records) this deviation from normality was considered to have mild impact on the 
fitted values.  
The standard plots for detecting linearity were plots of observed versus fitted 
values, or residuals versus fitted values. The latter plot was used to assess whether 
the homoscedasticity (constant variance) assumption was met, together with plots 
of residuals versus time. These three graphs are presented below. 
 
. 
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Figure 3-26. Plot of observed against fitted values of the final model. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-27. Residuals against time of the final model. 
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Figure 3-28 Residuals against fitted values of the final model. 
 
The observed and fitted values of salbutamol prescribing in Figure 3-26 were 
symmetrically distributed around a diagonal line. Exceptions formed a number of 
observations at the left bottom corner of the graph, indicating that the model made 
unusually small estimations. Figure 3-27 illustrates that residuals against time 
formed a horizontal line as they should. Figure 3-28 shows that residuals remained 
constant in relation to fitted values with the exception of a few residuals that 
increased in relation to very small fitted values. In order to further investigate the 
exceptions on those graphs I created the same plots by GP practice Figure 3-28, 
Figure 3-29 and Figure 3-30. Because of the big number of practices is difficult to 
look in detail the diagnostic per practice therefore the three graphs are also 
presented in detail in Appendix H. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-29. Observed against fitted values of the final model by GP practice. 
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Figure 3-30. Residuals against time of the final model by GP practice. 
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Figure 3-31. Residuals against fitted values of salbutamol prescribing by GP practice. 
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Figure 3-29, Figure 3-30 and Figure 3-31 demonstrate the symmetrical distribution 
of GP-specific residuals, with the exception of mainly two GP practices. One of them 
was practice A86027 which had the lowest prescribing rate and an unusual 
distribution of age and sex of patients registered within it, as discussed earlier. 
Unusual patterns also emerged from the residuals of practice A86029, for which an 
abrupt increase in salbutamol prescribing occurred approximately in the middle of 
the study period. Overall, the distribution of observed values versus fitted, as well 
as residuals versus time, and predicted values, were symmetrical for the vast 
majority of GP practices, thus implying that the assumptions of linearity and 
homoscedasticity were met. 
 
Interdependence in Time - Temporal Autocorrelation 
Interdependence (correlation) between observations was anticipated for the same 
GP practices, due to unknown influences, varying randomly over practices. For 
example, the prescribing patterns that individual General Practitioners may have, 
could cause the prescribing in a given month to correlate with prescribing in the 
next or previous month. When a variable correlates to itself the term 
autocorrelation is used to describe this interdependence. As a next step, I 
examined the temporal autocorrelation of the residuals.  
An important guide to correlation of temporal data was given by the autocorrelation 
function (acf) that measured the correlation between observations at different 
times (Chatfield, 2004). I estimated and plotted the set of autocorrelation 
coefficients, arranged as a function of separation in time that I defined to be 12 
monthly intervals or lags (Figure 3-32). By presenting the coefficients at increasing 
lags (e.g., l=1,2,…12) I could assess whether dependence was restricted to one or 
more lags.  
When the correlation coefficient at any given lag fell within the 95% confidence 
interval, there was no temporal autocorrelation on this lag. An approximation of the 
95% confidence limit was calculated with the equation: 
Nr /2095. ±≅                                                                                          3-13 
where N is the number of observations. This is based on the assumption that if a 
time series is completely random, and the sample size is large, the lagged-
correlation coefficient is approximately normally distributed with mean 0 and 
variance 1/N (Chatfield, 2004). For a sample of 55 months the confidence interval 
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is approximately 27.0± . The correlation coefficients for the mixed effects model 
were around 0.3 (Figure 3-32) at some lags, which was considered minor positive 
temporal autocorrelation. The persistent temporal autocorrelation indicated that 
some monthly variation was not accounted sufficiently over time. This could be 
possible related to the measurement of monthly air pollution exposure, however I 
consider that the reliability of the model output is sufficient as the observed 
temporal autocorrelation is minor.   
 
Figure 3-32 Interdependence of residuals in time (temporal autocorrelation) 
 
Interdependence in Space - Spatial Autocorrelation 
 
Spatial autocorrelation is a mode of spatial statistics that has been developed 
mainly over the past five decades. Models have to be checked as to whether the 
interdependence assumption of observations in space is satisfied. Not meeting this 
assumption again calls into question the reliability of a model’s output. I needed to 
examine whether the random effects were correlated spatially. I assessed the 
spatial interdependence of random effects, using geoR that is a package for 
geostatistical data analysis using the R software (Ribeiro JR. and Diggle, 2001). 
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If the random effects were not independent that would indicate that the model did 
not account sufficiently for some explanatory process or event that exhibits spatial 
correlation (e.g. air pollution, deprivation). Random effects can be a combination of 
factors that depend on facilities within the practice, as well as the training, 
experience and prescribing pattern of individual General Practitioners. Such random 
influences should not be spatially correlated.  
I used empirical variograms to assess the spatial interdependence of random 
effects. The empirical variogram (Figure 3-37) shows an increasing trend over distances 
up to 3000m, suggesting that there might be some positive spatial correlation over this 
range. I compared the variogram with the computed envelope of variograms. Figure 
3-34 indicates no spatial autocorrelation as the empirical variogram fall within the 
upper and lower simulation envelope.  
 
 
Figure 3-33 Empirical variogram for random effects 
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Figure 3-34 MonteCarlo envelop for the variogram of random effects 
3.4.3 Final Results 
So far I have screened covariates for significant p-values and have gradually 
developed a model (L21PM_30TR, section 3.4.1.3) that I believe to be both 
parsimonious and adequate. I needed to evaluate the p-values associated with 
various explanatory variables. The p-values of the final model were informative, but 
it was of equal importance to examine how exact they were. Therefore, I examined 
the confidence intervals associated with the coefficients of the model. The 
confidence intervals provided information of how precise the estimates of the model 
were and it can be argued that they are at least as important as p-values.  
In Table 3-7, I present the p-values, coefficients and their confidence intervals 
produced by the final model “L21PM_30TR”. The columns L_CL and U_CL, in Table 
3-7, show the 95% lower confidence limits and upper confidence limits respectively. 
The confidence intervals were not wide indicating a sufficiently precise estimate of 
the coefficients. 
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Model L21PM_30TR 
 Estimate Std.Error t value Pr(>|t|) L_CL U_CL 
(Intercept) -2.01821 0.15007 -13.447986 <0.0001 -2.31235 -1.72406 
PM10_lag21days 0.00102 0.00047 2.185799 0.0288 0.00011 0.00194 
Traffic_lag30days 0.00007 0.00002 3.032136 0.0024 0.00003 0.00012 
Time (months) -0.00066 0.00012 -5.629881 <0.0001 -0.00089 -0.00043 
Income Deprivation 2.81133 0.30695 9.158998 <0.0001 2.20972 3.41295 
Average Age of Patients 0.03296 0.00316 10.439382 <0.0001 0.02677 0.03915 
Table 3-7 Coefficients and confidence intervals for L21PM_30TR model 
 
I then examined the strength of association between salbutamol prescribing and 
covariates.  I assessed the impact of an increase on fixed effects (covariates) to 
salbutamol prescribing. I quantified the impact on salbutamol prescribing rate in 
the case of: 1) an increase of 10μg/m3 in ambient PM10, 2) an increase of one 
standard deviation (s.d.) of the traffic index (513 on traffic index score), 3) one 
year elapsing 4) an increase of one standard deviation (s.d.) of income deprivation 
(equals 0.1 income deprivation score) and 5) an increase of 3 years in average age 
of patients registered per GP practice.  
The association of explanatory variables with salbutamol prescribing is presented in 
Table 3-8. I transformed the log salbutamol prescribing rate back to a normal scale, 
in order to be able to interpret the results meaningfully. 
Table 3-8 presents the percentage change in salbutamol prescribing with given 
increases in predictors’ units. An increase of 10 µg/m3 of PM10 was associated with 
a 1% (95% CI, 0.1 to 2.0%) increase in salbutamol prescribing. An increase of one 
standard deviation (513) in traffic index score was associated with an increase of 
3.8% (95% CI, 1.6 to 5.8%). One year in elapse of time was related to a 0.6% 
reduction (95% CI, 0.4% to 1.1%) indicating a marginal decrease in salbutamol 
prescribing over the study period. An increase of one standard deviation (0.1) in 
income deprivation was associated with a much larger increase in salbutamol 
prescribing rate of 32.5% (95% CI, 24.7 to 40.7%) to salbutamol prescribing rate. 
Finally, three years increase in the average age of patients registered with a GP 
practice was associated with a 10.4% (95% CI, 8.4 to 12.5%) increase in 
salbutamol prescribing rate. 
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Model L21PM_30TR 
 Covariates’ increase 
Change on salbutamol 
prescribing rate 
Lower CL Upper CL 
PM10 (lag 21 days) 10μg/m
3 1.0% 0.1% 2.0% 
Traffic (lag 1 month) 1 s.d. (513) 3.8% 1.6% 5.8% 
Time (months) 12 months -0.6% -1.1% -0.4% 
Income deprivation 1 s.d. (0.1) 32.5% 24.7% 40.7% 
Age 3 years 10.4% 8.4% 12.5% 
Table 3-8  Association of explanatory variables to salbutamol prescribing rate 
 
3.4.3.1 Parameter Evaluation using Markov Chain Monte Carlo simulations 
As a last step, I evaluated the parameters and p-values of the final statistical model 
(L21PM_30TR) using Markov chain Monte Carlo (MCMC) simulations. I evaluated p-
values for fixed effects from the MCMC sample using a function within the 
“languageR” extension in R software. This function for estimating the p-values 
based on MCMC sampling was not stable at the time I conducted the analysis (July 
2009). This analysis was to great extent motivated by my interest to test the most 
recent algorithms and techniques in the highly active field of mixed effects models, 
in an attempt to evaluate the results of my final model. Therefore, I did not intend 
to accept the results as absolutely correct, but rather to examine whether its output 
would be close to that of my final model, as would be expected in theory. 
 
Method 
I generated MCMC sampling from the posterior distribution of my final model’s 
parameters. I plotted the densities of the sample in Figure 3-35, which shows that 
the posterior density of the fixed-effect parameters was reasonably symmetric and 
close to a normal distribution. 
I fitted the final model using a Markov chain Monte Carlo (MCMC) technique and 
compared the p-values of the new model to my final model. I denoted the new 
model, created by MCMC analysis, as “L21PM_30TR_mcmc”. The fixed effects, as 
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well as respective prediction intervals were also estimated, based on repeated-
sampling properties.  
The MCMC model (L21PM_30TR_mcmc) would be expected to produce similar p-
values to the final model (L21PM_30TR), where the sample is not small (Baayen et 
al., 2008). The sample in this study (55 observations from 64 practices) could not 
be considered small; therefore I expected the MCMC technique to confirm the p-
values of my final model.  
 
 
 
 
 
 
 
 
 
Figure 3-35 Empirical density estimates for the MCMC sample for the posterior 
distribution of parameters in the final model 
Results 
The results of L21PM_30TR_mcmc are presented in Table 3-9. The last column 
(Pr(>|t|)) of the table shows the p-values of the final model “L21PM_30TR” (Table 
3-7). Comparing the p-values based on the posterior distribution (pMCMC) and on 
the t-distribution (Pr(>|t|)), a  difference appeared in the p-value associated with 
the covariate “Traffic_lag30days”. The high p-value of 0.294, estimated by the new 
model, meant that the traffic flow index had no statistically significant relationship 
to salbutamol prescribing. The p-values related to the other explanatory variables 
remained significant. 
 
  
 
Model L21PM_30TR_mcmc 
 Estimate MCMCmean HPD95lower HPD95upper pMCMC Pr(>|t|) 
(Intercept) 
-2.0182 -2.2035 -2.4446 -1.96 0.0001 <0.0001 
PM10_lag21days 
-0.0007 -0.0007 -0.0009 -0.0004 0.0001 0.0289 
Traffic_lag30days 0.001 0.001 0.0001 0.002 0.0324 0.0024 
Time (months) 0.0001 0 0 0.0001 0.2774 <0.0001 
Income deprivation 2.8113 2.8703 2.6102 3.1309 0.0001 <0.0001 
Average age of patients 0.033 0.0386 0.0328 0.0441 0.0001 <0.0001 
 
Table 3-9 Results of L21PM_30TR model based on Markov chain Monte Carlo analysis
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I then examined whether the magnitudes of the coefficients had changed. The 
columns L_CI and U_CI, in Table 3-7, show the 95% lower confidence limits and 
upper confidence limits, respectively. The confidence intervals were not wide and 
showed a sufficiently precise estimate of the coefficients. The same held for the 
equivalent MCMC intervals observed in Table 3-9, where the columns “HPD95lower” 
and “HPD95upper” show the lower and upper 95% Highest Posterior Density (HPD) 
intervals respectively, for the parameters in the MCMC sample. A 95% prediction 
interval is an estimate of an interval in which future observations will fall, with a 
95% probability, given what has already been observed. 
In order to investigate the mcmc model further, I plotted the MCMC estimates of 
covariates in association with salbutamol prescribing rate (Figure 3-36). In Figure 
3-36, the dotted lines depict the 95% prediction intervals associated with 
salbutamol prescribing. The estimates related to large values of traffic flow index 
(diagram “Traf_30lag” in Figure 3-36), fell outside the 95% prediction interval, 
making this relationship not statistically significant according the MCMC analysis as 
discussed earlier. However, I observed that the prediction interval was wider 
towards the large values of traffic index, showing increased uncertainty in this 
prediction. Overall, I accepted the result of the final model (L21PM_30TR). This was 
because the function for estimating the p-values based on MCMC sampling was not 
stable at the time I conducted the analysis. At the same time, I would re-visit the 
calculation of that index, taking into account the issues I discussed in Section 
2.2.2.4.  
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Figure 3-36  MCMC estimates of predictors in association to log average salbutamol prescribing  
                      Income                                                             Age 
                          PM10                                                             Traffic                                                          Months 
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3.4.3.2 Goodness-of-fit  
I created a graph (Figure 3-37) of the predicted values of log salbutamol 
prescribing based on the final model (L21PM_30TR) against the observed values by 
GP practice. Figure 3-37, Figure 3-38, Figure 3-39 and Figure 3-40 illustrate the 
goodness-of-fit of the final model. The predicted value captured the GP practice 
specific prescribing (intercept), while the within GP practice variation was not 
captured in an equally successful manner in some practices. The highest 
discrepancy occurred in practices with high within group variability, showing that 
the model was not adequate to capture the variation of salbutamol prescribing on 
the edges.  
The coefficient of determination (R-squared) shows the proportion of variability in a 
data set, which is accounted for by the statistical model and provides a measure of 
how well future outcomes are likely to be predicted by models. R-squared is 
appropriate for models that use the Ordinary Least Squares (OLS) approach to 
calculate the minimum variance. The estimates of a mixed-effects model are 
maximum likelihood estimates though, so the OLS approach as a measure of 
goodness-of-fit is not appropriate. To evaluate the goodness-of-fit of mixed-effects 
model, other approaches have been developed. These are called pseudo R-squares, 
the usefulness of which is debatable (Orelien and Edwards, 2008). I used a pseudo 
R-square which is meant to be appropriate for mixed-effects model with random 
intercepts. I extracted the total variance explained by a mixed-effects models and 
the total variance explained by the same mixed-effects model when fitted only with 
the random effects. More details on this estimation are presented in  Appendix I. 
The pseudo R-squared value for the final statistical model (L21PM_30TR) was 
48.3%.  
In the absence of a widely accepted statistic such as R2 of traditional linear 
regression for the linear mixed model, I used correlation as a last step to gain a 
quantitative estimate of how well the model fitted the data. The correlation 
coefficient was 0.96 between the observed and the fitted values. 
Overall, the final model captured the GP practice specific prescribing satisfactorily. 
The within GP practice variability was captured satisfactorily for the vast majority of 
GP practices but not for the few that exhibited very high prescribing variability. The 
model performed reasonably well but robust external validation of its outcome will 
be required if there is any interest to predict salbutamol prescribing in the future. 
 
  
  
 
Figure 3-37  Final model: Predicted values (pink line) of log salbutamol prescribing against the observed (blue line) per GP practice 
Statistical
 M
od
elling
 
151
 
  
 
Figure 3-38 Final model: Predicted values (pink line) of log salbutamol prescribing against the observed (blue line) per GP practice 
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Figure 3-39 Final model: Predicted values (pink line) of log salbutamol prescribing against the observed (blue line) per GP practice 
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Figure 3-40 Final model: Predicted values (pink line) of log salbutamol prescribing against the observed (blue line) per GP practice 
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Chapter 4. Discussion  
This study demonstrated an association between patients’ exposure to ambient air 
pollution and the risk of increased quick-relief medication usage by asthma and 
COPD patients at primary care level. These findings, added to current 
understanding of the link between air quality, asthma & COPD exacerbation and 
prescribing, can ultimately increase the scope of primary care management. The 
study demonstrated that respiratory prescribing can be a useful indicator of 
respiratory health outcomes with great scope for use in epidemiological surveillance 
of air pollution health effects. The study found that an increase of 10µg/m3 in 
monthly ambient PM10 concentrations was associated with increases of 1% in 
salbutamol prescribing. This is the first study in the UK to quantify the relationship 
of respiratory prescribing and its predictors, in primary health care. 
 
4.1 Ecological Study  
This study had an ecological design. An ecological study is defined as “a study in 
which the units of analyses are populations or groups of people, rather than 
individuals” (Last, 1995). Often, the primary reason for an ecological design is not a 
specific interest in effects of contextual, ecological variables but rather the lack of 
individual data. This study had as its central interest the effects of contextual, 
ecological variables that occur at primary care level. In the UK, a consistent priority 
for NHS reform is the shift from provision of hospital-based acute care to proactive 
care delivered in primary care (Department of Health, 2005, Department of Health, 
2006, Department of Health, 2010). Appropriate tools and studies, on this level of 
care, are required to provide information to help make decisions to support 
effective and efficient management. Ecological studies are useful tools for 
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surveillance of disease as well as risk prediction. Surveillance analyses are often 
ecological, since they describe trends in groups of individuals (Teutsch and 
Churchill, 2000). 
The concept of ecological studies is covered by all major epidemiological textbooks, 
explaining at the same time the major concern linked to these studies, called 
ecological fallacy. The ecological fallacy (bias) stems from making inferences on 
individual risks based on group-level associations. In the context of environmental 
or air pollution epidemiology, making inference of exposure-outcome associations 
on individuals rather on the group level, would create an ecological fallacy. Brenner 
et al. (1992)  as well as Richardson et al. (1987) made the point that inference at 
the level of the individual, based on ecological studies, can only be judged as 
posterior,  meaning after the establishment of the individual-level cause-effect 
association. Their work compared relative risks for lung, bladder and oesophageal 
cancer derived from ecological and individual studies, with smoking as the risk 
factor. Their study demonstrated that ecological estimates of smoking-related lung 
cancer risk are similar to those derived from individual (cohort) studies, but the 
same did not hold for the cases of bladder and oesophageal cancer (Richardson et 
al., 1987).  
This ecological study aimed to capture the association of respiratory prescribing and 
air pollution in primary care. The study described correctly the direction of the 
relationship of air quality and asthma/COPD exacerbations that has been previously 
documented by individual level studies on asthma and COPD. The study’s results 
confirmed that respiratory prescribing can be a useful indicator of respiratory health 
outcomes with great scope for use in epidemiological surveillance of air pollution 
health effects. 
 
4.2 Latency Periods  
A delayed response of respiratory prescribing to ambient pollution was investigated 
and evidence was found on the statistical models with different PM10 lag times. 
Long-term exposure to air pollution makes patients more susceptible to 
asthma/COPD triggers leading to exacerbation of symptoms, which in turn causes 
an increase in medication use. The increase in respiratory medication use 
eventually leads to the issue of a new prescription. Because the urgency by which a 
prescription would be issued would vary by individuals, and with their initial stock of 
medication, short-term effects are more difficult to observe, using prescribing data.  
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I used long periods (months) of prescribing, and long air pollution latency periods 
(weeks). As the prescribed data were averaged monthly, examining their 
relationship to daily latency periods would not be appropriate. During those longer 
periods of time, increased air pollution would be expected to be related to increased 
prescriptions, over and above the short term fluctuations driven by individuals’ 
needs for medication replacement or opening hours of practices and pharmacies. 
The studies discussed in the literature review section (Section 1.3.2.2), used daily 
respiratory medication data looking at short term associations, the only exception 
being the study by Vegni et al. (2005) that used weekly data. Additional issues 
were revealed in studies examined the short-term associations, such as days that 
practices or pharmacies were closed (e.g. weekend, bank holidays), which added to 
the complexity of their statistical models. Vegni et al. (2005) used 7-days average 
of respiratory medication, in order to avoid over-complication of his statistical 
model. 
The PM10 concentrations recorded 21 and 14 days before the prescribing month 
were positively associated with the salbutamol prescribing rate. This meant that 
there was a time window between 14 and 21 days for this relationship. The final 
statistical model assessed this relationship, after I had firstly accounted for the 
prescribing variation attributable to seasonal factors, captured by temperature at 
various latency periods. This initial analysis, described as Stage A of the statistical 
model (section 3.3), showed a significant association of salbutamol prescribing and 
temperature on 7-, 14- and 21-days lag. The results indicated a time window 
between 7 and 21 days. Therefore, even though the relationship between PM10 and 
prescribing appeared to be significant at approximately 14-21 days, the time 
window increased to 7-21 days when taking into account all explanatory variables 
of monthly salbutamol prescribing. 
Previous similar studies have focused on latency periods that did not exceed 14 
days. The study by Zeghnoun et al. (1999) examined the longest latency periods 
(14 days) compared to other studies. Their study did not use PM10 but BS, for which 
associations were found for 1-day lag as well as for 8-days lag. The most recent 
study by Laurent et al. (2009) was the most comparable to mine, as they assessed 
the relationship between short-acting β2-agonists and PM10, among other 
pollutants. Their study observed statistically significant associations involving 
latency periods of 4-10 days.  
The latency period for respiratory prescribing in relation to trigger factors is 
complex process, being partly related to management of medicine supplies and 
partly to pathophysiological response. Based on the exploration of prescribing data,  
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the time windows observed were plausible, in terms of medication consumption. I 
examined further studies that reported latency periods on air pollution and 
prescribing, aiming to find evidence as to whether the longer latency periods I 
found as significant could be biologically plausible. To assess the pathophysiological 
responses I looked at studies based on individuals that assessed whether the 
impact of air pollution can induce respiratory disorders expressed by use of short-
acting β2-agonist consumption. I found that air pollution can induce respiratory 
disorders within a few hours (Rabinovitch et al., 2006), to a few days (Schildcrout, 
Sheppard et al. 2006) and a few weeks (von Klot et al., 2002).  
A latency of several hours was observed in the study by Rabinovitch et al. (2006), 
but their subjects had severe asthma and therefore the findings are not relevant for 
the majority of asthmatics and are of limited relevance to my study which included 
asthmatics at all levels of severity. The few weeks latency period was reported by 
von Klot’s et al. (2002) using 5-, 10- and 14-day running averages for the 
relationship between ultrafine particles and short-acting β2-agonist consumption. A 
key difference between von Klot’s et al. (2002) study and most previous 
investigations was that their study examined effects of air pollution with lags of up 
to 14 days, rather than just a few days. Von Klot et al. (2002) concluded that the 
full range of air pollution effects would not have been presented if their study had 
used exposure on the same or the previous few days only. This could be explained 
by a provocation of an inflammatory reaction in association with exposure to 
accumulated ultrafine particle concentration. This was in line with Neukirch et al. 
(1998) who had found effects of air pollution on symptoms that continued for 
several days after the exposure, and who had suggested that the inflammatory 
process in the airways was the reason for this. 
One of the findings of my ecological study is that longer latency periods (over 14 
days), in addition to the most frequently used (1 - 14 days) should be examined. 
The results of this ecological study are in line with those studies that have used 
individual data. My overall conclusion is that the model successfully captured the 
presence of delayed responses between salbutamol prescribing and asthma/COPD 
exacerbations trigger factors.  
  
4.3 Random Effects  
I analyzed data at the Primary Care level for Newcastle and North Tyneside. The 
differences between practices were modelled jointly by means of random effects 
and the effect of GP practices was found to be statistically significant. In other 
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words, the effect of GP practices was unlikely to be zero, or more accurately the 
effect found in this sample of 64 GP practices was not the sort of effect one would 
expect to see if there was no effect in the population from which this sample was 
drawn. An important aspect of mixed-effects models is that the question of interest 
is for the whole population and not only for the population being sampled (Pinheiro 
and Bates, 2000). Consequently, inferences can be made for the population of 
practices that the practices I used came from rather only for those specific 
practices. When analysing health data requiring ethical and confidentiality 
considerations, using as little patients’ data as possible to make inferences with 
same level of accuracy is desirable. 
A characteristic of mixed effects models is that they have two sources of variation, 
both within and between groups. The final model predicted the prescribing 
variability between GP practices (random effects) satisfactorily, while the within GP 
practice variability (fixed effects) was predicted satisfactorily for the majority of GP 
practices but not for all. I would expect that a variable that I have missed including 
in my model would improve the prediction value of the model on some practices 
with high within practice variability (e.g. A86027, A87615), as presented in Figure 
3-37. The fact that the variance between GP practices was better captured than the 
within group variance, illustrated the importance of random effects in this analysis. 
The findings showed that the variation of salbutamol prescribing was subject not 
only to health needs caused by deprivation and air quality, but also practice specific 
random effects. Random effects can be a combination of factors that depend on 
facilities within the practice, as well as the training, experience and prescribing 
pattern of individual General Practitioners. None of these are captured by any 
accessible data source.  
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Chapter 5. Concluding Chapter 
5.1 Overall Discussion and Conclusions 
Asthma and COPD are the two most common respiratory diseases (World Health 
Organization, 2009a). Asthma had been classed as epidemic during the 1970s and 
1980s world-wide, with Western countries having some of the highest prevalence 
rates (World Health Organization, 2000). Over the past 10-15 years the findings on 
time trends of asthma have been conflicting. Even though some ISAAC centres in 
Western countries have reported either no increase or even a decrease, an increase 
of asthma prevalence has been reported in Spanish and Portuguese speaking 
centres (Asher et al., 2006).  The ISAAC study also found an increase in the 
prevalence of reported symptoms in children in younger age groups, in Western 
countries with high prevalence (Asher et al., 2006). A few studies in England and 
Switzerland have reported that asthma prevalence has reduced, probably because 
allergic asthma has declined (Anderson et al., 2004, Bollag et al., 2009, Braun-
Fahrlander et al., 2004). It appears that prevalence of asthma is still rising in 
low and middle income countries, therefore on a worldwide scale asthma 
prevalence is still increasing (World Health Organization, 2009a).  At the 
same time, it is commonly accepted that COPD prevalence is increasing 
and it is predicted to be the third leading cause of death in coming decades 
(World Health Statistics, 2008). 
It is estimated that 90% of deaths from asthma are preventable and 75% of 
hospital admissions for asthma are avoidable (Asthma UK, 2010). No similar data 
are available for COPD.  In the UK, a consistent priority for NHS reform is the shift 
from provision of hospital-based acute care to proactive care delivered in primary 
care (Department of Health, 2006, Department of Health, 2005, Department of 
Health, 2010). This ecological study focused on data from a primary health care 
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setting, linking different datasets and developing a model that would be able to 
address the main methodological issues related to a statistical model at primary 
care level. The approach to summarising GP catchment areas allowed me to reduce 
the degree of overlap that proved almost prohibitive for spatial analysis. In 
addition,  the formation of GP service areas that did not conform to administrative 
boundaries increased the scope to link GP level data to determinants of ill health  
that are not provided within administrative boundaries, such as air pollution. 
Finally, I demonstrated that mixed-effects models can address, to a great extent, 
the temporal autocorrelation issues associated with data grouped by GP practice. 
The study’s model of the primary care setting contributes to the 
development of evidence based research in primary health care as well as 
strengthening of health information systems. 
The majority of primary care consultations in the UK are for patients with 
respiratory disease (Pinnock and Sheikh, 2009, British Thoracic Society, 2006). I 
am arguing that this emphasises the importance of exploiting respiratory data at 
this level and the need for evidence at this level. Most epidemiological studies use 
data from secondary and tertiary care such as hospitals and emergency care 
(Walters et al., 1994, Schwartz, 1994, Atkinson et al., 2001a, Tolbert et al., 2000, 
Arbex M A  et al., 2009, Sunyer et al., 1993, Sunyer et al., 1997, Medina-Ramon et 
al., 2006), even though the vast majority of patients are fully treated in primary 
care. Medication prescribing data in primary care has been suggested for 
monitoring and surveillance of chronic diseases (World Health Organization, 
2008a). I used prescribing for respiratory disease as an indicator of asthma and 
COPD exacerbations.  This outcome has the advantage that it can capture patients 
with any level of severity of the disease from mild to severe. In contrast, traditional 
indicators such as hospital admissions and emergency care tend to capture events 
in patients who suffer severe symptoms, representing only a minority of the 
population of asthma and COPD patients. A few studies in France, Italy and USA 
have reported respiratory prescribing as a useful indicator of respiratory mortality 
as well air pollution health effects (Laurent et al., 2009, Naureckas et al., 2005, 
Pitard et al., 2004, Vegni et al., 2005, Zeghnoun et al., 1999). This study was the 
first in the UK to use respiratory prescribing as a marker of health outcome 
for asthma and COPD, and demonstrates that salbutamol prescribing can 
be useful for epidemiological studies and surveillance of air pollution 
health effects, in a primary care setting.  
The relationship between prescribing rate of salbutamol and air pollution was 
quantified and latency effects on this relationship were assessed. I found that an 
increase of 10μg/m3 in ambient PM10 was associated with a 1% increase (95% C.I. 
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0.1% to 2%) in salbutamol prescribing rate. The association of PM10 levels 14 and 
21 days before the prescribing month were both found to be statistically significant, 
but the stronger association was found for the 21 days latency period. This was the 
first ecological study to assess the relationship between a short-acting β2-agonist 
medication and air pollution with such long latency periods. A similar study of 
individuals had examined effects of air pollution on consumption of asthma 
medication using lags up to 14 days (von Klot et al., 2002) and suggested that long 
latency periods should also be examined. The latency periods for respiratory 
prescribing and air pollution are complex, being partly explained by the 
management of medicine supplies and partly by provocation of an inflammatory 
reaction in association with exposure to air pollution (Neukirch et al., 1998).  An 
increase of 10 µg/m3 of PM10 was associated with a 1% (95% CI, 0.1 to 
2.0%) increase in salbutamol prescribing. The effect size of exacerbation 
of respiratory symptoms triggered by daily variation of air pollution has 
been found to be between 1% (Atkinson et al., 2001; Donaldson, K.  
Medina-Ramon, M., et al., 2006; Pope C.A. et al., 1995) and 7% (Laurent et 
al., 2009) per 10µg/m3. One of the findings of this ecological study was 
that longer latency periods over 14 days should also be examined. Fitting 
the same model to new datasets would be required in order to confirm the 
results of this ecological study. 
The modelling process was separated into two stages. The first stage captured the 
area-wide seasonal variation in prescribing. Its results were then used as an offset 
input to the second stage of the model. The second stage comprised a mixed-
effects model, which assessed the remaining unexplained spatio-temporal variation 
of salbutamol prescribing in relation to air quality, deprivation and demographic 
variables. In the first stage, I modelled the seasonal variation of salbutamol 
prescribing using just temperature data. This was possible by employing a dynamic 
harmonic regression model. Previous studies on respiratory prescribing have used 
seasonal data such as pollen counts and respiratory infections as well as weather 
data to account for seasonal variation (Zeghnoun et al., 1999, Vegni et al., 2005, 
Pitard et al., 2004, Laurent et al., 2009). To my knowledge this is the first study of 
asthma or COPD epidemiology that has used such methods to account for seasonal 
variation. In the absence of pollen or respiratory infections data this 
method is a pragmatic way to capture seasonal variation. Even in cases 
where pollen and respiratory infections data exist, the use of temperature 
data with a dynamic harmonic regression model is an efficient way to 
model seasonal variation of prescribing or other health outcomes that 
follow a seasonal pattern. In addition, the two stage modelling strategy 
can be useful for studies that aim to disentangle the effect of seasonal 
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trigger factors from the effect of air pollution or other explanatory 
variables. 
 
 
5.2 Limitations and Strengths 
5.2.1 Exposure Misclassification 
One of the main limitations of this study was the unavailability of a dense air 
pollution monitoring network. I therefore had to assume spatially homogenous 
exposure to ambient PM10 concentrations. The lack of any variation on ambient air 
quality within the study area was partially addressed by the construction of a traffic 
flow index by GP practice.  
Exposure misclassification also arose from a lack of indoor air quality data. 
Exposure to indoor air pollution is associated with life style, such as smoking, 
housing conditions and occupation. Such data is difficult to include in an ecological 
study. However, such factors are correlated with income deprivation; therefore I 
consider that indoor air quality has been accounted for to some extent by the 
inclusion of the income deprivation index.  
5.2.2 Respiratory Prescribing as Indicator of Health Outcome 
In this study I used respiratory prescribing data as the health indicator of the 
outcome. This has been used by very few epidemiological studies as a proxy 
measure of respiratory health outcomes. Based on the results of studies from other 
countries, this indicator has appeared to be a useful proxy of respiratory morbidity 
when compared to traditional indicators such as hospital admissions and emergency 
room visits. Its main advantage is that it captures patients with any severity, while 
traditional indicators mainly capture patients who suffer from relatively severe 
symptoms. In the case of asthmatic patients, only 20% suffer from severe 
symptoms. In the case of COPD it is also estimated that the patients who suffer 
from severe symptoms are not the majority.  
Population based prescribing data are not available in every country, their 
availability depends on the organisation of the health system. For example, in the 
United Kingdom and France it is possible to know the population that the 
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prescribing refers to, while in other countries such as Germany this is not known, 
making it impossible to use this as a health indicator of a population.  
It was not possible to disentagle the prescribing data for asthmatic and COPD 
patients, due to limitations of the Prescribing Unit database. The RDTC had 
mentioned that the database would be developed further, so in the future it would 
be possible to access prescribing data by diagnosis.   
5.2.3 Model in Primary Health Care 
The majority of primary care consultations in the UK are for patients with 
respiratory disease (Pinnock and Sheikh, 2009, British Thoracic Society, 2006). This 
emphasizes the important role of primary care in managing respiratory diseases. 
The World Health Assembly set out an action plan in 2008, to prevent and control 
chronic non-communicable diseases, including asthma and COPD (World Health 
Organization, 2008a). Part of the action plan was to strengthen the management of 
the diseases at primary care level. They also suggest that accessibility to 
medication in primary care can be used as an indicator to monitor progress (World 
Health Organization, 2008a). This ecological study focused on data in primary care, 
linking them to environmental and lifestyle datasets and developing a model that 
would be able to address some of the methodological issues related to a statistical 
model in primary care. The approach to summarise the GP catchment areas allowed 
a reduction in the degree of overlap between practice areas. In addition, I 
demonstrated that the mixed effects model was an appropriate choice of statistical 
model that could address the autocorrelation issues linked to data grouped by GP 
practice.  
5.2.4 Methodological Application 
I used data that was collected routinely by different government bodies. This 
study’s methodology demonstrated that such existing data can be subject to new 
tools and techniques, allowing extraction of new information and evidence from 
them. Current policies such as INSPIRE, support the spatial analysis of existing data 
(Commission of the European Communities, 2004). This has been followed by a 
pan-government initiative to improve the sharing and re-use of public sector 
location information and the implementation of INSPIRE, called UK Location 
(DEFRA, 2010). 
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To my knowledge this is the first study in asthma and COPD epidemiology to 
employ a harmonic regression model to account for the seasonal variation of the 
health outcome indicator. The output of the harmonic regression was used as input 
to a mixed effects model. The application of mixed effects models has increased in 
public health and epidemiology over the last decade. This study contributed to this 
field by expanding their applicability, through using a mixed model with offset. 
Implementing a mixed effects model with offset was one of the most recent 
developments in R statistical software. I initially faced problems executing the 
mixed models with offset (library lme4 in R software). I achieved fitting the 
statistical models after communicating with the developer of the algorithm for 
mixed effects models in lme4 and an updated version was released on the R 
website. 
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Chapter 6. Appendices 
6.1 Appendix A 
 Asthma Insights and Reality in Europe  
The AIRE findings are based upon nearly 75,000 households selected by random 
digit dialling in seven Western European countries (UK, France, Germany, 
Netherlands, Sweden, Italy and Spain) forming the largest survey in Europe to 
assess control of asthma. The estimated asthma prevalence from the AIRE study 
showed the UK to have the highest asthma prevalence rate and it was at least two 
fold greater than that in any other European country (Vermeire et al., 2002). The 
sample of the AIRE study has been found to be representative of the asthmatic 
population in the countries surveyed, after comparing AIRE’s estimated asthma 
prevalence with prevalence rates found by the International Study of Asthma and 
Allergy in Childhood (ISAAC) and European Community Respiratory Health Survey 
(ECHRS) (Vermeire et al., 2002). More details on the results of the ISAAC and 
ECHRS are presented in section 1.1.1.1  and 1.1.1.2 respectively. 
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6.2 Appendix B  
Prescription of Salbutamol Prescribing 
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6.3 Appendix C 
GP Practices in the Study Area 
ID 
GP practice 
code GP practice name 
Primary Care 
Trust Easting Northing 
1 A86003 SAVILLE MEDICAL GROUP NEWCASTLE 425050 564650 
2 A86004 PROSPECT MEDICAL CENTRE NEWCASTLE 422750 564450 
3 A86006 ROSEWORTH SURGERY NEWCASTLE 424450 567450 
4 A86007 AVENUE MEDICAL PRACTICE NEWCASTLE 425450 566050 
5 A86008 PARK MEDICAL GROUP NEWCASTLE 422750 568850 
6 A86009 FALCON HOUSE NEWCASTLE 426950 564950 
7 A86010 BIDDLESTONE HEALTH GROUP NEWCASTLE 427150 566150 
8 A86011 WALKER MEDICAL GROUP NEWCASTLE 429250 564350 
9 A86012 WEST ROAD MEDICAL CENTRE NEWCASTLE 422050 564650 
10 A86013 DENTON PARK MEDICAL GROUP NEWCASTLE 419350 566550 
11 A86015 HOLLY MEDICAL GROUP NEWCASTLE 425350 566150 
12 A86017 CRUDDAS PARK SURGERY NEWCASTLE 423750 563750 
13 A86018 THE GROVE MEDICAL GROUP NEWCASTLE 424450 567550 
14 A86020 THE SURGERY-OSBORNE ROAD NEWCASTLE 425050 566950 
15 A86021 HOLMSIDE MEDICAL GROUP NEWCASTLE 421850 563850 
16 A86022 PARKWAY MEDICAL CENTRE NEWCASTLE 418150 566850 
17 A86023 37A MEDICAL CENTRE NEWCASTLE 426950 565050 
18 A86024 42 HEATON ROAD NEWCASTLE 426950 565050 
19 A86025 WESTERHOPE MEDICAL GROUP NEWCASTLE 420150 567050 
20 A86026 
THROCKLEY PRIMARY CARE 
CENTRE NEWCASTLE 415550 566550 
21 A86027 NEWCASTLE MEDICAL CENTRE NEWCASTLE 424650 565150 
22 A86028 ELMFIELD HEALTH GROUP NEWCASTLE 424250 567550 
23 A86029 THORNFIELD MEDICAL GROUP NEWCASTLE 427050 564950 
24 A86030 
BETTS AVENUE MEDICAL 
GROUP NEWCASTLE 420850 564350 
25 A86031 FENHAM HALL SURGERY NEWCASTLE 421850 565550 
26 A86032 ETHEL STREET SURGERY NEWCASTLE 421950 563950 
27 A86033 BRUNTON PARK NEWCASTLE 424150 570450 
28 A86034 
ARMSTRONG ROAD HEALTH 
CENTRE NEWCASTLE 420650 564050 
29 A86036 
GOSFORTH MEMORIAL 
MED.CTR NEWCASTLE 424450 568150 
30 A86037 ADELAIDE MEDICAL CENTRE NEWCASTLE 422150 564050 
31 A86038 NEWBURN SURGERY NEWCASTLE 416550 565750 
32 A86040 ST.ANTHONY'S HEALTH CENTRE NEWCASTLE 428550 563550 
33 A86601 
DENTON TURRET MEDICAL 
CENTRE NEWCASTLE 420150 565550 
34 A86607 ELSWICK HEALTH CENTRE NEWCASTLE 423150 563950 
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35 A86618 
WELBECK ROAD MEDICAL 
CENTRE NEWCASTLE 428550 564550 
36 A86005 WEST FARM SURGERY 
NORTH 
TYNESIDE 426650 568650 
37 A86016 LANE END SURGERY 
NORTH 
TYNESIDE 427150 568350 
38 A86041 SWARLAND AVENUE SURGERY 
NORTH 
TYNESIDE 427050 568050 
39 A87002 
SPRING TERRACE HEALTH 
CENTRE 
NORTH 
TYNESIDE 435250 568650 
40 A87003 PORTUGAL PLACE HEALTH CTR 
NORTH 
TYNESIDE 429650 566250 
41 A87004 COLLINGWOOD SURGERY 
NORTH 
TYNESIDE 434850 568650 
42 A87005 WHITLEY BAY HEALTH CENTRE 
NORTH 
TYNESIDE 435850 572050 
43 A87006 49 MARINE AVENUE 
NORTH 
TYNESIDE 435150 572550 
44 A87007 FOREST HALL HEALTH CENTRE 
NORTH 
TYNESIDE 427750 569650 
45 A87008 MARINE AVENUE MEDICAL CTR 
NORTH 
TYNESIDE 434850 572350 
46 A87009 PRIORY MEDICAL GROUP 
NORTH 
TYNESIDE 435250 568550 
47 A87011 BEAUMONT PARK SURGERY 
NORTH 
TYNESIDE 433750 572750 
48 A87012 WIDEOPEN MEDICAL CENTRE 
NORTH 
TYNESIDE 424050 572750 
49 A87013 BEWICKE MEDICAL CENTRE 
NORTH 
TYNESIDE 432150 567050 
50 A87014 
EARSDON PARK MEDICAL 
PRACTICE 
NORTH 
TYNESIDE 431650 571650 
51 A87015 APPLEBY SURGERY 
NORTH 
TYNESIDE 434850 568650 
52 A87016 THE VILLAGE GREEN SURGERY 
NORTH 
TYNESIDE 430250 566950 
53 A87017 WOODLANDS PARK HEALTH CTR 
NORTH 
TYNESIDE 423850 572450 
54 A87019 THE WESTGARTH PRACTICE 
NORTH 
TYNESIDE 435150 568450 
55 A87020 
MONKSEATON MEDICAL 
CENTRE 
NORTH 
TYNESIDE 433850 571550 
56 A87022 THE BOWMAN PRACTICE 
NORTH 
TYNESIDE 431650 571650 
57 A87023 THE SMITH PRACTICE 
NORTH 
TYNESIDE 431650 571650 
58 A87027 GARDEN PARK SURGERY 
NORTH 
TYNESIDE 432250 567550 
59 A87029 PARK ROAD MEDICAL PRACT 
NORTH 
TYNESIDE 430050 566550 
60 A87030 WALLSEND ROAD SURGERY 
NORTH 
TYNESIDE 434050 568050 
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61 A87600 PARK PARADE PRACTICE 
NORTH 
TYNESIDE 435250 572150 
62 A87608 FRIARSLEIGH HEALTH CENTRE 
NORTH 
TYNESIDE 426550 568650 
63 A87612 WELLSPRING MEDICAL PRACT. 
NORTH 
TYNESIDE 427950 571450 
64 A87615 PRESTON & AUSTIN PRACTICE 
NORTH 
TYNESIDE 427950 571450 
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6.4 Appendix D 
Service areas by GP practice 
 
  
 172 
 
 
 
 173 
 
 
 
 174 
 
 
 175 
 
 
 
 176 
 
 
 177 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 178 
 
 
6.5 Appendix E 
Service areas per year (2002-2006), by GP practice 
 
 179 
 
 
 180 
 
 
 181 
 
 182 
 
 
 
 183 
 
 
 
 
 
 
 
 
 
 
 
 184 
 
6.6 Appendix F 
Traffic Monitoring Sites 
ID 
Site 
code Location Easting Northing 
Road 
Type 
Road 
Name 
1 1 
B1318 GT NORTH ROAD N OF 
FORSYTH RD 424690 566610 Broads B1318 
2 2 
A189 REDHEUGH BRIDGE (ON NORTH 
SIDE) 424220 563500 Aroads A189 
3 5 A167 TYNE BRIDGE (ON NORTH SIDE) 425180 564040 Aroads A167 
4 7 
A1058 COAST ROAD W OF STATION 
RD. WALLSEND 429000 567240 Aroads A1058 
5 8 
B1318 Great North Road  South of 
Brunton Lane 424220 570400 Broads B1318 
6 14 A1 NORTH OF SEATON BURN INT. 423140 575000 Aroads A1 
7 16 
A1058 COAST ROAD W OF NORHAM 
ROAD 432990 568680 Aroads A1058 
8 29 
A167 NORTH WEST RADIAL S.E. 
GRANSTAND RD 423820 565750 Aroads A167 
9 35 
A193 BYKER BRIDGE 20M E OF 
STODDART STREET 425970 564570 Aroads A193 
10 59 A189 SPINE ROAD N OF SANDY LANE 426160 571900 Aroads A189 
11 69 
A19 NORTH OF TYNE TUNNEL 
APPROACH R/BOUT 433070 567020 Aroads A19 
12 70 
A19 SOUTH OF COAST ROAD 
INTERCHANGE 432440 568040 Aroads A19 
13 71 
A19 NORTH OF COAST ROAD 
INTERCHANGE 431710 568970 Aroads A19 
14 73 
A19 NORTH OF B1322/B1318 -
BACKWORTH LANE 428200 573440 Aroads A19 
15 80 
A1148 MONKSEATON DRIVE W OF 
REDHOUSE DRIVE 433300 572350 Aroads A1148 
16 88 
A1058 BEACH ROAD W OF PRESTON 
NORTH ROAD 434280 569520 Aroads A1058 
17 89 
A192 PRESTON NORTH ROAD S OF 
A191 RAKE LANE 434700 570533 Aroads A192 
18 205 A19 Tyne Tunnel (south portal) 433181 565125 Aroads A19 
19 206 
A1058 (CRADLEWELL) JESMOND RD. 
S.W. OSBORNE AVE. 426000 565850 Aroads A1058 
20 401 
A1056 SANDY LANE E OF M.O.T. 
STATION 425160 571830 Aroads A1056 
21 402 
A1056 OLD GT. NORTH RD. N OF 
GOSFORTH PK HOTEL 424180 571470 Aroads A1056 
22 403 
A191 HILLHEADS ROAD W OF 
MARDEN ROAD 435340 571840 Aroads A191 
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23 404 A189 SPINE ROAD S OF SANDY LANE 426170 571470 Aroads A189 
24 405 A1056 KILLINGWORTH RD 426690 571710 Aroads A1056 
25 407 
A186 EARSDON ROAD S.W. OF PARK 
LANE SHIREMOOR 431630 571740 Aroads A186 
26 408 
A186 STATION ROAD NORTH N OF 
HOTSPUR ROAD 429000 568370 Aroads A186 
27 409 
B1505 GREAT LIME ROAD E OF 
NORTHFIELD DRIVE 426920 570500 Broads B1505 
28 410 
A191 WHITLEY ROAD E OF STATION 
ROAD NORTH 429270 569350 Aroads A191 
29 415 
A193 WALLSEND ROAD E OF A1 
INTERCHANGE 433090 567410 Aroads A193 
30 423 
A1056 CAMPERDOWN E. OF 
NORTHGATE 427350 571850 Aroads A1056 
31 424 
A191 RAKE LANE 330M S.W. PRESTON 
NORTH ROAD 434300 570480 Aroads A191 
32 429 
A1058 COAST ROAD 270M W OF ST. 
PETER'S ROAD 430690 567850 Aroads A1058 
33 430 
A193 THE LINKS 200M S OF 
MONKSEATON DRIVE 435170 573140 Aroads A193 
34 458 A189 N. NORTH FARM AVENUE 425650 568900 Aroads A189 
35 461 A190 30M E. A189 (DUDLEY) R/BOUT 427270 573580 Aroads A190 
36 611 
A1 WESTERN BY-PASS N OF BLAYDON 
BRIDGE 419430 564730 Aroads A1 
37 612 
A1 WESTERN BY-PASS N OF A69 
INTERCHANGE 419870 565900 Aroads A1 
38 617 
A696 S.W. OF BLACK CALLERTON 
LANE 418900 570300 Aroads A696 
39 618 
A696 WOOLSINGTON BY-PASS S OF 
AIRPORT R/BOUT 418430 571050 Aroads A696 
40 619 
A696 WOOLSINGTON BY-PASS N OF 
AIRPORT R/BOUT 418230 571570 Aroads A696 
41 628 
A189 HADDRICKSMILL ROAD 50M N 
OF DENE CRESCENT 425440 567720 Aroads A189 
42 632 
B1307 SANDYFORD ROAD 40M N.E. 
OF GOLDSPINK LANE 425840 565550 Broads B1307 
43 650 
A695 SCOTSWOOD ROAD 350M E. OF 
SCOTSWOOD BRIDGE 420450 563650 Aroads A695 
44 660 
A695 SCOTSWOOD BRIDGE 
INTERCHANGE GATESHEAD SIDE 419970 563510 Aroads A695 
45 1071 
A189 WEST CENTRAL ROUTE N. OF 
SUNDERLAND ST 424227 563977 Aroads A189 
46 1072 
A189 WEST CENTRAL ROUTE N. 
WESTGATE ROAD 424280 564120 Aroads A189 
47 1073 
A189 WEST CENTRAL ROUTE S. 
GALLOWGATE 424287 564300 Aroads A189 
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48 1075 
A189 WEST CENTRAL ROUTE NORTH 
OF WALTER TER 423757 564909 Aroads A189 
49 1076 
A189 WEST CENTRAL ROUTE NORTH 
OF BRIGHTON GROVE 423273 565394 Aroads A189 
 
  
6.7 Appendix G 
Traffic index per month over the 5 years study period, by GP practice 
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6.8 Appendix H 
Diagnostics of the final model – 
Observed against fitted values of the final model by GP practice 
(a)  
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Observed against fitted values of the final model by GP practice (b) 
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Observed against fitted values of the final model by GP practice (c) 
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Observed against fitted values of the final model by GP practice (d) 
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Residuals against time of the final model by GP practice (a) 
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Residuals against time of the final model by GP practice (b) 
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Residuals against time of the final model by GP practice (c) 
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Residuals against time of the final model by GP practice (d) 
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Residuals against fitted values of the final model (a) 
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Residuals against fitted values of the final model (b) 
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Residuals against fitted values of the final model (c) 
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Residuals against fitted values of the final model (d) 
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6.9 Appendix I 
R squared for mixed models 
The coefficient of determination (R-squared) provides a measure of how well future 
outcomes are likely to be predicted by models. R-squared is appropriate for models 
that use the ordinary least squares (OLS) approach to calculate the minimum 
variance. The estimates of a mixed-effects model are maximum likelihood 
estimates though, so the OLS approach as a measure of goodness-to-fit is not 
appropriate. To evaluate the goodness-of-fit of mixed-effects model other 
approaches have been developed, called pseudo R-squares, the usefulness of which 
is debatable (Orelien and Edwards, 2008).  
I have used the following equation to estimate pseudo R-squared that is 
appropriate for mixed-effects model with random intercept like the final statistical 
model  (Snijders and Bosker, 1999). 
2
_
2
_2 1
Intercepttotal
FulltotalR
σ
σ
−=                                                                            
where 
2
_ Fulltotalσ  is the total variance explained by a mixed-effects model and 
2
_ Intercepttotalσ  is the total variance explained by an the same mixed-effects model 
when fitted only with the random effects. As a result, this pseudo R-squared 
measure can only capture the predictive power of fixed effects on a model and not 
the random effects. I fitted a model with only GP practice random effects and 
compared that to the final model (L21PM_30TR). The pseudo R-squared value for 
the final model was 48.3%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
6.10 Appendix J 
Conference Abstracts  
Sofianopoulou, E., Pless-Mulloli, T. and Rushton, S. (2009) 'Estimating Traffic 
Exposure in Primary Care Service Areas', Epidemiology, 20, (6), pp. S203-S203. 
Sofianopoulou, E., Rushton, S. and Pless-Mulloli, T. (2009) 'Analysis of Spatio-
Temporal Patterns of Short-Acting beta(2) Prescribing', Epidemiology, 20, (6), pp. 
S204-S204. 
Sofianopoulou, E., Pless-Mulloli, T. and Rushton, S. (2009) ‘Estimating  traffic 
conditions  within GP practice service areas’, GISRUK, 1 - 3 April 2009. 
Sofianopoulou, E., Rushton, S. and Pless-Mulloli, T. (2010) ‘Spatio-temporal 
Analysis in Environmental Health: Respiratory Medication in Relation to Air Pollution 
and Deprivation’, INSPIRE conference 2010, 22 -25 June 2010 
 
Other presentations 
I presented the final results of my work “Spatio-temporal analysis – respiratory 
prescribing in relation to air pollution and deprivation” at: 
• Imperial College, Department of Occupational and Environmental Medicine,  
London, 27th May 2010 
• Durham University, Wolfson Research Institute, Durham, 25th January 2010 
• NHS Regional Drug & Therapeutics Centre, Newcastle, 14th July 2009 
• Colt Foundation Day, King’s College London, London, December 2009 
 
I also had the chance to present interim results at: 
• Colt Foundation Day, King’s College London, London, December 2008  
• Lancaster University, School of Health and Medicine, Lancaster, 1st October 
2008 
• North Tyneside Primary Care Trust, Meeting of Public Health Directors, 05th 
February 2008 
• Colt Foundation Day, King’s College London, London,  December 2007    
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